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“Microglia are the best cells ever. Microglia are like soldiers, policemen, chameleons, 
spiders, housekeepers, gardeners, electricians and garbage collectors. Microglia can be 
active or resting, branched or blobby, harmful or protective, and they are everywhere 
and always moving. Are you in love yet?” 
-Virginia Hughes National Geographic, only human: January 11, 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The greatest pleasure in life is doing what people say you cannot do. 
-Walter Bagehot 
  
ABSTRACT 
Microglia, the immunocompetent cells of the central nervous system (CNS) and the brain’s 
own macrophages are the most motile cells in the CNS and those with highest plasticity, as they 
rapidly move their projections to actively screen their environment for any type of injury. Upon 
cell damage or infection, microglia respond quickly: they proliferate, change morphology from 
ramified to amoeboid state to migrate or invade towards the injury, secrete many types of 
cytokines and chemokines to communicate with other inflammatory cells, and phagocytose cell 
debris.  
WNTs are secreted lipoglycoproteins, which bind to and act through the Frizzled family of 
receptors. The Frizzled (FZD) surface receptors belong to a family of seven transmembrane 
receptors listed as G protein-coupled receptors because of their structural similarities. 
WNT/FZD-signaling was historically divided into two main branches of pathways, depending 
whether or not they induce β-catenin stabilization. With increasing knowledge the WNT 
pathways are mainly named after their protein-induced intracellular events. WNT/FZD-
signaling is important during embryonic development, neurogenesis, synaptogenesis, and tissue 
homeostasis.   
Even though WNTs are expressed in the brain and definitely in contact with microglia 
cells, a link between microglia and WNTs has just recently begun to emerge. The aim of this 
thesis is to study how microglia cells respond to stimulation with recombinant WNTs with 
regards to WNT-induced intracellular signaling and physiological outcome. We have 
investigated this by the use of classical biochemical techniques, such as immunoblotting, 
immunochemistry, RT/QPCR, GDP/GTP exchange assay and proliferation assay.  
The results show that primary microglia cells isolated from mice and a microglia-like cell 
line (N13) express several receptors for WNTs and respond to recombinant WNT stimulation. 
Stimulation with WNT-3A induced the WNT/β-catenin-dependent pathway, and, in parallel, a 
classical GPCR pathway leading to phosphorylation of the MAPKs ERK1/2. Interestingly, by 
the use of the Gαi/o protein inhibitor, pertussis toxin (PTX), we pinpoint a central role for 
heterotrimeric G proteins in both WNT-3A-induced pathways. Further, stimulation of microglia 
with recombinant WNT-5A induced a classical GPCR MAPK signaling pathway recruiting 
Gαi/o-protein, PKC, calcium and MEK1/2 to phosphorylate ERK1/2.  
In addition, WNT stimulation of microglia induced a substantial proinflammatory 
response by increasing the expression of several proinflammatory cytokines, prostaglandin 
synthase COX2, proliferation and invasion. Notably, some of these WNT-induced 
inflammatory markers could be inhibited by PTX or by a MEK1/2 inhibitor, pointing towards a 
WNT-induced G protein-dependent mechanism.  
Furthermore, in Alzheimer’s disease, a chronic neuroinflammatory condition associated 
with activated microglia, amoeboid-like microglia cells show high levels of β-catenin, 
suggesting that WNT/β-catenin signaling in microglia plays an important role in AD-associated 
microglia activation.  
In addition, WNT-3A and WNT-5A induced the expression of COX2 dose-dependently, 
but if microglia are preactivated by the proinflammatory bacterial wall derivate 
lipopolysaccharide (LPS), WNTs counteract LPS-induced COX-2 expression. This suggests a 
dual regulatory, i. e. pro-and anti-inflammatory effect of WNTs on microglia.  
In conclusion, WNTs are expressed in the brain and have impact on microglia’s 
inflammatory activity; this suggests that WNTs may play important roles as modulators of 
microglia activity in neuroinflammation and tissue homeostasis. 
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INTRODUCTION 
The brain and spinal cord are collectively named the central nervous system (CNS), 
and are made up of different cell types, including neurons and glial cells. Neurons 
process and transmit information throughout the nervous system. The brain is 
composed of 90% glial cells, which in turn include of astrocytes, ependymal cells, 
microglia, oligodendrocytes, Schwann cells and satellite cells. These cells serve many 
functions, such as neuronal support and maintenance, production of cerebrospinal fluid, 
immune defense, myelin production and, to some extent, synaptic transmission.  
Microglia 
The immunocompetent microglia, are known as the fastest moving cells of the CNS, 
which constantly and actively screen their surrounding for any imbalance in tissue 
homeostasis (Nimmerjahn et al., 2005; Hanisch and Kettenmann, 2007; Polazzi and 
Monti, 2010; Kettenmann et al., 2011). Microglia account for approximately 20% of 
the glial cell population and around 5-20% of the total cells of the adult CNS, 
depending on the species (Lawson et al., 1990; Polazzi and Monti, 2010; Aguzzi et al., 
2013).  
Microglia, were first named microgliocytes when they were discovered around 
1920 by the Spanish neuroscientist Pio del Rio-Hortega, who identified the cells with a 
silver carbonate staining (Kettenmann et al., 2011; Marin-Teva et al., 2011). The 
developmental origin of microglia remains a matter of debate either they are derived 
from invasion of mesodermal or mesenchymal origin, from neuroectodermal matrix 
cells together with macroglia (astrocytes and oligodendrocytes), from pericytes, from 
invading circulating monocytes in early development, or, according to later research, 
are derived from macrophages produced by primitive hematopoiesis in the yolk sac 
(Ling and Wong, 1993; Alliot et al., 1999; Ginhoux et al., 2010; Ranshoff and 
Cardona, 2010). Despite their origin, there are not any fundamental or functional 
differences between microglia and peripheral macrophages; thus microglia are still 
classified as the CNS’s own macrophages, expressing several macrophage-associated 
markers (Guillemin & Brew, 2004; Saijo and Glass, 2011). Microglia cells have high 
plasticity and mobility as they can rapidly transform from a ramified phenotype, with 
small body and multiple branches, into a more active amoeboid-like cell (reactive 
microglia) (Figure 1) with capacity to proliferate or migrate, invade and phagocytose 
(Lynch, 2009; Kettenmann et al., 2011, 2013; Marin-Teva et al., 2011). Although the 
ramified shape was long considered as the “resting state” of microglia waiting for 
pathology, evidence indicates that ramified microglia actively move their fine processes 
in the healthy brain (Nimmerjahn et al., 2005; Olah et al., 2011; Kettenmann et al., 
2013), making the term “surveying microglia” a more accurate description (Hanisch 
and Kettenmann, 2007; Lynch, 2009). Further, the ramified microglia have shown to 
play critical roles in determination of neuronal fate, axonal growth and synaptic 
remodeling during CNS development (Smith et al., 2012; Kettenmann et al., 2013). 
 
Carina Halleskog 
2 
Microglia cells are the first line of defense in the CNS and are the key regulators of 
neuroinflammation (Rivest, 2009; Kettenmann et al., 2011; Smith et al., 2012). To be 
able to detect and recognize possible dangerous signals that disturb homeostasis, and to 
respond to injury signals, microglia express a panoply of receptors, including 
neurotransmitter receptors and pattern recognition receptors (PRRs) (Pocock and 
Kettenmann, 2007; Kettenmann et al., 2011). Via the receptors for neurotransmitters, 
neuropeptides, and neuromodulators, microglia have the capacity to sense neuronal 
activity. These receptors are speculated to suppress microglia during normal conditions 
and rapidly influence them when pathological processes occur (Pocock and 
Kettenmann, 2007). PRRs are a group of innate receptors that recognize DAMPs 
(damage associated molecular patterns) and PAMPs (pathogen associated molecular 
patterns) (Kettenmann et al., 2011; Jounai et al., 2012). DAMPs include molecules 
released from damaged cells or tissue, such as high levels of ATP, DNA and RNA 
outside the nucleus (or mitochondria) and molecules that become modified as a 
consequence of tissue damage, such as oxidized lipoproteins and fragments from 
extracellular matrix proteins. PAMPs warn of the presence of foreign molecules such as 
the bacterial wall component lipopolysaccharide (LPS) or repeats of bacterial and viral 
nucleotide acids. DAMPs and PAMPs share many receptors, such as Toll-like receptors 
(TLRs) and induce overlapping sets of genes (Kettenmann et al., 2011). Upon a change 
in the brain micro-environment, stimulation of microglia’s receptors induces signaling 
cascades that further lead to transcription and expression of new proteins, including 
cytokines, inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX2) and 
major histocompatibility complex II (MHCII) (Hanisch, 2002; Rock and Peterson, 
2006; Brown and Neher, 2009; Graeber, 2010; Kettenmann et al., 2011). In addition, 
to clean areas from pathogens, dying cells and their fragments, and to accumulate in 
areas where neuronal death occurs, microglia migrate or/and invade, proliferate and/or 
phagocytose cellular debris (Brown and Neher, 2009; Neumann et al., 2011; Marin-
Teva et al., 2011).  
  
 
 
Figure 1: Microglia undergoes phenotypic transformation. A schematically image show 
how activated microglia change phenotype from a ramified surveying microglia (a2) towards a 
more round microphage like (a4), with migrating/invading capacities or into a chronically active 
microglia (a1).  
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It is well established that neurons, other glia and immune cells exist in several subtypes, 
and recent evidence indicates that microglia are likewise not a uniform cell type 
(Lynch, 2009; Scheffel et al., 2013). Not only may they vary in terms of regional 
densities but also in their functional properties (Lawson et al., 1990; Kim et al., 2000; 
Hanisch and Kettenmann, 2007; Olah et al., 2011). It has been suggested that 
microglia achieve this broad range of capabilities by task splitting, which can help 
explain how activated microglia can simultaneously manage proliferative expansion 
and executive functions, such as invasion, cytokine secretion and proliferation 
(Hanisch, 2013; Scheffel et al., 2013).  
Inflammatory markers of microglia activity 
As described earlier in the text, upon pathological activation, microglia transform into a 
more active pro-inflammatory state characterized by change of morphology, enhanced 
proliferation, phagocytosis, invasion/migration, or/and induction of transcription of 
distinct inflammatory molecules and proteins (Figure 2) (Hanisch, 2002; Lynch, 2009; 
Kettenmann et al., 2011). Some of these classical changes – the hallmarks of microglia 
activity – are commonly used as readouts for microglia activation. The proteins and 
molecules studied in this thesis are listed below.  
Cytokines  
Cytokines are small polypeptides (8-30 kDa), which are tremendously diverse in their 
potential actions as they signal in an autocrine or paracrine fashion, and when they bind 
to their specific receptor trigger signal transduction pathways that ultimately alter gene 
expression in the target cell (Akiyama et al., 2000b; Smith et al., 2012). At low 
concentrations they can locally modulate cellular activities including survival, growth 
and differentiation. For example, the maintenance of microglia’s immature state under 
normal conditions in the CNS is probably related to the cytokines present in the 
microenvironment, and two cytokines – transforming growth factor-β (TGF-β), and 
interleukin-10 (IL-10) – have been strongly implicated not only in this process, but also 
in deactivation of proinflammatory microglia (Smith et al., 2012). Further, cytokines 
released from astrocytes, namely TGF-β, macrophage colony-stimulating factor (M-
CSF) and granulocyte/macrophage colony-stimulating factor (GM-CSF) promote the 
ramified morphology of microglia (John et al., 2003; Smith et al., 2012). Microglia - 
being the dominant cytokine secretor within the CNS - are experts in promoting and 
suppressing inflammation (Hanisch, 2002; John et al., 2003; Graeber, 2010).  
One of the major proinflammatory cytokines microglia produce and release is 
interleukin-6 (IL-6). IL-6 is normally expressed in the nervous system during 
development, but at scarcely detectable levels. Under pathological conditions, IL-6 
expression strongly increases due to secretion by microglia, macrophages and T cells to 
stimulate immune response to inflammatory trauma (Akiyama et al., 2000) IL-6 is 
capable of crossing the blood-brain barrier and binds to its soluble or membrane bound 
receptor to form biologically active IL-6 receptor complex, which can regulate cell 
growth, proliferation, survival and differentiation. IL-6 can for example initiate the 
synthesis of prostaglandin E2 in the hypothalamus to affect the body temperature set 
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point (Marais et al., 2011). IL-6 has even been discussed as a target for regulating 
chronic inflammation and cancer (Scheller et al., 2006; Smith et al., 2012). Another 
classical proinflammatory cytokine is interleukin IL-1β. LPS-induced IL-1β expression 
in microglia has shown to have negative impact on learning and memory in rats (Oitzl 
et al., 1993). IL-12 is a heterodimeric cytokine expressed by microglia to enhance 
phagocytic activity and increase other immune cells’ ability to release proinflammatory 
cytokines, including IL-12, thereby regulating innate immunity and determining the 
type and duration of an adaptive immune response (Trinchieri, 1998). 
Tumor necrosis factor α (TNFα) is another proinflammatory cytokine contributing 
to both physiological and pathophysiological processes, and is mainly produced by 
microglia and macrophages (Sriram and O'Callaghan, 2007; Chu, 2013). Because 
TNFα stimulates the production of other inflammatory cytokines, including its own, 
TNFα is considered a key mediator of both acute and chronic reactions (Chu, 2013). 
However, it has both a neurotoxic and a neuroprotective role in the inflammation to 
maintain tissue homeostasis (Sriram and O'Callaghan, 2007) TNFα has a prominent 
role in tumor development, i.e., its increased expression and activation is often 
associated with increased tumorigenesis, tumor progression, invasion and metastasis 
(Cordero et al., 2010), rendering TNFα a common readout for proinflammatory 
activity. 
Chemokines are a superfamily of small polypeptides, which are basically 
chemoattractive cytokines that control chemotaxis, adhesion, and activation of many 
types of immune cells under both physiological and pathophysiological conditions 
(Woodcock and Morganti-Kossmann, 2013). Some chemokines are constitutively 
expressed to regulate homeostasis or development, while others are involved in the 
inflammatory process. The chemokines possess four conserved cysteine residues, and 
based on the position of two of the four invariant residues, they fall into four 
subgroups: C, CC, CXC and CX3C chemokines (X stands for another amino acid 
separating the conserved cysteine residues). Chemokines exert an effect by binding to 
their G protein coupled receptor, which is classified in accordance to the ligands (e.g. 
CCR, CXCR). Pathological activation of microglia may induce expression of cytokines 
to engage peripheral infiltrating cells to support neuroinflammatory processes 
(Kettenmann et al., 2011; Woodcock and Morganti-Kossmann, 2013). For example, 
CCL7 and CCL12, also known as monocyte chemotactic protein 3 and 5, respectively, 
induced in activated microglia are important for monocyte and leukocyte recruitment 
(Opdenakker et al., 1993; Sarafi et al., 1997).  
Cluster of Differentiation (CD)  
CDs are a group of cell membrane molecules that antibodies bind to, providing suitable 
targets for immunophenotyping cells. CD11b is expressed by immune cells and 
commonly used as a microglia marker to distinguish microglia from surrounding cells 
within the CNS (Kettenmann et al., 2011). CD11b is also known as macrophage-1-
antigen (Mac-1), CD18, and complement receptor 3 (CR3) (Akiyama and McGeer, 
1990). However, CD11b is a heterodimeric integrin involved in several immune 
responses in the innate immune system, and its expression levels seem to increase upon 
microglia activation (Kettenmann et al., 2011). Thus, the macrophage marker ionized 
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calcium-binding adapter molecule 1 (IBA-1), a protein with a suggested role in calcium 
homeostasis, is constitutively expressed by microglia and often used as microglia 
marker (Akiyama and McGeer, 1990).    
CD40, is a type I cell surface protein and a member of the TNF receptor family 
mediating a broad variety of immune and inflammatory responses, where increased 
expression/stimulation is in line with increased TNFα, IL-6 and NO synthesis 
(Ponomarev et al., 2006; Kawahara et al., 2009). CD69, is a type II integral membrane 
glycoprotein, a C type lectin, induced in active immune cells and serves for 
communication with astrocytes and other peripheral immune cells such as lymphocytes 
and natural killer cells (Marzio et al., 1999). Thus, an increased expression of CD40 
or/and CD69 provides targets for activated microglia. 
 
 
 
Figure 2: Surveying microglia transform into activated microglia upon inflammatory 
stimuli. Surveying microglia constantly screen for any imbalance in tissue homeostasis. Upon a 
change in the brain micro-environment, different inflammatory mediators stimulate microglia to 
become activated by change of morphology, enhanced proliferation, phagocytosis, 
invasion/migration, or/and induction of transcription and secretion of distinct inflammatory 
molecules and proteins. PAMPs, pathogen associated molecular patterns; DAMPs, damage 
associated molecular patterns, NO, nitric oxide; Aβ, β-Amyloid; CD, cluster of differentiation; 
PG; prostaglandin.  
Cyclooxygenase 
Cyclooxygenase 1 and 2 (COX1 and COX2), also known as prostaglandin-
endoperoxide synthase-1 and 2, are enzymes that catalyze the conversion of the 
prostanoid precursor arachidonic acid to prostaglandin endoperoxide H2, and further to 
prostaglandins (PGs) (Smith et al., 2000; Choi et al., 2009). COX1 is constitutively 
expressed in most tissue and is primarily responsible for homeostatic PG synthesis 
(Phillis et al., 2006). COX2 is normally weakly expressed in tissues but increases upon 
inflammation. Thus, COX2 provides a major target for non-steroidal anti-inflammatory 
drugs (NSAIDs) (Smith et al., 2000). Inhibition of COX2 by NSAID decreases fever 
and pain, and might also have neuroprotective effects in Alzheimer’s disease (Akiyama 
et al., 2000). Upon stimulation with PAMP or DAMP and cytokines, microglia 
increase the expression of COX2 to secrete PGs (Choi et al., 2009; Jamieson et al., 
2012), thus, increased COX2 expression is a common readout for proinflammatory 
activated microglia.  
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Nitric Oxide and Inducible Nitric Oxide Synthase (iNOS) 
Nitric oxide (NO) is both a signaling and an effector molecule in diverse biological 
systems (Garthwaite, 1991). Inducible NO synthase (iNOS), also known as NO 
synthase 2 (NOS2), is normally expressed in the brain by neurons (Wen et al., 2011). 
Induced expression of iNOS in microglia is in line with continuous production of high 
levels of NO, that on one hand have neuroprotective effects by blocking neuronal cell 
death, but on the other hand, NO can react with superoxide to form peroxynitrite which 
is toxic to neurons and oligodendrocytes (Garthwaite, 1991; Brown and Neher, 2009; 
Wen et al., 2011). 
Matrix metalloproteinase  
Matrix metalloproteinases (MMPs) are proteolytic enzymes, capable of degrading 
components of the extracellular matrix (ECM), which is a fundamental biological 
process for normal growth, development and repair of the CNS (Candelario-Jalil et al., 
2009). MMPs are divided into subgroups of collagenases, gelatinases, and other MMPs 
according to their substrate specificity and function (Candelario-Jalil et al., 2009). 
MMPs are considered to be important effectors of the inflammatory process, to serve 
during migration and invasion of immune and cancer cells (Ii et al., 2006). MMP-13 
for example, is expressed by microglia upon stimulation with IL-1, -6 and TNFα, or 
LPS (Choi et al., 2010). In addition to ECM-degrading capability, MMPs play also a 
central role in signalling through modulation of other MMPs (Leeman et al., 2002). 
Neuroinflammation 
Inflammation is a reaction of living tissues to repair a chemical, biological or physical 
injury. As mentioned before, a foreign molecule may trigger an inflammatory state in 
which components of the innate immune response attempt to clear away and/or destroy 
the invader (Medzhitov and Janeway, 2000; Rivest, 2009). The intrinsic immune 
capacity of microglia has a crucial point of convergence for the innate immune 
response in the brain and spinal cord (Rivest, 2009; Smith et al., 2012; Aguzzi et al., 
2013). Interestingly, microglia are not the only cell type in the CNS with the immune 
response capability of secreting cytokines or phagocytosis; astrocytes also play a role in 
the generation of proinflammatory mediators (von Bernhardi and Eugenín, 2004; Li et 
al., 2011). 
Inflammation is divided into acute and chronic inflammation. Acute inflammation 
is the immediate response to an injury, defined by four cardinal signs of “heat, pain, 
redness and swelling” and is usually short-lived. Chronic inflammation, on the other 
hand, is when inflammatory stimuli persist for a longer time and the inflammation is 
not completely turned off or extinguished (Streit et al., 2004). Neuroinflammation, is 
also known as “reactive gliosis”, and is characterized by the accumulation of enlarged 
glial cells, i.e. active microglia (microgliosis) and astrocytes (astrogliosis) appearing 
immediately after CNS injury has taken place. After limited acute neuronal damage, 
involving loss of either afferents or efferents, there is a more subtle response of the 
brain’s own immune system, i.e. rapid activation of glial cells. In the absence of blood-
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brain barrier breakdown and leukocyte infiltration, the microglia and astrocytes can 
fulfill their programmed repair functions, going through a resolution stage back to 
ramified stage, to benefit the organism as a whole (Streit, 2002; Streit et al., 2004; von 
Bernhardi and Eugenín, 2004; Li et al., 2011). However, the term 
“neuroinflammation” is actually more relevant to the concept of chronic inflammation, 
when the inflammation persists due to active, transformed glia cells expanding the 
initial neurodestructive effects, thus maintaining and worsening the disease progress 
through their actions (Streit et al., 2004; O'Callaghan et al., 2008; Brown and Neher, 
2009; Aguzzi et al., 2013). However, the actual underlying cause and the activating 
trigger of neuroinflammatory diseases remains elusive. 
Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS) 
are some examples of well-characterized neuroinflammatory/degenerative diseases that 
take place in the CNS where microglia cells are key regulators of the 
neuroinflammatory processes (Dheen et al., 2007; Farfara et al., 2008; Amor et al., 
2010; Heneka et al., 2010; Miller and Streit, 2007; Morales et al., 2010). Microglia 
exert underlying, molecularly diverse effects on disease pathology, which compromise 
neuronal survival and function. The microglia response to neuropathology results in 
initiating production of cytotoxic and neurotrophic factors, such as NO, and is the 
major source of proinflammatory cytokines, such as IL-1, IL-6 and TNFα (Akiyama et 
al., 2000; Dheen et al., 2007; Hanisch and Kettenmann, 2007; Walter and Neumann, 
2009). The importance of NO in microglia-mediated neurodegeneration is supported by 
the observation that addition of NO synthase inhibitors to neuron-glia cultures inhibits 
LPS-induced accumulation of nitrite and reduces neuronal cell loss (Boje and Arora, 
1992; Chao et al., 1992). As mentioned before, short-term microglia activity is 
generally accepted to serve a neuroprotective role, while during chronic inflammation, 
microglia seem to have a more neurotoxic influence in neurodegenerative disorders 
(Minghetti and Levi, 1998; Brown and Neher, 2009; Morales et al., 2010). For this 
reason, proinflammatory microglia are discussed as potential targets for drugs against 
neuroinflammatory diseases (Rock and Peterson, 2006; Heneka et al., 2010).  
Alzheimer’s disease 
Alzheimer’s disease (AD) is a chronic neurodegenerative disease and the most common 
cause of dementia in the elderly. AD is characterized by progressive CNS 
neuroinflammation and neurodegeneration, deposition of insoluble β-amyloid (Aβ) 
peptides forming senile plaques and the formation of intracellular neurofibrillary 
tangles (NFTs) made of the microtubule-associated protein tau (Heese et al., 2004; 
Morales et al., 2010). However, these features characterize late stage AD, and the 
earlier stages are not clear defined.  
Aβ plaque formation 
Aβ is formed from the integral transmembrane glycoprotein amyloid precursor protein 
(APP), which is abundant in the CNS. APP is sequentially cleaved by two enzymes, β- 
and γ-secretase to form Aβ monomers, which then aggregate successively into dimers, 
oligomers, protofibrils, and are ultimately deposited as Aβ plaques (De-Paula et al., 
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2012). In fact, most cases of familial AD involve a mutation in the presenilin (PS) 
genes, 1 and 2. These proteins together form the γ-secretase, a catalytic enzyme that 
cleaves APP (Schellenberg and Montline, 2012). Aβ40-42 is associated with AD, and 
the subscripted number stands for how many amino acids γ-secretase has cleaved off 
APP. Aβ42, in comparison to Aβ40, is more likely to form toxic plaques. Mutations in 
APP, PS1 and PS2 increase Aβ42 formation which also has been proved in transgenic 
mouse models (Duff et al., 1996).  
Tau, NFT and Braak stages of AD 
Tau is a microtubule-associated protein, and an important component of the 
cytoskeleton in neurons, to maintain neuronal structure, axonal guidance and neuronal 
plasticity (De-Paula et al., 2012). Tau activity is regulated by phosphorylation and 
dephosphorylation at serine threonine and phosphoepitopes. NFT is formed when this 
phosphorylation balance is interrupted, and tau becomes hyperphosphorylated to an 
insoluble form. This leads to impaired axonal transport and synaptic metabolism, 
collapse of the microtubular cytoskeleton, which ultimately lead to neuronal death (De-
Paula et al., 2012).  
The initial symptom and one of the earliest features of AD is impairment of 
memory. This slowly worsens and gradually transforms into personality changes, 
language impairment, and ultimately motor dysfunction (Braak and Braak, 1991, 
1995). These clinical symptoms reflect the gradual development of brain destruction 
and the formation of NFTs, which begins in a few limbic areas of the cerebral cortex 
(Braak stage I and II)) and spreads in a nonrandom manner across hippocampus (Braak 
stage III and IV), neocortex and a number of subcortical nuclei (Braak stage V and VI) 
(Braak and Braak, 1991, 1995).  
Microglia in AD 
There is growing evidence that the chronic immune response may contribute 
significantly to the damage and degeneration of neurons leading to dementia (Akiyama 
et al., 2000; Streit et al., 2004). Microglia play a crucial role in inflammation and 
clearance of destroyed neurons and Aβ (Pocock et al., 2002; Farfara et al., 2008). With 
a specific stimulatory factor such as anti-Aβ antibodies or growth factor β1, or by 
secretion of degrading enzymes, microglia can phagocytize and/or clear off Aβ 
(Koenigsknecht-Talboo and Landreth, 2005; Farfara et al., 2008). However, in 
response to multiple damage signals, Aβ peptides and neurofibrillary tangles, microglia 
becomes overactive and release neurotoxic products such as reactive oxygen species 
(superoxide and NO) and proinflammatory cytokines (Akiyama et al., 2000; Morales 
et al., 2010). Further, Aβ plaques contain IL-6 and IL-1β, which attract infiltrating 
reactive microglia and activate mitogen-activated protein kinase (MAPK) signaling, 
further triggering the release proinflammatory cytokines (TNFα, IL-1β, IL-6), and other 
neurotoxic factors such as superoxide (Pocock and Liddle, 2001). This will proceed by 
increasing the number of proinflammatory, active microglia and infiltrating immune 
cells. Meanwhile, the AD is still progressing with increased formation of Aβ plaques, 
while microglia have lost their ability to clear Aβ (Wilkinson and El Khory, 2012).  
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WNT/Frizzled background 
Frizzled 
Frizzled surface receptors (FZD) are seven-transmembrane receptors (7TMR), 
structurally reminiscent of G protein-coupled receptors (GPCRs) (Vinson et al., 1989). 
FZDs were recently included in the International Union of Basic and Clinical 
Pharmacology (IUPHAR) GPCR list as a separate family – the Class Frizzled (Foord et 
al., 2005; Schulte and Bryja, 2007; Schulte, 2010a; Katanaev, 2010). FZDs were first 
discovered as products of the frizzled locus in Drosophila melanogaster, where the 
name FZD refers to the irregularly arranged and tightly curled hairs and bristles on 
thorax wings of the frizzled mutant of D. melanogaster (Vinson et al., 1989). Mammals 
are known to have ten different isoforms of FZDs, all of which contain a large 
extracellular N terminus with a cysteine-rich domain (CRD) (Schulte, 2010a). Even if 
FZDs are listed as GPCRs, the absence of biochemical evidence supporting such 
interaction meant that it was initially believed that FZDs can act independently of G 
proteins (Schulte, 2010a; Nichols et al., 2013). Ligand binding to a GPCR induces a 
conformational change that catalyzes guanine diphosphate (GDP) release and guanine 
triphosphate (GTP) capture by the α-subunits of the heterotrimeric G proteins (Oldham 
and Hamm, 2008). This leads to a dissociation of the heterotrimer, after which both the 
Gα and βγ-subunits activate effector proteins. Heterotrimeric G proteins are grouped 
according to the α subunit’s characteristics into four subgroups: Gαi/o, Gαs, Gαq/11 and 
Gα12/13 (Gilman, 1987). The Gαi/o proteins are ADP ribosylated upon activation and are 
thereby inhibited by the bacterial toxin from Bordetella pertussis (pertussis toxin, PTX) 
(Birnbaumer et al., 1990). In fact, the first initial study of potential G protein signaling 
downstream of FZDs demonstrated that Xenopus WNT-5A (XWNT-5A) induced 
calcium release via FZD2 in a PTX–sensitive manner (Slusarski et al., 1997a-b). This 
result has been confirmed in another study on Danio rerio embryos (Sheldahl et al., 
1999) and in a more recent study on mouse embryonic cells (Ma and Wang, 2006). In 
summary, these data indicate classical GPCR coupling to Gαi/o protein signaling 
through release of βγ subunits, activation of phospholipase C (PLC) and the release of 
calcium-dependent protein kinases (Dorsam and Gutkind, 2007) and was named the 
WNT/Ca
2+
 pathway (Kühl et al., 2000a). Further, due to lack of purified, active 
WNTs or drugs acting on FZDs, chimeric receptors have been constructed with the 
ligand-binding and the transmembrane segment from the β1- or β2-ardenergic receptor 
combined with the cytoplasmic domains from FZD1 or FZD2 (Liu et al., 1999; Li et al., 
2004). This in vitro system supported requirement of PTX-sensitive G proteins upon β-
adrenergic receptor agonist binding to the chimeric β- FZD2, and argues for different 
induced signaling between different FZDs (Li et al., 2004). Additional studies show 
involvement and/or interaction of Gα protein activation downstream of FZDs, which 
has impact on several of the WNT-induced signaling pathways (Liu et al., 1999, 2001, 
2005; Egger-Adam and Katanaev, 2008; Bikkavilli et al., 2008; Nichols et al., 2013). 
However, these studies on the role of heterotrimeric G protein for WNT signaling 
have been employed in overexpression systems such as mammalian cells (Liu et al., 
1999; Ahumada et al., 2002; Ma and Wang, 2006; Bikkavilli et al., 2008), or non-
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mammalian species (Slusarski et al., 1997; Sheldahl et al., 1999; Katanaev et al., 
2005, Katanaev and Buestorf, 2009), except in a recent study on membrane 
preparations with endogenously expressed FZDs, WNT induced a PTX-sensitive 
GDP/GTP-exchange on heterotrimeric G proteins (Kilander et al., 2011a). Despite 
more recent and direct proof of WNT-induced and FZD-mediated activation of 
heterotrimeric G proteins the direct coupling of FZDs to heterotrimeric G proteins 
remains to be clarified (Schulte, 2010b, Schulte, 2013). 
WNTs 
WNTs are a family of secreted lipoglycoproteins, whose name originates from the 
names of two genes: wingless and int (Nusse et al., 1991). The D. melanogaster gene 
wingless (wg) was first identified for its function in wing, where it halts wing formation 
during embryogenesis (Cabrera et al., 1987). The Int-1 gene was identified as a 
mammary carcinoma promotor, due to an insertion of the mammary tumor virus 
(MMTV) into the int-1 locus on chromosome 15 (Nusse and Varmus, 1982). With a 
54% protein sequence homology (Rijsewijk et al., 1987), the name WNT (wingless-
related MMTV integration site) designates a novel family of signaling molecules 
(Nusse et al., 1991).  
There are 19 different WNTs in mammals, which were subdivided into two main 
categories. Those with ability to morphologically transform C57MG mammary cells  
(Wong et al., 1994) through β-catenin stabilization were called “canonical/WNT1” 
class (WNT-1,-2,-3/A, -7A, -8A/B) (Shimizu et al., 1997; Willert et al., 2003). The 
rest of the WNTs were grouped into the “non-canonical class” (originally including 
WNT-4, -5A, and -11) that triggered signaling independently of β-catenin, the non-
transforming WNTs. For example, WNT-5A regulates convergence and extension 
movements during gastrulation and axis duplication in Xenopus embryos (Moon et al., 
1993; Kühl et al., 2000a; Park et al., 2006). However, the ability of WNTs to induce 
particular downstream signaling pathways highly dependent on context (e.g. receptor 
repertoire and subcellular distribution) (Cadigan and Liu, 2006), and various reports 
have shown activation of the WNT/β-catenin dependent signaling pathway by WNTs 
from the “non-canonical class” (He et al., 1997; Mikels and Nusse, 2006b) and vice 
versa (Habas et al., 2003). Although, the nomenclature “canonical” and “non-
canonical” WNT signals is used to refer to the WNT/β-catenin dependent signaling 
which was discovered first, new discoveries have increasingly revealed the complexity 
of the WNT signaling networks, and the WNT-induced pathways should be named 
after the main components involved (Schulte, 2010a). 
Secreted WNTs are hydrophobic molecules with poor water solubility, carrying 
several posttranslational modifications such as glycosylation, palmitoylation and 
palmitoleoylation, and require a membrane protein Wntless/Evi/Sprinterfor secretion 
(Ching and Nusse, 2006). These modifications are necessary not only for WNT 
secretion but also for their signaling capabilities (Willert et al., 2003; Takada et al., 
2006; Ching et al., 2008). Consequently, only a few purified and recombinant WNTs 
are available on the market and most studies are done on WNT-3A and WNT-5A, the 
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first two WNT ligands purified (Willert et al., 2003; Schulte et al., 2005; Mikels and 
Nusse, 2006a).   
WNT/Frizzled signaling 
WNT/FZD-signaling plays a critical role in a vast array of biological processes, such as 
cell proliferation, migration, polarity establishment and stem cell self-renewal. 
Dysfunction of WNT-signaling is associated with cancer and developmental deficits 
(Logan and Nusse, 2004; Moon et al., 2004; Clevers, 2006). WNTs interact with the 
highly conserved cysteine-rich domain (CRD) of FZDs, or with accessory proteins, or 
co-receptors, to define specific downstream signaling events and exert physiological 
effects (Xu and Nusse, 1998; Schulte and Bryja, 2007; Janda et al., 2012). Due to the 
lack of recombinant purified WNTs (Willert et al., 2003; Willert and Nusse, 2012) and 
despite the recent advances on structural aspects of WNT-FZD interaction (Janda et al., 
2012) it is still not known which WNT binds to which FZD (or co-receptor) to exert an 
effect (except for a few cases). As mentioned, the β-catenin signaling was the first one 
described, and was referred to as the canonical pathway (Shimizu et al., 1997; Chien et 
al., 2009), the increasing knowledge about the complex signaling of the “non-
canonical” network induced by WNTs, makes it better to designate the WNT-induced 
pathway in terms of the main components involved (He, 2003; Schulte, 2010a; 
Marchetti and Pluchino, 2013; Schulte, 2013). In fact, several studies have emphasized 
the importance of G proteins in the WNT/β-catenin signaling pathway (Liu et al., 2001; 
Malbon et al., 2001; Bikkavilli et al., 2008; Jernigan et al., 2010). 
Disheveled  
A central player in most of the WNT/FZD signaling pathways, is the cytosolic scaffold 
protein disheveled (DVL) (Shan et al., 2005; Gao and Chen, 2010). DVL is highly 
conserved during evolution and three DVL homologs were identified in mammals, 
DVL1, 2 and 3. The DVL protein is composed three conserved domains: the N-
terminal DVL-Axin (DIX) domain, a central Postsynaptic density 95-Disc Large-
Zonula occludens (PDZ) motif and a C-terminal DVL-Egl-10-Plectsrin (DEP) domain 
(Gao and Chen, 2010). The PDZ motif plays an important role in WNT-induced 
pathways, where it binds to the KTxxxW (x= any amino acid) conserved motif on 
FZDs (Wong et al., 2003). Upon WNT binding, the DIX domain of DVL interacts with 
the homologous DIX domain of Axin, which brings DVL to the destruction complex. 
In this way DVL inhibits the function of Axin in the β-catenin destruction complex and 
plays a crucial role in the WNT/β-catenin dependent pathway (Julius et al., 2000). The 
DEP domain is important for DVL interactions with other proteins (Gao and Chen, 
2010). WNT stimulation induces DVL phosphorylation (and possible ubiquitinylation) 
which can be visualized by the western blotting (WB) technique when DVL appears as 
a slow-migrating band, also known as the formation of PS-DVL (phosphorylated and 
shifted). However, this WNT-induced phosphorylation of DVL, possible through a 
casein kinase 1 (CK1) δ and CK1ε dependent mechanism, is not necessarily related to 
its functional degree of activity (Bryja et al., 2007a-b; Bernatik et al., 2011; Gonzalez-
Sancho et al., 2013).  
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WNT/β-catenin-dependent signaling 
In absence of WNTs, a constitutively active destruction complex consisting of 
glycogen synthase 3β (GSK3β), casein kinase 1α (CK1α), the scaffold protein Axin and 
adenomatous polypsis coli (APC), phosphorylates cytosolic β-catenin (CK1 at Ser45 
and GSK3β at Ser33/37/Thr41). This sequential phosphorylation primes β-catenin for 
ubiquitionation by β-transducin repeats-containing protein-1 and thereby for 
proteasomal degradation to keep cytosolic β-catenin levels low (Clevers., 2006; 
MacDonald et al., 2009; Marin-Teva et al., 2011; Li et al., 2012). In the presence of 
WNT-1-like ligands (including WNT-1, -3A, -8), WNTs form a ternary complex 
together with FZD and the single-pass co-receptor low density lipoprotein receptor 
related protein 5 or 6 (LRP5/6). This leads to a rapid recruitment of CK1γ and GSK3β 
to phosphorylate LRP5/6, which in turn redistributes the destruction complex, and 
forms an LRP5/6 signalosome consisting of a WNT-FZD-LRP5/6-DVL-axin platform 
(Bilic et al., 2007). This redistribution and displacement of proteins in the destruction 
complex, leads to its inhibition allowing β-catenin accumulation, stabilization and 
further translocation to the cell nucleus. Once in the nucleus, β-catenin binds and 
activates the transcription factors T-cell factor/lymphoid enhancer binding factor 
(TCF/LEF). Without nuclear β-catenin TCF/LEF represses gene transcription of target 
gene promoters (Malbon et al., 2001; MacDonald et al., 2009) such as c-my and cyclin 
D1 (He et al., 1998; Tetsu and McCormick, 1999), Figure 3.  
 
 
Figure 3: The WNT/β-catenin-dependent pathway 
In absence of WNTs, the continuously active destruction complex consisting of Axin, APC, 
CK1α, and GSK3β, phosphorylates β-catenin for proteosomal degradation. In presence of 
WNTs, WNT binds to FZD and the co-receptor LRP5/6 leads to inhibition of the destruction 
complex. In turn, β-catenin accumulates and stabilizes for its translocation into the cell nuclei, 
where it binds the transcription factors TCF/LEF to activate transcription of WNT target genes. 
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WNT/β-catenin-independent signaling 
The WNT signaling that occurs independently of β-catenin stabilization, consists of a 
network of signaling pathways, such as the planar cell polarity (PCP) pathway 
(including WNT/RHO and WNT/Ras-related C3 botulinum toxin substrate (RAC) 
signaling axis), the WNT/Calcium (Ca
2+
)-signaling or WNT/cAMP signaling routes 
(Moon et al., 1993; Kühl et al., 2000b; Semenov et al., 2007; Schulte, 2010a; 
Schellenberg and Montline, 2012). However, as mentioned earlier, some of these 
signaling events are cross-linked or even identical, depending on cell type, receptor 
repertoire and their subcellular distribution (Dejmek et al., 2006; Mikels and Nusse, 
2006a; van Amerongen et al., 2008; Chien et al., 2009). This indicates that WNT-
signaling works through what might better be described as a signaling network, rather 
than individual signaling pathways. 
WNT/PCP-signaling 
WNT/PCP-signaling, governs the orientation of cells within an epithelial plane, a 
layered sheet a single cell thick. The best described samples are the uniform array of 
hairs on the wing of Drosophila (Seifert and Mlodzik, 2007) and the orientation of 
stereocilia in the inner ear of mammals (Montcouquiol et al., 2006). In Drosophila the 
PCP pathway acts independently of WNTs; however, the “PCP core proteins” FZD and 
DVL are still present, and signaling occurs through relocation of the core proteins, 
including Strabismus and Prickle (Seifert and Mlodzik, 2007).   
In vertebrates, WNT/PCP signaling involves activation of several small Rho 
GTPases, which have different intracellular targets and appear constitute separate 
pathways (Dejmek et al., 2006; Seifert and Mlodzik, 2007). Upon WNT binding to 
FZDs, DVL can associate with the small GTPase Rho via the Formin homology 
adaptor protein Daam 1 (DVL associated activator morphogenesis 1) (Habas et al., 
2001). Daam1 is a cytoplasmic auto-inhibited protein, which goes through a 
conformational change and activation upon DVL-binding, enabling its interaction with 
RhoA and the formation of a Rho-GTP complex which in turn activates Rho-associated 
kinases (ROCK) and remodels the cytoskeleton, eliciting changes in cell morphology 
(Habas et al., 2001; Kishida et al., 2004). 
Another small GTPase of the Rho family that can be activated upon WNT-FZD 
binding and activation of DVL is RAC1. Activation of RAC stimulates the downstream 
effector c-Jun N-terminal kinase (JNK), to further activate JNK targeting transcription 
factors, such as c-Jun. This pathway for example regulates convergent extension 
movements during Xenopus gastrulation (Habas et al., 2001, 2003). JNK activation 
leads subsequently to activation of transcription factors such as c-Jun (Rosso et al., 
2005).   
ROR1/2 and RYK belongs to the family of receptor tyrosine kinases (RTK). ROR 
is characterized by extracellular FZD-like CRDs and intracellular tyrosine kinase (Trk) 
domains, resembling those of the Trk-family, while RYK has a homology to WNT 
inhibitory factor (WIF) to enable interaction with WNT ligands (Forrester, 2002; 
Fradkin et al., 2010). The lack of specific ROR/RYK ligands makes it is somewhat 
unclear under which circumstances WNT/ROR and WNT/RYK signaling involves 
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cooperation with FZDs, or as autonomous WNT receptors (Cadigan and Liu, 2006; Li 
et al., 2008; Fradkin et al., 2010). Although, it has been shown that WNT-5A binding 
to ROR2, independently of FZD, triggers the WNT-JNK pathway and/or inhibit the β-
catenin-dependent pathway (Oishi et al., 2003; Mikels and Nusse, 2006a). The 
WNT/ROR2-induced JNK activation involves PI3K, the GTPase Cdc42, protein kinase 
C (PKC) and the transcription factors of JNK target genes, such as c-Jun, where its 
activation regulates convergence and extension movements in Xenopous (Oishi et al., 
2003; Schambony and Wedlich, 2007). This pathway is activated downstream of both 
FZD and ROR2, suggesting crosstalk between WNT/PCP and WNT/Ca
2+
 pathways 
(Choi and Han, 2002). In cooperation with FZD and DVL, RYK support WNT/β-
catenin-dependent pathway. However, WNT-5A can recruit RYK in a β-catenin 
independent manner, to increase the release of intracellular Ca
2+
 (Li et al., 2009), 
Figure 4. 
 
 
 
Figure 4:  WNT /β-catenin-independent signaling network 
WNT/RHO: WNT can activate RhoA, which requires DVLs’ recruitment of Daam1. RhoA 
activates RhoKinase which regulates actin cytoskeleton rearrangements. WNT/RAC: WNTs 
binds to FZD to activate JNK via DVL and RAC1. JNK in turn activates transcription of JNK 
target genes via c-Jun..WNT/ROR: WNT binds ROR2 (or/and FZD) to activate JNK via P13K 
and Cdc42. WNT/Ca2+: WNT binding to FZD activates PLC directly or via DVL which 
elevates intracellular Ca2+ levels via DAG and IP3, which in turn activates PKC and CaMKII. 
CaMKII activates the transcription factor NFAT, while PKC may regulate Cdc42.   
WNT/ Ca
2+
 signaling 
WNT/FZD binding activates phospholipase C (PLC) and/or phosphodiesterase (PDE) 
via heterotrimeric G proteins leading to the generation of diacylglycerol (DAG) and 
inositol triphosphate (IP3) which in turn leads to generation of Ca
2+
 fluxes (Ahumada et 
al., 2002). Ca
2+
 is a second messenger i.e. a central regulator of cell function and 
controls the activity of multiple intracellular proteins, including PKC, Ca
2+
/calmodulin-
dependent kinase (CamKII) (Kühl et al., 2000a; Choi and Han, 2002), calcineurin and 
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the transcription nuclear factor of activated T-cells (NFAT) (Cook et al., 1996; 
Saneyoshi et al., 2002; Dejmek et al., 2006). The WNT-induced Ca
2+ 
release is 
dependent on signaling through the Gi/o and Gq family of proteins, as demonstrated by 
the fact that PTX blocks this pathway (Slusarski et al., 1997a; Sheldahl et al., 1999, 
2003; Kühl et al., 2000b). Recombinant WNT-5A has further been shown to induce a 
dose-dependent Ca
2+
-signaling in mammary epithelial cells expressing low levels of 
endogenous WNT-5A (Dejmek et al., 2006). 
Mitogen-activated protein kinase in microglia  
The family of mitogen activated protein kinases (MAPK) is highly conserved during 
evolution. MAPKs represents one of the most important kinase families in 
inflammatory cells, whose activity is regulated in response to variety of stimuli, 
including growth factors, cytokines or even environmental stress (Turjanski et al., 
2007; Kaminska et al., 2009). The MAPK family includes the extracellular signal-
regulated kinases (ERK1/2; also known as p44/42), the c-jun N-terminal kinases 
(JNKs; also known as stress-activated protein kinases (SAPKs)), the p38 MAPKs, and 
the ERK5/big MAP kinase1 (BMK1) (Koistinaho and Koistinaho, 2002; Turjanski et 
al., 2007; Keshet and Seger, 2010). Microglia express several receptors that exert 
physiological effects after activation through MAPKs. For example, stimulation of 
calcium/calmodulin-activated K
+
 channels are linked to activation of p38 MAPK, 
which in turn induce iNOS expression leading to neurotoxic effects (Kaushal et al., 
2007); stimulation of the ionotropic ATP receptor P2X4 induce p38 signaling and may 
contribute to neuropathic pain (Ji & Suter, 2007; Gong et al., 2009); norepinephrine 
acting through β1/2 receptors and via p38/ERK signaling inhibits ATP-induced release 
of TNFα (Morioka et al., 2009); and the Gi/o- and Gq-coupled cannabinoid CB1 and CB2 
receptors reduce microglia neurotoxicity but increase microglia proliferation through 
MAPK signaling (Stella, 2009). Further, the cellular effects of chemokines are 
mediated through GPCRs and are linked to several intracellular cascades such as 
adenylate cyclase, PLC, GTPases (Rho, RAC, and Cdc42) and several MAPKs (Pierce 
et al., 2000; Kielian, 2004).  
ERK1/2, which are the MAPKs studied in this thesis, are connected to the 
regulation of cell growth, differentiation and proliferation, and in the brain ERK1/2 is 
also connected to cellular responses, including stress stimuli, such as oxidative stress 
and increased intracellular calcium levels (Koistinaho and Koistinaho, 2002; Keshet 
and Seger, 2010). ERK1/2 is located in the cytoplasm and is upon phosphorylation also 
found in the cell nucleus which appears to phosphorylate transcription factors (Ahn et 
al., 2004). ERK1/2 is encoded by two genes, ERK1 and ERK2, which encode two 
main proteins, p44 and p42, respectively (Keshet and Seger, 2010). ERK1/2 is a serine 
threonine kinase, whose activation is regulated through phosphorylation of both of the 
Tyr and Thr residues (Koistinaho and Koistinaho, 2002; Turjanski et al., 2007). 
Upstream of ERK1/2 we find the MAPK kinase (MAPKK) MEK1/2, which 
phosphorylates ERK1/2, which in turn is phosphorylated by the MAPKK kinase 
(MAPKKK) RAF. This MAPK cascade is regulated by many kinds of receptors and 
pathways, especially receptor tyrosine kinases and GPCRs (Keshet and Seger, 2010). 
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Activation of ERK1/2 in microglia leads to activation of several nuclear transcription 
factors, cytoskeletal, nuclear and signaling proteins, that in turn leads to microglia 
secretion and release of numerous of cytokines and inflammatory/neurotoxic mediators 
(Koistinaho and Koistinaho, 2002; Kaminska et al., 2009).  
WNT/MAPK crosstalk  
Stimulation with WNT-3A on mouse fibroblasts has been shown to induce proliferation 
both via the activation of WNT/β-catenin pathway and via a Ras-Raf-1-MEK-ERK 
cascade independently (Yun et al., 2005). Further, findings suggests that proline-
targeted-kinases from the MAPK family can phosphorylate an intracellular motifs on 
the LRP6, which is required in LRP6’s regulation of the β-catenin destruction 
complex, thus suggesting a sufficient role of MAPK activation in LRP6-initiated 
downstream signaling (Wolf et al., 2011). In addition, receptor tyrosine kinases have 
been shown to crosstalk via ERK1/2 to potentiate LRP6 and regulate β-catenin 
phosphorylation, thus enhancing the WNT/β-catenin signaling (Krejci et al., 2012). In 
a breast cancer cell-line, transactivation of the epidermal growth factor receptor 
(EGFR) and the WNT/β-catenin pathway induces proliferation via ERK1/2 activation 
in a WNT- and DVL-dependent manner, independent of β-catenin stabilization 
(Schlange et al., 2007). In summary, the MAPKs have been assigned an important, yet 
poorly defined role in the regulation of and crosstalk with the WNT/β-catenin pathway 
on different levels (Bikkavilli and Malbon, 2009).  
WNT-signaling pathophysiology 
WNTs are important in mediating cell-cell communication, and are therefore crucial for 
the development of the CNS and stem cell differentiation. Given the wide range of 
processes affected by WNT-signaling in the developing and adult brain, such as 
neuronal induction and pattering, cell proliferation, cell fate specification, cell 
polarization and migration, axon guidance, synaptogenesis, adult neurogenesis and 
neuron maintenance and regeneration, it comes as no surprise that defects in WNT-
induced pathways lead to disease and cancer (Alvarez et al., 2004; Clevers, 2006; 
Kurayoshi et al., 2006; Malaterre et al., 2007; Inestrosa and Arenas, 2010; Salinas, 
2012; Marchetti and Pluchino, 2013). Several studies illustrate the emerging role of 
WNT and/or WNT/β-catenin signaling in postnatal brain plasticity (Inestrosa and 
Arenas, 2010). Neuronal expression of components of the WNT signaling, such as 
GSK3β and β-catenin, and several FZDs has been described in the adult animal brain 
(Inestrosa and Arenas, 2010). Studies in humans indicate that WNT signaling involved 
in the pathophysiology of AD, especially due to its role in the regulation of GSK3β 
activity (Anderton et al., 2000; Ghanevati and Miller, 2005). Ever since the loss of 
WNT signaling was shown to associated with Aβ-induced neurotoxicity, studies have 
been demonstrating numerous WNT components to be altered in AD, and drugs 
capable of modulating WNT signaling have been discussed as potential tools against 
diseases associated with neuronal loss (Inestrosa and Toledo, 2008; Toledo et al., 
2008; Inestrosa and Arenas, 2010). However, WNT’s involvement in the development, 
homeostasis and diseases of the CNS is mainly based on studies focused on neurons, 
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and it was not until recently that the WNT signaling components were identified in 
cells of the immune system (Staal et al., 2008; Marchetti and Pluchino, 2013).  
The GSK3 hypothesis in Alzheimer’s disease 
GSK3 is a serine/threonine inhibitory protein kinase, encoded by GSK3α and β in 
vertebrates. GSK3 participates in numerous cell signaling cascades and in contrast to 
other kinases, GSK3 is highly active in resting cells, and its activity is reduced upon 
stimulation (Cohen & Goedert, 2004; Kockeritz, et al., 2006). Both isoforms are 
regulated by phosphorylation: GSK3α at tyrosine 279 and GSK3β at tyrosine 216, 
which increases their overall catalytic activity (Cohen & Goedert, 2004; Kockeritz, et 
al., 2006). Both isoforms are also inhibited by phosphorylation: GSK3α at the amino-
terminal domain serine 21, while GSK3β has the equivalent residue serine 9 (Cohen & 
Goedert, 2004; Kockeritz, et al., 2006). However, little is known about isoform-
specific functions. Several protein kinases have been identified as capable of 
phosphorylating and inactivating GSK3, such as phosphatidylinositol 3’ kinase (IP3K) 
activation of protein kinase B in response to insulin stimuli, or cyclic AMP-dependent 
protein kinase (PKA) and atypical protein kinase C (PKC) (Cohen & Goedert, 2004; 
Kockeritz, et al., 2006). In WNT/β-catenin signaling GSK3β, as mentioned, belongs to 
the β-catenin destruction complex, where GSK3β plays a central role to increase the 
complex stability by phosphorylation of the other proteins (Axin, APC) at multiple sites 
(Jope et al., 2007)).    
GSK3 overactivity is associated with several neuropathological diseases 
(Kockeritz et al., 2006; Hooper et al., 2008), diabetes 2 (Kockeritz et al., 2006) cancer 
(Jope et al., 2007) and even schizophrenia (Lovestone et al., 2007). In AD, several 
agents associated with neuronal death are affected by GSK3 activity, such as tau, the 
APP fragment, and Aβ (Hooper et al., 2008). Tau filaments are hyperphosphorylated at 
more than 20 sites, at both primed and non-primed phosphorylation sites by activation 
of GSK3β and -α (Hooper et al., 2008). Further, GSK3α has been shown to regulate 
APP cleavage, which results in an increased production of Aβ (Phiel et al., 2003).  
The progressive neuronal dysfunction in AD and in transgenic AD-mouse models 
is associated with decreased WNT/β-catenin signaling in neurons (Pei et al., 1999; De 
Ferrari and Moon, 2006; Inestrosa and Arenas, 2010), where APP seems to be a major 
factor in the abnormal down-regulation of β-catenin in neurons (Chen and Bodles, 
2007). In addition, restoring WNT/β-catenin signaling through GSK3 inhibition seems 
to have a neuroprotective potential by diminishing Aβ neurotoxicity and by reducing 
tau hyperphosphorylation (De Ferrari et al., 2003; Alvarez et al., 2004; Inestrosa et al., 
2007; Chacón et al., 2008). This was confirmed in a mouse model of AD where LiCl (a 
GSK3 inhibitor (O'Brien and Klein, 2009)) improved memory performance, which 
suggests that it alleviated the underlying neuronal deficits (Hooper et al., 2008; Toledo 
and Inestrosa, 2009). In addition, cortical neurons exposed to Aβ-peptides have 
increased expression of the WNT/β-catenin signaling inhibitor Dickkopf 1 (DKK1), 
and are associated with neuronal degeneration (Caricasole et al., 2004). DKK1 
antagonizes WNT/β-catenin signaling through interaction of LRP5/6, and inhibits the 
formation of WNT/LRP5/6/FZD complex that would block the continuously active 
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GSK3β in the β-catenin destruction complex (MacDonald et al., 2009). Further, 
GSK3 promotes inflammation through induction of proinflammatory cytokines and 
their receptors, and reduction of anti-inflammatory cytokines in monocytes and 
peripheral blood mononuclear cells (Jope et al., 2007).  
In summary, “the GSK3 hypothesis of AD” refers to the central role GSK3 plays 
in AD development and the observation that GSK3 deregulation accounts for many of 
the pathological hallmarks of the disease: inflammation, APP, Aβ and tau 
phosphorylation (Jope et al., 2007; Hooper et al., 2008; Koistinaho et al., 2011). This 
GSK3 over-activity drives drug industry currently towards development of GSK3 
inhibitors (Jope et al., 2007; Hooper et al., 2008; Palmer, 2011).  
WNT signaling in microglia 
Despite the important influence WNTs have on adult neurogenesis, neuron 
maintenance and regeneration, etc. (Malaterre et al., 2007; Inestrosa and Arenas, 
2010) and the crucial role microglia have on CNS homeostasis and neuroinflammation 
(Rock and Peterson, 2006; Miller and Streit, 2007; Amor et al., 2010), it was not until 
recently that the link between WNTs and microglia began to emerge. For example, 
overexpression of WNT-5A signaling in microglia/macrophages has been associated 
with increased invasiveness of breast cancer cells, and especially their metastasis in the 
brain (Pukrop et al., 2006, 2010).  
This thesis reports how recombinant WNTs induce WNT/β-catenin-dependent and 
–independent signaling pathways through endogenously expressed FZDs in mouse 
microglia. The data shows that stimulation with recombinant WNT-3A on microglia 
induce β-catenin-dependent signaling and, in parallel, a β-catenin independent pathway 
resembling a classical GPCR cascade, resulting in the phosphorylation of the MAPK 
ERK1/2 (Halleskog and Schulte, 2013a). Interestingly, the data suggest a central role 
of Gαi/o proteins in the WNT/-catenin pathway since the Gαi/o protein inhibitor 
pertussis toxin blocks both WNT-3A/-catenin and WNT-3A/ERK1/2 signaling 
(Halleskog & Schulte, 2013a). In addition, WNT-3A stimulation induces a substantial 
proinflammatory fingerprint in microglia and together with the increased β-catenin 
stabilization found in amoeboid-like microglia cells in postmortem AD brains, we 
suggest that WNT are involved in the regulation of microglia in neuroinflammation 
(Halleskog et al., 2010). 
Further, stimulation of microglia with recombinant WNT-5A induces a classical 
GPCR cascade in microglia involving Gαi/o protein, βγ, PLC, PKC, Ca
2+
, and MEK1/2 
to phosphorylate ERK1/2. This pathway is responsible for WNT-5A-induced 
expression of some cytokines, MMPs, proliferation and invasion of microglia 
(Halleskog et al., 2011).  
Finally, in the last study, the data show that both WNT-3A and WNT-5A 
counteracts on LPS-induced COX2, IL-6 and TNFα in microglia suggesting WNTs as 
homeostatic regulators of microglia (Halleskog and Schulte, 2013b). However, more 
detailed studies are required to elucidate underlying mechanism.  
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AIMS 
The general aim of my studies was to investigate how microglia cells respond to 
stimulation with recombinant WNT. Based on the facts and considerations described in 
the introduction, the following specific aims were established for this thesis:  
 
1. To investigate if microglia cells express WNT receptors  
 
2. To identify specific intracellular signaling pathways induced by stimulation 
with recombinant WNT-3A and WNT-5A  
 
3. To characterize WNT-mediated G protein activation in microglia, and to 
further dissect the WNT-induced intracellular signaling network 
 
4. To validate WNT-3A- and -5A-induced activation of microglia with regard to 
proinflammatory markers, cytokine expression, proliferation, and invasion 
 
5. To investigate WNT/β-catenin-induced signaling in activated microglia in a 
human neuroinflammatory condition (AD) and in a corresponding mouse 
model of AD 
 
6. To determine whether WNTs would promote or attenuate LPS-induced 
proinflammatory changes in microglia  
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MATERIAL AND METHODS 
The material and methods that were used in this thesis are all described in the 
individual papers, and the descriptions will therefore not be repeated here. Most of the 
techniques are standard procedures and are listed in table 1, and the remainder of this 
section will bring up different methodological considerations of importance for the 
study. 
 
Table 1: Techniques used in this thesis 
 
Methods Paper 
Cell line culturing I, III 
Isolation and culture of primary microglia from mice I, II, IV, V 
Inhibitor treatment/ WNT-stimulation I-V 
SDS-PAGE/ Western blotting (immunoblotting) I, II, III, IV, V 
Immunocytochemistry I, IV 
Immunohistochemistry I 
RNA extraction and cDNA synthesis I, IV, V 
Reverse transcription polymerase chain reaction (RT-PCR) I 
Real-time/quantitative RT-PCR (QPCR) I, IV, V 
Affymetrix Expression Analysis I 
Mesoscale for TNFα IV 
Enzyme-linked immunosorbent assay (ELISA) I 
[Ca
2+
]i imaging IV 
cAMP measurements   IV 
Invasion assay IV 
[γ-35S]-GTP assay III, IV 
MTT-assay III, IV 
Cell counting I, IV 
Methodological considerations 
Cell line culturing and isolation of microglia  
Cultured cell lines are often used as in vitro models for the study of specific cellular 
mechanisms. N13 is a cell line which manifests microglia-like features because it is 
obtained by immortalization of primary microglia cultures isolated from the ventral 
mesencephalon and cerebral cortex of CD1 mice at embryonic day 12-13 (Righi et al., 
1989; Ferrari et al., 1996). However, after prolonged time in culture, cell lines have the 
drawback that they become more homogenous and adapt to growing in culture, which 
in turn leads to loss of physiological features. In order to obtain more realistic and 
physiological readout closer to in vivo situations, we have isolated microglia cells and 
astrocytes from fresh tissue, so-called primary cultures. In Paper I-II, IV and V we 
obtained cells from newly decapitated C57BL/6 wild-type (wt) mouse pups (postnatal 
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day 1-3; P1-3), according to our ethical permits (N26/05, N144/08, and N436/10, 
approved by Stockholms Norra Djurförsksetiska Nämnd). The animals were bred at the 
Department of Physiology and Pharmacology, Karolinska Institute, and housed at a 
constant room temperature (22°C; 12h light/dark cycle) and the handling of the animals 
was in the accordance with the NIH Guide for the Care and Use of Laboratory 
Animals. The isolation protocol follows a standard procedure described by Giulian and 
Baker (1986) (Giulian & Baker, 1968)), with modifications, that are described in 
greater detail in Paper IV (Halleskog et al., 2012). After microglia cells were harvested 
from the astrocytic layer, their purity was checked, mainly by immunocytochemistry 
with the antibodies against microglia marker CD11b (Mac-1) or IBA-1 (Akiyama and 
McGeer, 1990) in combination with antibodies against the astrocytic marker GFAP 
(Glia fibrillary acidic protein) (Cahoy et al., 2008). 
Animal model for AD: the APdE9 mice 
Rodents do not develop AD as humans, with formation of plaque or tangles; but 
creation of transgenic mice allows us to mimic various aspects of the disease. A few 
mouse models of human AD are available, all of which involve mutation of the gene 
encoding APP to form Aβ plaques. The APdE9 mouse is a double transgenic mouse 
model where AP stands for the Swedish mutation (K595N and M596L) in the gene 
coding for amyloid precursor protein (APP) and dE9 for the deletion of the presenilin 1 
(PSEN1) gene at exon 9. Combining these two mutations, APP and PSEN1, increases 
the likelihood of early disease onset and an alteration of Aβ42 formation. The APdE9 
mice have been examined both biochemically for Aβ plaque formation followed by 
chronic inflammation, astrogliosis and microgliosis, and behaviorally for memory 
deficits (Jankowsky et al., 2004; Garzia-Alloza et al., 2006). PSEN1 has been shown 
to interact with β-catenin and its stability (Satoh and Kuroda, 2000), i.e., loss of 
PSEN1 function results in increased stability of cytosolic and this association has 
been implicated in modulating the WNT/β-catenin signaling pathway (Kang et al., 
1999). However, the PSEN1 mutation used in Paper I does not affect β-catenin 
steady-state levels in cells (Soriano et al., 2001). 
The tissue from transgenic mice was purchased from the University of Eastern 
Finland, Kuopio, and kept at the Department of Medical Biochemistry and 
Biophysics, Karolinska Institute. In accordance with ethical permit N26/05, it was 
only used for immunological postmortem studies.  
Stimulation and inhibitor treatment 
Pharmacological inhibitors are useful tools for in vitro studies to dissect signaling 
pathways. To note, it is quite common that inhibitors are rather unspecific for their 
actual target protein. To overcome this and to confirm blockade or non-blockade, 
several inhibitors against the same protein were used in this thesis, and if possible, 
structurally different inhibitors were selected, e.g., wortmannin and LY294002 
inhibiting PI3K, and BIS and RO318220 inhibiting PKC. Additionally, when it comes 
to experimentation on immune cells like microglia cells, it is difficult to use inhibitors 
dissolved in certain substances (such as DMSO), or to attach carrier proteins that can 
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affect their activity, such as BSA (Hopper et al., 2009). This was overcome by the use 
of sham-stimulated cells. Therefore, for longer treatment, inhibitors were preferentially 
chosen based on their solubility in ethanol (SL327 blocking MEK1/2 instead of 
PD98059), and only carrier-free WNTs dissolved in PBS were used (except in Paper I). 
In order to block WNT-induced signaling, we have used endogenous inhibitors in 
recombinant form, such as Dickkopf 1 (DKK1) and a soluble form of FZD, secreted 
Frizzled-Related Proteins (SFRP1). DKKs (DKK1-4), is a family of secreted 
glycoproteins that inhibit WNT-ligands interaction with LRP5/6-FZD complexes and 
prevents the WNT/FZD/LRP5/6 formation. DKKs are therefore seen as negative 
regulators of the WNT/β-catenin signaling pathway (Bourhis et al., 2010; Krupnik et 
al., 1999; Mao et al., 2001; MacDonald et al., 2009). Expression of DKK1 is required 
for proper neuronal development during the embryonic period, regulating normal 
formation of the midbrain structure (Glinka et al., 1998). The family of SFRP1-5 is 
structurally related to the WNT-binding CRD of the FZDs. The SFRPs are suggested 
to interact with WNTs and thereby inhibit WNT-ligands interaction with FZDs and 
induced signaling (Kawano and Kypta, 2003; Rattner et al., 1997). In addition, 
increased WNT signaling due to decreased expression of SFRPs is related to human 
breast tumors and associated with poor prognosis (Schlange et al., 2007). However, 
the CRD of SFRP can interact with other CRDs, including FZDs (Bafico et al., 1999), 
and this results in biphasic effects, i.e. high concentrations of SFRP1 decrease 
WNT/β-catenin signaling, whereas low SFRP1 concentrations induce β-catenin 
stabilization (Uren et al., 2000). 
Proliferation assay 
Since proliferation is one of the hallmarks of microglia proinflammatory 
transformation, we have measured cell number by two techniques: MTT assay and 
direct cell counting. This use of the MTT assay is somewhat indirect, since it actually 
measures cell viability (Gerlier & Thomasset, 1986). This non-radioactive colometric 
assay uses MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and is 
based on the capacity of mitochondrial enzymes of active cells to transform and cleave 
the MTT tetrazolium salt into MTT formazan. The readout is a measure of cell 
viability, which is proportional to the number of living cells (Mosmann, 1983). We 
have additionally confirmed the proliferation by counting trypsinized cells in a Bürker-
chamber. 
Gene-expression analysis 
There are various methods for detecting expression of genes. In this thesis, polymerase 
chain reaction (PCR) techniques have been used to detect and quantify mRNA levels of 
FZD receptor expression and inflammatory molecules. PCR is a fast and straight 
forward method which does not require much material. Reverse transcriptase–PCR 
(RT-PCR) is an end-point technique to analyze the presence of genes, such as 
receptors. For a more quantitative method, where it is possible to track every cycle, and 
to measure differences between gene expression in different samples we have used 
Real-Time-PCR (QPCR). Primer efficiency has been tested by the manufacturer 
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(Applied Biosystems) and shown to be close to 100% for all the primers we used. In 
Paper IV, the same primer efficiency was additionally confirmed on the FZD probes by 
the CT slope method over six serial cDNA dilutions. Thus, direct comparison and 
quantitative statements about relative FZD expression levels are justified. QPCR is an 
easy-to-use technique that does not require a postreaction analysis as for the RT-PCR 
(end-product is loaded onto a gel to analyze). However, the mRNA levels do not 
always correspond to the actual protein levels expressed, and in this thesis, some of the 
data are additionally confirmed by combining expression analysis with a protein 
detection technique: immunoblotting, ELISA or mesoscale. In order to perform protein 
detection, it is essentially that functional and reliable antibodies are available. 
Microarray mRNA technique is a useful method for comparing many genes at the same 
time in different stimulated cells, and was used in Paper I: the Affymetrix Expression 
Analysis on 6 h 300 ng/ml WNT-3A vs. control stimulated primary microglia cells. To 
trace any DNA contamination, the mRNA was first quality controlled with the sensitive 
Agilent Bioanalyzer and further analyzed on an Affymetrix Mouse Gene 1.0 ST Array 
at the Bioinformatics and Expression Analysis Core Facility, Department of 
Biosciences and Nutrition, Karolinska Institute. This technique allowed us to analyze 
the expression of 28 000 genes at the same time.  
Antibody-based techniques: Immunohistochemistry, 
immunocytochemistry and immunoblotting 
Upon activation, many proteins become phosphorylated, such as several of the MAPKs 
e.g. ERK1/2 and the scaffold protein DVL, or the protein expression is regulated, as in 
the case of β-catenin. These changes can be visualized by many antibody-based 
techniques because today, many companies sell antibodies against both the normal and 
the phosphorylated form of a protein. To test antibody specificity, the antibodies were 
used on whole cell lysates from unstimulated control cells vs. stimulated cells, 
separated according to size and charge by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to protein binding membranes 
(immobilon-P membranes (Millipore)). After incubation with primary antibody, 
proteins could be visualized by enhanced chemiluminescence with the secondary 
antibodies conjugated to horseradish peroxidase. By loading a known protein-ladder 
next to the sample, the size of visualized proteins can be determined. If only one band 
appears at the right size, the antibody has high specificity and can be considered 
reliable for immunohistochemistry or immunocytochemistry, when the secondary 
antibody is labeled to a fluorophore. What needs to be considered is that in 
immunoblotting, proteins are denatured and elongated which can lead to exposure of 
epitopes that are normally hidden in the 3-D-structure. This can be overcome by the use 
of polyclonal antibodies, i.e., antibodies against several epitopes on the same protein. 
G protein activation assays 
Heterotrimeric G proteins represent the immediate cytoplasmic transducers of GPCRs. 
GPCR-mediated signaling is a fast response: upon ligand-GPCR-interaction the 
receptor undergoes a conformational change which enhances its guanine nucleotide 
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exchange factor activity towards the α-subunit. This results in a guanine nucleotide 
exchange of GDP for GTP at the heterotrimeric Gα protein and a dissociation of the βγ 
subunit (Cabrera-Vera et al., 2003; Oldham and Hamm, 2008). Depending on the G 
protein family that is involved, both α and βγ subunits activate diverse effectors 
(Gilman, 1987; Dorsam and Gutkind, 2007; Oldham and Hamm, 2008). In the [γ-
35
S]GTP assay, which involves preparing cell membranes and stimulating them with 
WNTs in the presence of GDP and the non-hydrolyzable GTP analogue [γ-35S]GTP, it 
is possible to measure the increase in the rate of GDP/GTP exchange of membrane-
associated G proteins (Harrison and Traynor, 2003).  
Adenosine 3’5’-cyclic monophosphate (cAMP) is a second messenger important 
in many biological processes. cAMP is synthesized from ATP by adenylyl cyclase 
which is located on the inner side of the plasma membrane and is in turn activated by 
the Gαs subunit of a G protein, and inhibited by the Gαi/o subunit. The response is 
compared with that elicited by forskolin, a direct adenylyl cyclase stimulator: if cAMP 
levels decrease in a dose-dependent manner, this would functionally confirm activation 
of Gαi/o proteins. The method that has been used is a sensitive semiautomatic 
modification of a protein binding assay, in which cAMP-dependent protein kinase from 
bovine adrenal cortices is used for binding protein and [
3
H]cAMP is used as a tracer 
(Nordstedt and Fredholm, 1990). Before incubation with drugs, the cells are washed in 
the presence of a phosphodiesterase inhibitor, and cAMP can be extracted with 
perchloric acid. Defined concentrations of cAMP and [
3
H]cAMP are added in 
combination with the binding protein, and later transferred onto filter plates which can 
be measured by a Ria-Gamma counter.  
Changes in intracellular Ca
2+
 are regulated via GPCR activation through the 
release of βγ and the subsequent PLC-dependent production of inositoltrisphosphate 
(IP3). The WNT-induced Ca
2+ 
release is dependent on Gi/o and Gq family proteins and 
was the first WNT-induced β-catenin independent pathway described (Moon et al., 
1993; Kühl et al., 2000b). In this thesis Ca
2+
 influx has been measured in Fluo-3 
stained, unfixed microglia cells. Fluo-3 is a single wavelength dye and one of the 
most popular and widely used Ca
2+
 indicators (Paredes et al., 2008), and has been 
used for Ca
2+
 influx in microglia (Nolte et al., 1996).  
Invasion assay 
Enhanced capability to invade into surroundings is a hallmark of proinflammatory 
activation of microglia. We have implemented a three-dimensional collagen assay to 
trace fluorescently labeled invading microglia into a collagen matrix. The microglia are 
seeded on top of the collagen matrix layer, and at the same time stimulated with WNTs. 
WNTs are small lipoglycoproteins, and can diffuse freely in the collagen, therefore, this 
is not considered as a chemotactic assay. Microglia invasion actually requires both 
migration and degradation of the basement gel component, collagen 1.  
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RESULTS AND DISCUSSION 
 
WNT-proteins and receptors in microglia and N13  
WNTs are widely expressed in the human and mouse brain (Inestrosa and Arenas, 
2010; Malaterre et al., 2007), and today it is known that WNTs are important for 
regeneration and for homeostatic maintenance of neurons (Chien et al., 2009; Inestrosa 
and Arenas, 2010). It is not known what type of influence WNTs have on microglia 
functions. The first thing to investigate, is if microglia express WNT-receptors at all, 
since such receptors are required if the cells are able to respond to WNT-stimulation, 
and second, to evaluate the microglia-like cell line N13 is a good model by comparison 
with cultured primary microglia cells isolated from mice. By using RT-PCR in paper I 
we found out that N13 expresses FZD2,4,5,7,8,9 and the co-receptors LRP5/6, thus being 
similar to primary microglia that have a receptor repertoire consisting of FZD4,5,7,8 
(paper I) and the co-receptors LRP5/6. At the same time, neither of the cell types 
expressed the co-receptor ROR1/2 or RYK. Using affimetrix gene microarray and 
QPCR (paper IV) we confirmed our findings in primary microglia, however, according 
to the microarray, a low expression of ROR2 and high expression of RYK was detected 
(Figure 5). With the microarray we also profiled the WNTs that microglia cells express 
themselves (Figure 6). In paper I, we also used RT-PCR on whole mouse brain cDNA 
to show that WNT-1,-2,-3 and 7A are expressed in CNS and can putatively induce the 
WNT/β-catenin signaling pathways in microglia (Shimizu et al., 1997; Nusse, 2003; 
Hwang et al., 2004; Malaterre et al., 2007; Schulte, 2010a). 
 
 
 
Figure 5: The WNT-receptor expression profile of mouse primary microglia according to 
affimetrix microarray. The dotted line shows the baseline of expressed genes. Mouse microglia 
have the receptor repertoire consisting of FZD1,3,5,7,8,10 and the co-receptors LRP5/6. To note, 
according to the microarray, microglia also express ROR2 and RYK.  
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Figure 5: The WNT-expression profile of mouse primary microglia. According to the 
affimterix expression analysis primay microglia express WNT-4, -5B, -6, and -9A. The dotted 
line shows the baseline of expressed genes.  
 
Recombinant WNT-3A effects on microglia 
WNT-3A-induced intracellular pathway in microglia  
It is widely accepted that WNT-3A belongs to the WNT family that activates the β-
catenin-dependent pathway (Shimizu et al., 1997; Nusse, 2003; Bryja et al., 2007a). In 
paper I, we show by immunoblotting and immunocytochemistry that microglia cells 
respond to recombinant and purified WNT-3A with a dose- and time-dependent 
accumulation of β-catenin and, furthermore, that β-catenin translocates into the cells’ 
nuclei. We also show that WNT-3A stimulation induces classical hallmarks of the β-
catenin-dependent pathway such as phosphorylation of the co-receptor LRP6 and 
phosphorylation and shifting of the scaffold protein DVL (MacDonald et al., 2009).  
In paper II, we show by immunoblotting that in parallel to the β-catenin pathway, 
but with slightly different kinetics, WNT-3A stimulation of microglia also induces a 
dose- and time-dependent phosphorylation of a classical downstream target of GPCRs, 
the mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase 
(ERK1/2) (Gutkind, 2000). ERK1/2 activation is a well-known modulator of microglia 
activity (Koistinaho and Koistinaho, 2002) and different MAPK have been assigned 
important but yet poorly defined roles in the regulation of and crosstalk with the 
WNT/β-catenin pathway (Bikkavilli and Malbon, 2009; Wolf et al., 2011; Krejci et 
al., 2012). The WNT-3A-induced P-ERK1/2 has an earlier onset, with a maximum at 
60 min, in comparison to WNT-3A-induced-β-catenin stimulation which has an onset 
at 30-60 min and a long-lasting response with maximal levels even after 24 h. By pre-
treating the cells with 1 mg/ml Dickkopf 1 (DKK1), a LRP5/6 inhibitor known to block 
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the WNT/β-catenin pathway (Mao et al., 2001), we could block WNT-3A-induced β-
catenin stabilization but not the formation of PS-DVL or P-ERK1/2. This indicates that 
the signaling routes are separate and that WNT-3A induction of P-ERK1/2 might be 
accomplished through a WNT/FZD complex independent of the LRP5/6 co-receptor. 
This finding was confirmed when by the use of casein kinase 1 inhibitor D4476 
(10µM), which is known to block the formation of PS-DVL and β-catenin stabilization 
(Bryja et al., 2007b). When D4476 was given prior to WNT-3A stimulation, ERK1/2 
was phosphorylated even though the upstream LRP6 phosphorylation remained 
unaffected. To further support our hypothesis that WNT-3A-induced P-ERK1/2 is a 
distinct signaling route not downstream of β-catenin, we used a pharmacological 
GSK3β inhibitor (GSK3β inhibitor 1V). In these experiments, the GSK3β inhibitor (20 
µM) induced comparable levels of β-catenin accumulation, but did not affect upstream 
events, i.e. the formation of PS-DVL or P-LRP6. Moreover, the GSK3β inhibitor could 
not induce P-ERK1/2.  
To dissect the signaling cascade induced by WNT-3A from the FZD receptor to 
phosphorylation of ERK1/2, we used a battery of well-characterized pharmacological 
inhibitors against different cascade proteins. It happens that recombinant proteins on 
the market are contaminated and impure, and may thus induce unspecific events 
(Cajanek et al., 2010). So to confirm the purity of the recombinant WNT-3A sample, 
we mixed WNT-3A with a soluble Frizzled-related protein 1 (SFRP1), that binds to the 
WNT protein and would inhibit any WNT-induced signaling pathway (Kawano and 
Kypta, 2003), before adding it on the microglia. After this treatment, addition of 
recombinant WNT-3A did not lead to LRP6 phosphorylation, PS-DVL formation, β-
catenin stabilization or phosphorylation of ERK1/2, proving that it is only WNT-3A in 
the sample that induces this cascade and not a contaminant. ERK1/2 phosphorylation is 
known to be induced by seven-transmembrane receptors, and our inhibitory battery was 
selected based on that knowledge. The first inhibitor we used was the well-known 
Gαi/o-protein inhibitor PTX (Birnbaumer et al., 1990), which ADP-ribosylates the α 
subunit of Gαi/o family of proteins. We also used a βγ-effector interaction inhibitor 
(M119) (Bonacci et al., 2006), a phospholipase C (PLC) inhibitor (U73122) (Bleasdale 
et al., 1989), a calcium chelator (BAPTA-AM) (Nq et al., 1988), an two MEK 1/2 
inhibitors (SL327 (Selcher et al., 1999) and PD098059) (Marchetti and Pluchino, 
2013), which all blocked the ERK1/2 phosphorylation induced by100ng/mL WNT-3A, 
at 30 min and 2h. Since the calcium chelator blunted WNT-3A-induced P-ERK1/2 we 
continued by using two different Ca
2+
-dependent protein kinase (PKC) inhibitors: BIS 
(VIII) and Ro 318220 (Davis et al., 1992), and two different Phosphatidylinositol 3’-
kinase (PI3K) inhibitors: Wortmannin and LY94002 (Wymann and Schultz, 2012), 
which did not block WNT-3A-induced P-ERK1/2. Figure 6 shows a schematic 
diagram summarize the WNT-3A induced signaling pathway investigated in this study. 
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Figure 6: Schematic diagram figure summarize the WNT-3A-induced WNT/β-catenin 
and WNT/ERK1/2 signaling in microglia. The WNT-3A-induced signaling pathway 
indicates the central role of the PTX sensitive Gαi/o proteins in both branches. Pharmacological 
inhibitors used in this study are labeled in light gray. The question mark indicates insecurity in 
the pathway continuation. 
 
Interestingly, in paper II, for the first time on endogenously expressed FZDs, we show 
by immunoblotting that pre-treatment with PTX, but not with the βγ-blocker M119, 
completely abolished the WNT-3A-induced LRP6-phosphorylation, PS-DVL 
formation and β-catenin stabilization. This indicates that WNT-3A-induced 
phosphorylation of LRP6 requires Gαi/o subunits, subsequent PS-DVL3 and β-catenin 
stabilization. This is in line with what has been shown on L929 cells, a mouse 
fibroblast cell line, where PTX blocks WNT-3A-induced disruption of the 
GSK3β/Axin complex (Katanaev et al., 2005; Liu et al., 2005). In addition, the use of 
the βγ inhibitor M119 clarifies that WNT-3A-dependent communication with PLC but 
not with LRP6/β-catenin requires the release of βγ subunits from the Gαi/o. Thus these 
data indicate that WNT-3A-induced signaling in microglia regulates and mediates 
crosstalk between β-catenin-dependent and –independent pathways through the PTX-
sensitive heterotrimeric Gαi/o proteins upstream of the FZD/LRP6 receptor complex 
(Figure 6). In paper III, by use of the [γ-35S] GTP-assay, we showed WNT-3A-induced 
GDP/GTP exchange on N13 membrane preparations, which in addition confirms 
WNT-3A-induced activation of G proteins in microglia, and that endogenous FZDs are 
capable of working as conventional GPCRs. However, it remains unclear if the WNT-
3A-induced signaling axes depend on identical or different FZD-isoforms. 
Hypothetically, WNT-3A stimulation could recruit LRP6-FZDx for the WNT/β-catenin 
pathway, whereas ERK1/2-induced signaling could be mediated by FZDy in the 
absence of LRP6 recruitment, or by another FZDy/z. To date, owing to the lack of 
pharmacological tools selective for the FZD isoforms, this hypothesis remains untested.  
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WNT-3A proinflammatory modulation of microglia activity  
Hallmarks for microglia proinflammatory activation can be proliferation, 
morphological changes, phagocytosis, increased cytokine and chemokine expression 
etc. (Kühl et al., 2000b; Lynch, 2009; Kettenmann et al., 2011). In addition, β-catenin-
dependent signaling can evoke proliferative effects in cell culture systems (Castelo-
Branco et al., 2003; Boland et al., 2004; Yun et al., 2005). We studied whether WNT-
3A effects microglia proliferation. To do this, N13 cells were seeded in 24-well plates 
and starved for 24 h before stimulation with 300 ng/mL WNT-3A, corresponding 
control (1% BSA), and 10% FBS. After 24 h the cells were detached with trypsin and 
counted in a Bürker-chamber. WNT-3A does not induce microglia proliferation, in 
comparison to cells with serum-starved media and the positive control FBS-stimulated 
cells whose numbers increased by 10%. These data are additionally confirmed in paper 
III by a MTT assay. The second step was to address another hallmark of 
proinflammatory microglia, namely cytokine expression and release (Lynch, 2009; 
Kettenmann et al., 2011). After 24 h of stimulation with 300 ng/mL of WNT-3A, 
medium was collected for ELISA and mRNA was isolated and synthesized to cDNA 
for QPCR analysis of the proinflammatory cytokines IL-6, IL-12 and TNFα. The 
increased mRNA levels were related to the released cytokines in the media. 
Furthermore, we continued the readout of these data by an affimetrix genome-wide 
expression profiling. After 6 h of stimulation with 300ng/mL WNT-3A, a whole range 
of proinflammatory  genes was induced, such as soluble proinflammatory factors (IL-6, 
IL-1α and chemokines), iNOS, members of the TNF superfamily, the crucial player of 
prostanoid synthesis COX2 (Minghetti and Levi, 1998), matrix metalloproteases etc. 
(see figure 7, paper I). These data show that WNT-3A induces proinflammatory 
(fingerprint) transformation of microglia.  
In paper II, where we dissected the WNT-3A induced signaling pathway, we also 
looked at COX2 expression by immunoblotting, and showed that the MEK1/2 inhibitor 
(SL327), completely blocked the WNT-3A-induced COX2 expression in microglia. 
These data are surprising because COX2 expression has been identified as a 
downstream target for WNT/β-catenin signaling (Haertel-Wiesmann et al., 2000; 
Pishvaian and Byers, 2007; Yun and Im, 2007). In another recent study, WNT-3A 
stimulation of primary rat microglia leads to the secretion of exosomes independently 
of GSK3 (Hooper et al., 2012). This further suggests an important role of the WNT-3A-
induced β-catenin-independent signaling pathway in microglia. 
β-catenin expression in microglia in AD 
AD is a serious neurodegenerative condition with chronic inflammation owing to a 
high presence of activated microglia (Pocock et al., 2002; Rivest, 2009; Morales et al., 
2010; Wilkinson and El Khory, 2012). The role of microglia in AD appears to be 
double-edged: on one hand microglia cells are supposed to diminish the disease by 
clearing amyloid-beta (Aβ) aggregates and dead neurons (Hanisch and Kettenmann, 
2007; Farfara et al., 2008), but on the other hand, when the neuroinflammatory 
condition persists, microglia seem to have detrimental effects (Farfara et al., 2008). In 
Carina Halleskog 
30 
AD, GSK3 plays a central role in the development of the disease with regard to 
inflammation, Aβ-formation, APP cleavage and the hyperphosphorylating of tau to 
form intracellular tangle (Pei et al., 1999; Hooper et al., 2008). Restoring WNT/β-
catenin signaling through GSK3 inhibition seems to have a neuroprotective potential 
both by diminishing Aβ neurotoxicity and by reducing tau hyperphosphorylation 
(Alvarez et al., 2004). In addition, Dickkopf-1 (DKK1) treatment reinforces beneficial 
effects of WNT signaling in neuronal survival (Caricasole et al., 2004) suggesting a 
beneficial effect of maintaining neuronal β-catenin by pharmacological GSK3 
inhibitors or enhanced WNT signaling (Alvarez et al., 2004; De Ferrari and Moon, 
2006; Dinamarca et al., 2008; Inestrosa and Arenas, 2010). Furthermore, GSK3 
blockade by LiCl has improved memory performance in the AD mouse model APdE9 
(Toledo and Inestrosa, 2009). Interestingly, no one has studied β-catenin levels in 
microglia cells before, and it is unknown whether the treatment with a GSK3 inhibitor 
would be able to exacerbate microglia-mediated inflammatory reaction.   
With protein-specific antibodies we could do immunohistochemistry on 
postmortem brain tissue from patients with AD vs. age-matched controls to evaluate the 
β-catenin levels in microglia cells. We found a low to moderate staining of β-catenin in 
perikarya and intensely labeled nuclei of cells with multipolar and fine-caliber 
processes, likely representing micro- or astroglia cells. By combining the β-catenin 
staining with the microglia marker Ionized calcium-binding adapter molecule-1 (IBA-
1) (Akiyama and McGeer, 1990) we found closely associated immunoreactivities in 
brain from patients with Braak stage VI. Cells that stained positively for IBA-1, i.e. 
activated microglia (or macrophages) which, were surrounded by dystrophobic neurons 
that were AT8-positive (i.e. hyperphosphorylated tau AT8 (Porzig et al., 2007). This 
was additionally confirmed by the co-expression of IBA-1 and the cannabinoid 
receptor: CB2R, which has enhanced expression on glia in neuritic plaques (Walter et 
al., 2003). Comparison of these data with data obtained in postmortem brain tissue 
from healthy subjects, suggests a shift of β-catenin expression from neurons towards 
(micro-) glia in patients with AD-related neuroinflammation. In addition, co-staining 
with β-catenin and the astrocytic marker glial fibrillary acidic protein (GFAP) showed 
that β-catenin levels are generally low in astrocytes, irrespective of the AD stage.  
Microglia cells have the capacity of phenotypic transformation, from a ramified 
stage to a more actively moving amoeboid/macrophage-like stage with phagocytic 
capability (Kettenmann et al., 2011; Marin-Teva et al., 2011). Therefore, we wanted to 
see if β-catenin stabilization in microglia cells can be connected particularly to any of 
the different phenotypes. From our histochemistry images we concluded that ramified 
microglia expressed less β-catenin, whilst active mobile microglia progressing towards 
an amoeboid structure were β-catenin positive. The β-catenin in these round microglia, 
appeared to be located in the cytosol, submembraneously or in the cell nuclei though 
the precise location could not be determined because of the limited resolution of the 
microscope (see Fig 2, paper I). To provide biochemical support for our hypothesis that 
microglia have higher expression of β-catenin in AD subjects, we did immunoblotting 
and densitometric quantification of the bands and normalization of β-catenin, GFAP, 
CB2R intensities to β-actin (as a loading marker). We plotted β-catenin-stained cells 
and CB2R-stained cells, for individual control, moderate AD and severe AD, and 
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compared it with the astrocytic marker GFAP together with β-catenin in a regression 
analysis. In comparison to aged-matched controls or subjects with moderate AD, we 
found significantly increased levels of CB2R in subjects with severe AD. Furthermore, 
we found a close relationship between β-catenin and CB2R in severe AD cases but only 
a quasi-random relationship in control and moderate AD cases. These neuroanatomical 
and biochemical findings, together, confirm that β-catenin expression is significantly 
increased in microglia, or invaded peripheral macrophages, in AD.  
To support our findings in human AD, we moved to an AD-like mouse model, the 
APdE9 mice. The APdE9 mice show pathology comparable with the human AD, such 
as chronic inflammation, microgliosis and astrogliosis, progressive β-amyloid 
production, increased production of inflammatory cytokines, and an increased activity 
of the complement system. TNFα is an example of a proinflammatory cytokine 
increased in neuroinflammatory processes (Jankowsky et al., 2004; Sriram and 
O'Callaghan, 2007). Thus, using QPCR to measure mRNA levels of TNFα in the brain, 
we could confirm the inflammation with a significantly increased TNFα expression in 
the APdE9 mouse vs. wild-type aged-matched controls, 7 and 12 months of age. 
Furthermore, immunoblotting showed that total β-catenin levels were increased, by 
29±13%, in APdE9 mice at 14 months of age. Interestingly, in the polymorph layer of 
the dentate gyrus, which is considered to play a crucial role in associative memory 
(Ohm, 2007), β-catenin was increased in microglia in the elderly wild-type mice 
(Figure 7), which can be explained by aging also being associated with a progressive 
inflammatory reaction with a transformation of microglia morphology and function 
(Akiyama et al., 2000; Pocock and Liddle, 2001). Additionally, β-catenin was 
accumulated in microglia in the brain of the APdE9 mice (Figure 7). Taken together, 
these facts show that β-catenin, is stabilized in activated and proinflammatory microglia 
in AD.  
 
 
Figure 7: Increased β-catenin levels in microglia in elderly and APdE9 mice. Fluorescent 
immunohistochemistry was performed on brain sections from wild-type and APdE9 mice. The 
image show cellular distribution of β-catenin (green), IBA-1 (red, microglia marker) and GFAP 
(blue, astrocyte marker) in the hippocampus. Co-localization of β-catenin and IBA-1 identify 
increased levels of β-catenin in microglia in the ageing and in the APdE9 mice. Scale bars 15 
µM and insets 5µM.  
 
To exclude other soluble molecules affecting microglia and/or GSK3 activity from 
being the cause of the β-catenin stabilization in microglia in AD and in the aging brain, 
we exposed N13 to several microglia activators for 1h: LPS, interferon α/β, ATP, 
insulin, TNFα, UTP, NECA, isoproterenol, apomorphine, thrombin, glutamate (Jin et 
Wild-type 9 month Wild-type 1 year APdE9 1 year 
 
Carina Halleskog 
32 
al., 2008; Amor et al., 2010). Displayed by immunoblotting, only the stimulation with 
WNT-3A and the GSK3 inhibitor LiCl (O'Brien and Klein, 2009) induced β-catenin 
stabilization, in microglia. Furthermore, considering that Aβ has been shown to bind 
and activate FZD (Magdesian et al., 2008), Aβ-treatment in N13 for 24h induced 
another hallmark of microglia proinflammatory activation: iNOS expression (Hanisch 
and Kettenmann, 2007; Brown and Neher, 2009). Nevertheless, the β-catenin levels 
remained unaffected. In paper III, in the screen of all the commercially available 
recombinant WNTs on the market, it was only WNT-3A that induced β-catenin 
accumulation in N13.  
Other WNTs affecting microglia in a G protein- dependent 
manner 
Because of difficulties purifying active WNTs only a subset of the 19 mammalian 
WNT isoforms have ever been available in recombinant form for use in experimental 
studies in vitro i.e., WNT-3A, -4, -5A, -5B, -7A and -9B (Willert, 2008). In paper I, we 
show on mRNA levels that the microglia-like cell line N13 has the FZD receptor 
repertoire of FZD2,4,5,7,8,9. These data are confirmed in another study by Kilander et al., 
(2011), where QPCR analysis revealed the following expression pattern: 
FZD5>FZD7>FZD2, and low levels of FZD4 and FZD2 in N13 (Kilander et al., 2011a). 
In paper III, we compared the efficacy of the different recombinant WNTs on N13, 
with regard to LRP6 phosphorylation, β-catenin stabilization, ability to form PS-DVL, 
G protein activation and a physiological outcome: proliferation. By immunoblotting on 
lysates of stimulated cells, we could see that all the WNTs induce phosphorylation and 
shift of DVL3, after 2 h of stimulation with 200 ng/ml WNT, and WNT-3A and -4 
elicited the strongest activation (Table 2). We evaluate the purity of the recombinant 
WNT samples, by using SFRP1 and found that all the WNT-induced PS-DVL3 
formation was completely blocked, except for WNT-9B. This can be explained by 
existence of other SFRPs that could be more specific for certain WNTs, for example 
SFRP4 has low affinity to WNT-3A, but high affinity to WNT-7A (Carmon and 
Loose, 2010). Continuing with immunoblotting we also could see that only WNT-3A 
induced the hallmarks of WNT/β-catenin signaling, i.e. P-LRP6 and β-catenin 
stabilization. To measure WNTs’ ability to activate G proteins, we measured WNT-
induced GDP/GTP-exchange in N13-membrane preparations, using an assay based on 
the hydrolysis-resistant γ-35S-labeled GTP (Milligan, 2003). All the WNTs induced the 
exchange, which corroborates the findings of other recent studies showing that WNTs 
are capable of activating heterotrimeric G proteins (Liu et al., 2005; Koval and 
Katanaev, 2011; Kilander et al., 2011a). FZD5 as the dominant receptor expressed by 
N13, is also an established WNT-5A receptor (He et al., 1997; Säfholm et al., 2006; 
Kurayoshi et al., 2007; Kilander et al., 2011a). The WNTs with highest efficacy to 
induce G protein (WNT-5A and -9B) also induced proliferation, measured by MTT-
assay, where the cells’ measured viability correlates with cell number (Gerlier and 
Thomasset, 1986), after 40 h of stimulation. 
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Table 2: Results of the WNTs used in paper III. The WNT preparations are commercially 
available from R&D Systems. The WNT's capacity to transform C57MG cells and their 
expression in the brain was summarized from the literature (for references see text in paper III). 
Further, data from the present study are summarized. - no activation; + weak activation; ++ 
intermediate activation; +++ strong activation. 
 
WNT 
Transformation 
of C57MG cells 
Expression 
in the 
brain 
P-
LRP6 
-catenin 
stabilization 
PS-
DVL3 
G protein 
activation 
Proliferation 
WNT-3A +++ - +++ +++ +++ + - 
WNT-4 - + - - +++ + - 
WNT-5A - + - - ++ +++ + 
WNT-5B - + - - + ++ - 
WNT-7A + + - - + + - 
WNT-9B + + - - + +++ + 
Effects of recombinant WNT-5A- on microglia 
WNT-5A-induced signaling pathway in microglia 
 
WNT-5A has a huge impact on morphogenesis, neurogenesis and tissue homeostasis 
(Castelo-Branco et al., 2006; Pukrop and Binder, 2008) and there is evidence that 
WNT-5A is crucial for macrophage-induced invasion of breast cancer cells (Pukrop et 
al., 2006). These observations, in combination with the fact that the N13 microglia-like 
cell line responds to recombinant WNT-5A signaling by activation of heterotrimeric G 
proteins, PS-DVL formation and proliferation (Kilander et al., 2011a) made us 
interested to investigate what intracellular pathways are induced by WNT-5A and what 
physiological outcome they can have on primary microglia. First of all, we searched for 
an endogenous source of WNT-5A, and using immunohistochemistry, immunoblotting 
and QPCR, we found that astrocytes express high levels of WNT-5A, and therefore can 
be a possible paracrine WNT-5A-based communication between astrocytes and 
microglia. In agreement with earlier findings (Bryja et al., 2007b, 2008), stimulation 
with 300 ng/ml WNT-5A induced a β-catenin-independent pathway in primary 
microglia. WNT-5A stimulation did not affect β-catenin stabilization or LRP6 
phosphorylation as WNT-3A, but induced a dose- and time-dependent phosphorylation 
of ERK1/2 and PS-DVL3 formation. The amount of WNT-5A-induced P-ERK1/2 
reached a maximum at 30 minutes (198±6.2%), and returned to basal levels after 2 h. 
When SFRP1 was used, the effect of WNT-5A on microglia was abolished, confirming 
the purity of the recombinant WNT-5A batches that have been used throughout this 
study.   
In order to dissect and characterize the WNT-5A-induced signaling route from 
FZD to ERK1/2 phosphorylation, we employed the same series of pharmacological 
inhibitors as in the study on WNT-3A, and continued by using several biochemical 
techniques to measure WNT-5A induced signaling activity. To start with, by 
immunoblotting we found that PTX, the inhibitor of Gαi/o proteins, abrogated the 
WNT-5A induced P-ERK1/2 but not the PS-DVL3 formation. PTX also blocked 
WNT-5A-induced P-ERK1/2 immunoreactivity as shown by immunocytochemistry. 
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The activation of heterotrimeric G proteins was measured by [γ-35-S]-GTP assay where 
the WNT-5A-induced GDP/GTP exchange was measured on primary microglia 
membrane preparations, and showed an activity of 157.7±4.3%. We went on by using 
RT-PCR to characterize the PTX-sensitive Gαi/o proteins expressed in microglia: Gαi1-
i3, Gαo. All these can typically reduce cAMP levels and induce changes in intracellular 
calcium concentrations ([Ca
2+
]i) through Gαi/o proteins with the release of βγ, and PLC-
dependent production of inositoltrisphosphate (Dorsam and Gutkind, 2007). Indeed, 
WNT-5A dose-dependently reduced the adenylyl cyclase inhibitor (forskolin)-induced 
cAMP levels, measured in a competitive protein binding assay with [
3
H]-labeled-
cAMP (Nordstedt and Fredholm, 1990). Further, changes in [Ca
2+
]i induced by WNT-
5A in a PTX-sensitive manner was measured through live cell imaging of Fluo-3-
loaded primary microglia. Based on these findings we hypothesized that WNT-5A-
induced P-ERK1/2 involves a classical MAPK cascade consisting of G protein 
activation, βγ release, recruitment of PLC, Ca2+ and Ca2+-dependent PKC (Dorsam and 
Gutkind, 2007), and independently of PS-DVL formation. This pathway was 
confirmed by immunoblotting when we employed all the previously described 
inhibitors where M119 (βγ-inhibitor), U73122 (PLC inhibitor), BIS (PKC-inhibitor), 
BAPTA-AM (Ca
2+
 chelator), and SL327 (MEK1/2 inhibitor) blocked the WNT-5A-
induced P-ERK1/2, but not wortmannin or LY294002 (PI3L inhibitor), or D4476 (CK1 
inhibitor). In summary, for the first time, we showed that WNT-5A can, besides 
activating the PS-DVL-dependent pathway, recruits a separate signaling axis consisting 
of Gαi protein, PLC, PKC, and MEK1/2 to regulate P-ERK1/2, see Figure 8. 
 
 
Figure 8: Schematic overview summarizes the WNT-5A-induced WNT/ERK1/2 signaling 
in microglia. WNT-5A is produced by astrocytes, received by microglia, where is triggers a 
Gαi-protein, PLC, PKC, and MEK1/2 axis to regulate P-ERK1/2. The pharmacological 
inhibitors that exerted an inhibitory effect in this study are labeled in light gray. The question 
mark indicates insecurity in the pathway continuation. 
WNT signaling in microglia 
  35 
WNT-5A-induced proinflammatory transformation of microglia 
The heterogeneity of microglia cells renders them capable of responding to an injury in 
different ways (Scheffel et al., 2013) An injury in vivo would induce the release of 
activators that would make microglia able to; proliferate, communicate (secreting 
cytokines), migrate towards the injury (through chemotaxis), or, if necessary, invade 
(by inducing the expression of metalloproteases) (Choi et al., 2010; Kettenmann et al., 
2011). Since WNT-5A-induced P-ERK1/2 and the ERK1/2 cascade is an established 
proliferative pathway with proinflammatory functions, it is likely that stimulation by 
WNT-5A induces a proinflammatory transformation of microglia. Indeed, WNT-5A 
stimulation for 6 h induces expression of iNOS, COX2 and TNFα in microglia, 
measured by immunoblotting. Release of TNFα was further confirmed by mesoscale 
measurements on medium after 24 h control versus WNT-5A-stimulation. Further, 
WNT-5A stimulation led to proliferation and invasion of microglia, in a G protein, 
ERK1/2-activation sensitive manner. The proliferation was both measured by the MTT 
assay and confirmed by counting in cell number. By employing 100 ng/ml PTX or 10 
µM SL327 (the MEK1/2 inhibitor) in the MTT assay, we inhibited WNT-5A-induced 
proliferation and supported our hypothesis that the Gαi-PLC-PKC-MEK1/2-ERK1/2 
signaling axis is involved in WNT-5A-induced proliferation of microglia. Additionally, 
in a three-dimensional collagen invasion assay, where microglia cells are seeded on top 
of a collagen-matrix gel and stained with a cell-tracker dye (measured by confocal 
microscope Z-stack scanning), 24 h stimulation with WNT-5A induced microglia 
invasion into the gel, which was completely blocked by SL327. To continue, we 
characterized the WNT-5A-induced inflammatory fingerprint on microglia by gene 
expression analysis. RNA was isolated after 6h stimulation with WNT-5A, then 
transcribed into cDNA and analyzed by QPCR for several proinflammatory microglia 
markers: All of the following were induced (Table 3 ).  
 
i) IL-1β, IL-6, IL-12, and TNFα. These cytokines are known to be secreted by 
proinflammatory microglia for communication with surrounding microglia, 
macroglia and neurons, and infiltrating immune cells in neurodegenerative 
diseases, trauma or infection (Lynch, 2009; Kettenmann et al., 2011).  
ii) CC motif chemokines CCL7 and CCL12. These chemokines are important for 
recruitment of peripheral infiltrating immune cells, specifically monocytes and 
leukocytes (Opdenakker et al., 1993; Sarafi et al., 1997). Whereas,  
iii) Cluster of differentiation CD40 and CD69. CD40 and CD69 are expressed to 
support neuroinflammatory processes by mediating communication with 
astrocytes, infiltrating lymphocytes and natural killer cells (Marzio et al., 1999; 
Hanisch, 2002).  
iiii) Matrix metalloproteases MM9 and MMP13. MMPs play a role in extracellular 
matrix remodeling and contribute to the processing, activation and release of 
growth factors, cytokines, integrins and additional MMPS (Candelario-Jalil et 
al., 2009; Choi et al., 2010).  
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Since the ERK1/2 activation is important for WNT-5A-induced proliferation and 
invasion, we continued to use the same MEK1/2 inhibitor (SL327) to assess the role of 
ERK1/2 activation in WNT-5A-induced regulation of gene expression. Our results 
showed regulation in a bi-directional manner: WNT-5A-induced MMP9 and MMP13 
induction was blocked, which can explain the inhibited invasion, whereas WNT-5A-
induced TNFα, CCL7, CCL12, COX2 and CD40 were instead amplified (Table 3). An 
explanation for these findings may be that the WNT-5A/ERK1/2 pathway has a bi-
directional regulative role in gene expression to integrate inflammatory input, and that a 
separate PS-DVL formation pathway or other candidate that was not further 
investigated, might provide crucial crosstalk on the incoming WNT-5A stimulus.   
 
Table 3: Summary of the gene expression analysis by QPCR of microglia stimulated 6 h 
with 300 ng/ml WNT-5A, with and without 10 µM of the MEK1/2 inhibitor SL327. The 
numbers provide the percentage of WNT-5A-induced increase over control or SL327 treatment 
alone, converted from arbitrary units (fold change of unstimulated control microglia, 2-ΔΔCt). 
The ratio provides a relative measure of decrease (value <1) or increase (>1). Rows in light 
grey indicate statistically significant increase in WNT-5A-induced gene expression 
upon SL327, whereas dark grey underlines the efficient block of WNT-5A-induced 
changes in gene expression by SL327, n=4. *, P<0.05; **, P<0.01 
 
 
Gene WNT-5A WNT-5A/SL327 Ratio 
IL1 209.8±78.2 88.1±16.3 0.4 
IL6 947.0±554.4 541.0±175.8 0.6 
IL12 33622.0±26855.0 31504.0±14202.0 0.9 
TNF 43.0±5.7 366.3±84.5** 8.5 
CCL7 29.1±5.1 574.7±348.2* 19.7 
CCL12 26.7±7.0 354.7±206.3** 12.9 
COX2 93.3±30.4 448.3±169.9* 4.8 
CD40 558.0±133.0 1989.0±398.0** 3.6 
CD69 456.0±155.0 1723.0±606.0 3.8 
MMP9 5.1±1.2 1.0±0.1* 0.2 
MMP13 28.3±8.0 6.7±0.9** 0.2 
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Differences between WNT-3A- and WNT-5A-regulated ERK1/2-
signaling in microglia 
The thesis data show that both WNT-3A and WNT-5A stimulation of primary 
microglia induce ERK1/2 phosphorylation, via a similar intracellular signaling route: 
WNT-5A via a Gαi/o protein, βγ, PLC, Ca
2+
, PKC and MEK1/2 pathway, while WNT-
3A via the same pathway but apparently PKC-independent and some as yet 
unidentified steps are connecting  Ca
2+
 with the MAPK. Interestingly, WNT-3A-
induced COX2 expression is dependent on activation of ERK1/2 (paper II) while 
WNT-5A-induced COX2 was instead amplified when the MEK1/2 inhibitor SL327 
was used (10 µM) (paper IV). This outcome might have several explanations: i) 
different receptor binding and efficacy; ii) WNT-3A and WNT-5A activate parallel 
intracellular proteins that are important in inflammatory activation of microglia, but 
which we have not investigated, e.g. phosphorylation and activation of the MAPK p38, 
and NF-κB; iii) the low expression of ROR2 and RYK (according to the affimetrix 
analysis) plays a role in WNT-5A-induced cytokine expression; iiii) differing degrees 
of activity of the heterogeneous microglia.  
WNT/FZD-receptor selectivity 
In paper III, we study the efficacy various WNTs on activation of FZDs in N13. Some 
FZDs are accepted as specific receptors of specific WNTs. For example WNT-5A 
binds FZD5 (He et al., 1997; Blumenthal et al., 2006; Kikuchi et al., 2007) and WNT-
3A binds FZD2 (Mikels and Nusse, 2006a). Nonetheless, different WNTs can act on 
the same FZD (Caricasole et al., 2003; Karner et al., 2009). The QPCR data from 
paper IV revealed the FZD receptor expression pattern in primary microglia: 
FZD7>FZD3>FZD8>FZD5, and in N13 cells FZD5 is more abundant (Kilander et al., 
2011a). Further, in paper III, we show that WNT-5A amplifies WNT-3A-induced PS-
DVL formation in N13, and in paper II and IV, that the Gαi/o blocker PTX inhibits 
WNT-3A-induced but not WNT-5A-induced PS-DVL formation in primary microglia. 
In summary, these data suggest that WNT-3A and -5A binds to and act via different 
FZDs; however, we still do not know which WNT binds and activates which FZDs. 
MAPK p38 and NF-κB  
The p38 MAPK cascade is associated with signaling pathways activated in response to 
cellular stress and inflammation (Koistinaho and Koistinaho, 2002; Keshet and Seger, 
2010). Phosphorylation of the MAPK p38 is involved in the regulation of several 
cytokines expressed by microglia (Koistinaho and Koistinaho, 2002). For example, 
p38 activation is increased in spinal cord microglia cells in neuropathic and 
inflammatory pain (Ji and Suter, 2007; Gong et al., 2009), and since p38 regulates 
release of PG and NO, it may contribute to the pain and inflammation (Matsui et al., 
2010). In one study done on murine macrophages, both WNT-5A and WNT-3A 
stimulation led to phosphorylation of p38, and WNT-5A seemed to have a bit higher 
potential for p38 phosphorylation (Ji and Suter, 2007; Neumann et al., 2010). In 
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microglia, only WNT-5A stimulation (300 ng/ml) for 30 min induces phosphorylation 
of p38 (unpublished data), (Figure 9).  
 
 
Figure 9: WNT-5A stimulation induces p-p38 in microglia. Stimulation for 30 min with 300 
ng/ml recombinant WNT-5A but not 300 ng/ml WNT-3A, induces phosphorylation of the 
MAPK p38 in microglia (unpublished data). 
 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein 
complex that becomes activated in cells in response to different inflammatory stimuli, 
such as LPS and cytokines. In microglia, NF-κB controls transcription of many 
important inflammatory molecules, such as TNFα, IL-6, and IL-1β (Morales et al., 
2010). NF-κB has been shown to be activated in bone marrow macrophages by both 
WNT-3A and WNT-5A stimulation – with somewhat different onsets – but only WNT-
5A drives the NF-κB reporter gene expression (Schaale et al., 2011). NF-κB activation 
in microglia cells upon WNT stimulation has not been investigated in this thesis.  
ROR/RYK  
The ROR family of RTKs does not appear to be strongly expressed in human tissues, 
but abnormal expression of individual receptors has been reported in different kinds of 
human cancers (Ford et a., 2012). Evidence indicates at WNT-5A as the ligand for 
ROR2 and that binding leads to antagonism of WNT/β-catenin-dependent signaling and 
an activation of the WNT-JNK and calcium pathway (Oishi et al., 2003; Mikels and 
Nusse, 2006a; Schulte, 2010a). Nothing has so far been published on WNT/ROR 
signaling in microglia, although there is one study describing WNT/ROR signaling in 
bone marrow macrophages being involved in the enhancement of osteoclastogenesis 
(Maeda et a., 2012). RYK is expressed by various cell types in the spinal cord of rats, 
suggesting a role of RYK in the spinal cord under normal physiological conditions. 
Further, after spinal cord injury, the RYK expression increased in several glia cells, 
notable in activated microglia/macrophages, suggesting a biological relevance for RYK 
activity during spinal cord injury (González et al., 2013).   
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Heterogeneous microglia 
The existence of subtypes of neurons, certain glia cells and immune cells is well 
established. Recent evidence suggests that microglia may not be a single, uniform cell 
type (Olah et al., 2011; Scheffel et al., 2013). The multitude of tasks microglia manage 
to perform upon activation, such as proliferation and executive functions, may be 
explained by subgroups of microglia performing different tasks (Hanisch, 2013; 
Scheffel et al., 2013). Further, microglia are heterogeneous and can as a group of cells 
co-exist in different active states (Lynch, 2009). The diverse WNT-induced genes in 
microglia might reflect different activation states and also performance of task 
splitting. The heterogeneity of microglia is clearly visible in mouse primary microglia 
when live cell imaging assay performed, such as the Fluo-3-loaded microglia for 
[Ca
2+
]i imaging, where only a minority of cells is responsive to WNT-5A stimulation 
(Figure 10). Thus, WNT-3A and WNT-5A seem to induce different activation states 
of microglia, and probably influence differently depending on microglia’s state of 
activation.  
 
 
Figure 10: WNT-5A-induced mobilization of [Ca
2+
]i, shows the heterogeneity of microglia. 
Stimulation of Fluo-3-loaded primary microglia with WNT-5A induced fast and transient 
elevation of [Ca2+]i. ATP was used as a positive control. The [Ca
2+]i trace shown in A originates 
from a single cell. B: Shows a representative view of Fluo-3-loaded cells at baseline and upon 
WNT-5A (300 ng/ml) exposure. The images are pseudocolored with warm colors representing 
high [Ca2+]i and cold colors low [Ca
2+]i. Size bar 20µM. Typically 15-30% of the cultured 
microglia responded to WNT-5A, with mobilization of [Ca2+]i, which can be explained by their 
heterogeneity, i.e. either they exist in different stages of activity and/or they perform task 
splitting.   
WNT signaling counteracts LPS-induced proinflammation in 
microglia 
Studies on peripheral macrophages indicate that WNTs can counteract or contribute to 
an ongoing inflammation: WNT-3A acting on the FZD1 receptor exerts anti-
inflammatory effects via the WNT/β-catenin pathway to reduce mycobacterium-
induced TNFα (Neumann et al., 2010) and WNT-5A plays a critical proinflammatory 
role in patients with severe sepsis, by becoming upregulated upon LPS- and 
interferon γ treatment (Blumenthal et al., 2006; Pereira et al., 2008).  Since microglia 
are considered as the macrophages of CNS (van Rossum and Hanisch, 2004) and share 
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many similarities with peripheral macrophages (Guillemin and Brew, 2005; Saijo and 
Glass, 2011), we wanted to investigate the WNT’s potential to attenuate or impair 
already activated microglia, by combining stimulation with WNT-3A or WNT-5A the 
bacterial cell wall component LPS. LPS is well known to induce proinflammatory 
activation of microglia via Toll-like receptor 4 (TLR4) and induction of the MAPKs 
ERK and p38 (Prinz et al., 1999; Lehnardt, 2010).  
In paper V, we show irrespective of the induced signaling pathway and the 
different proinflammatory effects that WNT-3A and WNT-5A exert on microglia, both 
WNT-3A and WNT-5A act anti-inflammatory by counteracting LPS-induced COX2, 
IL-6 and TNFα. Our earlier findings were confirmed by immunoblotting of lysates of 
whole microglia cells stimulated with WNT-3A or WNT-5A for 6 h (0, 30, 100, 300, 
1000 ng/ml). This treatment dose-dependently induced expression of COX2, a generic 
marker of proinflammatory transformation (Mitchell et al., 1995). The effect was 
statistically significant at doses of 300 ng/ml and 1000 ng/ml. Strikingly, a co-
stimulation with 100 ng/ml LPS together with increasing doses of WNT-3A or WNT-
5A, dose-dependently reduced the LPS-induced COX2 expression after 6 h stimulation. 
WNT-3A reduced LPS-induced COX2 expression to 66% (300 ng/ml) and 82% (1000 
ng/ml), and WNT-5A decreased the LPS-response to 62% (300 ng/ml) and 67% (1000 
ng/ml). This result was confirmed at the gene levels by QPCR on mRNA, where the 
combination of 100 ng/ml LPS with 300 ng/ml WNT-3A or WNT-5A for 6 h 
significantly reduced LPS-induced COX2 (WNT-3A to 25%, WNT-5A to 36%). In 
addition, WNT-3A and WNT-5A significantly diminished LPS-induced mRNA 
expression of two other important proinflammatory markers (IL-6 and TNFα), WNT-
3A to 35% and 35%, respectively, and WNT-5A to 46% and 57%, respectively.  
The dual effect WNTs exert on microglia, both the pro- and anti-inflammatory 
properties, mirrors the dual role microglia have in health and diseases, providing both 
supportive and inflammatory cues depending on the physiological context (Hanisch 
and Kettenmann, 2007; Kettenmann et al., 2011; Zhang et al., 2011). In this way, 
WNTs resemble cytokines such as TNFα, acting both anti- and pro-inflammatory on 
surveying microglia, i.e. simultaneously being anti-inflammatory on pre-activated 
microglia and maintaining tissue homeostasis (Figure 11) (Lawson et al., 1990). The 
findings in paper I, where β-catenin is dramatically increased in amoeboid microglia in 
postmortem brains of patients with AD, in the AD mouse model (APdE9) and in 
elderly mice, and the fact that WNT-3A was the only factor that induced β-catenin in 
microglia and induced a substantial proinflammatory fingerprint and transformation, 
suggests that WNT promotes proinflammatory effects on microglia. However, based on 
these new findings, that WNTs’ are capable of attenuate a LPS-induced 
proinflammation, instead suggests that WNTs could be there to attenuate the ongoing 
inflammation through microglia. Although, we do not know which WNT-3A-induced 
signaling pathway that are responsible for the anti-inflammatory effect, and despite the 
ability of both WNT-3A and WNT-5A to induce the WNT/β-catenin pathway and their 
opposing signaling profiles (Topol et al., 2003; Nemeth et al., 2007), both WNT-3A 
and WNT-5A reduced LPS-induced COX2, IL-6 and TNFα in a similar manner. These 
data suggest that the WNTs’ anti-inflammatory effect on microglia is mediated via 
common signaling pathways, such as heterotrimeric Gα protein-dependent ERK1/2 
WNT signaling in microglia 
  41 
activation, to crosstalk between LPS  receptor TLR4 and WNT signaling at receptor 
level, on intermediate steps or at transcription level. The commonly induced pathway 
leading to the ERK1/2 phosphorylation and activation provides mechanistic crosstalk 
downstream of G proteins. The TLR4 membrane expression, functionality and 
signaling has shown to be reduced upon costimulation with diverse pharmacological 
compounds (Lin et al., 2007; Park et al., 2011; Jung et al., 2013). Further, the LPS-
induced gene expression inhibited by WNTs, suggests that the WNT regulation is at 
transcriptional level. Thus, more detailed studies are required to elucidate underlying 
mechanisms.  
 
 
 
Figure 11: WNTs act as homeostatic regulators. Both WNT-3A and WNT-5A induce 
proinflammation in primary microglia. However, in presence of LPS, both WNTs counteract 
LPS-induced COX, IL-6 and TNFα. 
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GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
Chronic neuroinflammatory diseases are prolonged and devastating conditions with 
poor prognosis. In the last few decades, the CNS’ own macrophages – microglia – have 
emerged as an essential cellular component involved in brain homeostasis and disease 
development. That inflammation persists is mainly because of activated immune cells 
over-producing proinflammatory mediators, such as microglia secreting 
proinflammatory cytokines and chemokines. Thus, understanding and eventually being 
able to treat the underlying causes of the deregulation of cytokines and other factors 
involved in neuroinflammatory diseases, requires increased knowledge through 
examination of specific signaling pathways responsible for regulating microglia’s 
inflammatory activity.  
The pathophysiological significance of WNT/β-catenin-dependent and -
independent signaling in neuronal differentiation, growth and dysfunction is broadly 
accepted (Malaterre et al., 2007; Inestrosa and Arenas, 2010; Salinas, 2012; Marchetti 
and Pluchino, 2013). In fact, several studies have shown numerous WNT components 
to be altered in neurodegenerative diseases, and drugs capable of modulating WNT 
signaling have been discussed as potential tools against diseases associated with 
neuronal loss (Alvarez et al., 2004; Inestrosa and Arenas, 2010). The ongoing research 
studying the link between WNT-signaling and a growing number of disease conditions 
will uncover details that further contribute to our understanding of these complex 
signaling pathways (Chien et al., 2009). However, to date, many questions about WNT 
signaling remain unanswered, particularly with regard to its role in human disease. 
Microglia reside and act in an environment where members of the WNT family are 
expressed (Malaterre et al., 2007; Inestrosa and Arenas, 2010). A plethora of factors 
modulate microglia activity ranging from neurotransmitters, cytokines, chemokines, 
and cellular debris to pathogens, to name but a few (Kettenmann et al., 2011). Further, 
given the important role microglia play in CNS homeostasis and neuroinflammation in 
combination with the important influence WNTs have on adult neurogenesis and 
neuron maintenance, it is likely that also WNTs interact and influence microglia 
activity. Indeed, a link between microglia and WNTs has just recently begun to emerge.   
This thesis shows that stimulation with recombinant WNT-3A in cultured mouse 
microglia induces a WNT/β-catenin-dependent pathway, and release of 
proinflammatory cytokines. The observation that β-catenin stabilization in microglia is 
related to the activated amoeboid phenotype in AD, both in human postmortem brain 
slices, in the mouse model with AD-like pathology (APdE9), and in elderly WT mouse 
suggests that β-catenin stabilization is regulated, and – at one or more levels – 
participates in microglia-dependent inflammatory processes. In addition, in a multiple 
screening assay with compounds shown to affect microglia or β-catenin levels in other 
cell types, only WNT-3A and the GSK3β inhibitor LiCl induced β-catenin stabilization 
in microglia. Taken together, these data suggest that WNTs are responsible for the 
induced β-catenin stabilization in microglia. Further, stimulation with recombinant 
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WNT-3A induced a wide range of proinflammatory meditators in cultured microglia, 
which suggests that WNTs are involved in mediating the proinflammatory 
transformation of microglia during neuroinflammation. However, with regard to WNT-
3A’s attenuation of LPS-induced proinflammation in microglia, is it a bit unclear if 
WNTs enhance the inflammatory process or participate in the attenuation of ongoing 
neuroinflammation. To clarify the role of WNTs and the downstream signaling 
branches involved in the regulation of microglia more research will be required. 
 “The GSK3 hypothesis of AD” brings up the diverse roles GSK3 plays in 
different aspects of promoting the disease. Due to the relation between overactive 
GSK3 and the formation of toxic Aβ42 and neurofibrillary tangles, as well as the 
inflammation progression, the pharmaceutical industries are evaluating GSK3 
inhibitors as possible treatment for AD (Jope et al., 2007; Hooper et al., 2008; Palmer, 
2011). The potential usefulness of this approach is supported by several studies where 
restoring the WNT/β-catenin signaling via GSK3 inhibition seems to have 
neuroprotective potential, diminishing Aβ neurotoxicity and reducing tau 
hyperphosphorylation (De Ferrari et al., 2003; Alvarez et al., 2004; Chacón et al., 
2008; Toledo et al., 2008). Inhibition of GSK3 with LiCl has improved memory 
performance in a mouse model of AD, by alleviating the underlying neuronal deficits 
(Toledo and Inestrosa, 2009). Further, GSK3β has been shown to become insoluble 
early in the disease, suggesting that WNT pathway activation may be an initial step in 
the neurodegenerative process (Wiedau-Pazos et al., 2009). However, these studies 
explicitly looked at neurons, disregarding the presence of non-neuronal cells. The given 
increase of β-catenin in the proinflammatory phenotype of microglia (or invading 
macrophages), and treatment with GSK3 inhibitors might increase β-catenin 
stabilization in microglia and thereby exacerbate the inflammatory response.  
Research on WNT signaling is a fast growing field initiated by the discovery of the 
WNT/β-catenin pathway and continuing with the discovery of more and more β-
catenin-independent pathways (He, 2003; Nichols et al., 2013; Schulte, 2010a). For 
example, stimulation with recombinant WNT-5A induced formation of PS-DVL, and 
did not affect LRP6 phosphorylation or β-catenin levels. Instead, stimulation of 
microglia with recombinant WNT-5A induced a classical G protein-dependent axis: 
WNT-5A-induced GDP/GTP exchange at PTX-sensitive G proteins led to attenuation 
of forskolin–induced cAMP levels, and increases in Ca2+ influxes, and phosphorylation 
of the MAPKs ERK1/2. The central role ERK1/2 activation plays in microglia 
proinflammatory activity was also confirmed here, where the WNT-5A-induced 
invasion and proliferation were regulated in an ERK1/2-dependent manner. 
Interestingly, WNT-5A induced expression of several proinflammatory markers of 
microglia with bidirectional sensitivity to the MEK1/2 inhibitor, i.e. some markers 
increased in expression in presence of the MEK1/2 inhibitor. Hypothetically, this result 
can be explained by WNT-5A-induced gene expression being downstream of other 
signaling components, that have not been identified here, and that ERK1/2 activation 
provides a negative crosstalk with those other proinflammatory mediators limiting the 
inflammatory transformation. A proposed crosstalk could take place at different levels, 
such as the receptor level, intermediate signaling components or at the transcription 
level. To map the underlying mechanisms would require further investigations. 
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A major finding that provides the WNT field with new insight is that WNT-3A, a 
classical WNT/β-catenin pathway inducer, is capable of inducing ERK1/2 activation in 
parallel with β-catenin stabilization, to mediate a distinct, physiologically relevant 
response in microglia. In addition, we show that WNT-3A-induced LRP6 
phosphorylation, PS-DVL3 formation, and β-catenin stabilization are sensitive to PTX 
treatment, indicating that the WNT-3A-induced β-catenin-dependent pathway in 
microglia requires activation of heterotrimeric Gαi/o proteins. Thus, the crosstalk 
between the β-catenin-dependent and -independent pathways induced by WNT-3A lies 
upstream of the FZD/LRP6 receptor complex, i.e. at the level of PTX-sensitive 
heterotrimeric Gαi/o proteins. 
Microglia are present in large numbers within the CNS; however, these are 
multifaceted cells, with uneven distribution density, and variable morphology and 
activity state (Lawson et al., 1990; Lynch, 2009; Olah et al., 2011). In addition, recent 
discoveries indicate that microglia can perform task splitting, i.e. they can exist not 
only in surveying ramified or active amoeboid form, but also in several intermediate 
states, which explains how stimulated cultured microglia manage proliferative 
expansion and executive functions at the same time (Lynch, 2009; Scheffel et al., 
2013). This statement could be visualized in the live-cell imaging Ca
2+
 experiment, 
where not all the microglia responded to the WNT-5A treatment by mobilization of 
Ca
2+
. WNT-5A stimulation regulates gene expression, proliferation, and invasion of 
microglia, i.e. multiple tasks; it is likely that these tasks are split. Further, microglia can 
co-exist in different activation states, thus some microglia in the culture might already 
exist in an activated state, and thus respond to the WNT-5A stimuli by reduction of the 
inflammation, which might involve signaling pathways independent of Ca
2+
.  
Cytokines, such as TNFα, are known to act in a dual manner, being both 
cytotoxic/pro-inflammatory on surveying microglia as well as protective/anti-
inflammatory on pre-activated microglia to maintain and promote tissue homeostasis 
(Sriram and O'Callaghan, 2007). Interestingly, the last study in this thesis suggests that 
WNTs act on microglia to accomplish homeostatic functions and thus protect tissue in 
the CNS. The data shows that both WNT-3A and WNT-5A, in a similar manner, 
attenuate LPS-induced expression of the proinflammatory mediators COX2, TNFα and 
IL-6. These bidirectional effects of WNTs as both pro- and anti-inflammatory 
regulators mirror the dual role of microglia in health and disease, providing both 
supportive and inflammatory cues depending on the physiological context (Hanisch 
and Kettenmann, 2007; Kettenmann et al., 2011).  
In summary, these data laid the foundation for an understanding of WNT signaling 
in neuroinflammation where microglia are involved. In addition, microglia have served 
as a model for mechanistic studies of molecular aspects of WNT signaling in non-
transfected, genuine cells. Such models will undoubtedly be of value in the future, as 
additional studies under in vivo conditions will be required to clarify the mechanisms 
and intracellular crosstalk involved in WNT signaling. Nevertheless, this thesis shows 
that WNTs modify microglia activation – pro- and anti-inflammatory – to accomplish 
homeostatic functions that could serve of importance in the CNS. 
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CONCLUSIONS 
1. Primary microglia cells isolated from C57Bl/6 mice and the microglia-like 
cell line N13 express several WNT receptors, namely FZDs and the co-
receptors LRP5/6. Microglia respond to recombinant WNT-3A and WNT-5A 
stimulation by inducing β-catenin-dependent and –independent pathways. 
 
2. In primary microglia, WNT-3A stimulation leads to activation of the β-
catenin-dependent pathway and, in parallel, phosphorylation of the mitogen 
activated protein kinase ERK1/2, where both pathways are dependent on 
Gαi/o-protein activation. 
 
3. WNT-3A regulates ERK1/2 phosphorylation through a Gαi/o, βγ, PLC, Ca
2+
, 
and MEK1/2-dependent mechanism, which also is involved in WNT-3A-
induced expression of the pro-inflammatory protein COX2. 
 
4. WNT-3A stimulation modulates microglia activity with a strong 
proinflammatory response by inducing microglia’s expression of several 
proinflammatory cytokines, chemokines and innate immune response factors.  
 
5. β-catenin is increased in activated microglia cells in human AD, in the AD-
mouse model APdE9, and elderly WT mice. 
 
6. All the commercially available recombinant WNTs induce PS-DVL formation 
in N13 and activation of heterotrimeric G proteins, with different efficacy. 
The WNTs with higher efficacy for G protein activation also induce microglia 
proliferation. 
 
7. WNT-5A does not inhibit WNT-3A-mediated β-catenin signaling in N13, but 
rather increases the PS-DVL formation, which most likely has to do with 
N13s FZD receptor repertoire, and WNT/FZD-binding combinations.  
 
8. WNT-5A is highly expressed by astrocytes in the adult mouse brain, 
suggesting a paracrine WNT-5A-based communication from astrocytes to 
microglia.  
 
9. Stimulation of microglia with recombinant WNT-5A leads to an activation of 
β-catenin-independent signaling resulting in phosphorylation of ERK1/2 
through the activation of Gαi/o protein, βγ, PLC, PKC, Ca
2+
, and MEK1/2 axis.  
 
10. WNT-5A stimulation induces a proinflammatory transformation of microglia, 
where the WNT-5A-induced ERK1/2 phosphorylation is responsible for 
expression of matrix metalloproteases 9 and 13, invasion and proliferation. 
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11. Both WNT-3A and WNT-5A counteracts LPS-induced expression of COX2, 
IL-6 and TNFα, which suggests that WNTs have homeostatic functions on 
microglia, i.e. acting both in a pro- and anti-inflammatory manner dependent 
on the microenvironment. 
 
12. In conclusion, WNTs are expressed in the adult brain and have impact on 
microglia’s inflammatory activity; this suggests that WNTs may play 
important roles as modulators of microglia activity in neuroinflammation and 
tissue homeostasis. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Hjärnan består av flera olika typer av celler. Den största delen av dessa celler är  så 
kallade gliaceller. Gliaceller trodde man förr i tiden bara fungerade som stödjeceller för 
nervcellerna, medan man i dagsläget vet man att de kan göra mycket mer än så. 20% av 
alla gliaceller är nervsystemets egna immunförsvarsceller och kallas för mikroglia. 
Mikroglia är små celler med massor av små utskott som ständigt är i rörelse för att 
känna av eventuella förändringar i hjärnan, så som tecken på infektion eller 
inflammation.  Om mikroglia får en signal om infektion eller skada kan de ändra 
utseende, föröka sig, förflytta sig, äta upp cellrester och bakterier och kommunicera 
med omkringliggande celler genom att skicka ut signalerande molekyler. Hos 
människor med neruodegernativa sjukdomar såsom Alzheimers eller Multipel skleros, 
pågår en ständig inflammation i hjärnan, som i stor del beror på aktiverade mikroglia. 
Mikroglia ska hjälpa till att skydda friska nervceller och städa bort redan döda, dock har 
det visat sig att mikroglia kan bli överaktiva vilket leder till att de attackerar friska 
nervceller och på så sätt förvärrar inflammationen och vidare förvärrar sjukdomen.  
Cellerna i kroppen kommunicerar med varandra genom att skicka ut olika typer av 
signalmolekyler som kan binda till olika proteinstrukturer på cellytan, såkallade 
receptorer. När en specifik molekyl binder till sin receptor, ändrar receptorn 
konformation, som i sin tur leder vidare till en kaskad av händelser inuti cellen som 
leder vidare till en fysiologisk cellförändring, t ex förflyttning och utsöndring av andra 
molekyler. Ett exempel på sådan molekyler är WNTs och receptorerna för dessa kallas 
Frizzled. I tidigare studier har man visat att WNTs i hjärnan har en viktig funktion i 
nervcellernas utveckling, förbindelser och regeneration, men inget i hur WNTs 
påverkar mikroglia.  
Avhandlingen sammanfattar hur en mikroglia-lik cellinje (N13) och mikroglia 
cellkulturer isolerade från möss reagerar på stimulering av WNTs. Med hjälp av olika 
biokemiska metoder visar avhandlingen vilka Frizzled och andra WNT-receptorer som 
mikroglia uttrycker, vilka typer av intracellulära händelser som WNTs inducerar och 
några av mikroglias olika fysiologiska förändringar i svar på WNT-stimuleringen. Det 
visar sig att WNTs kan få mikroglia att bli proinflammatoriska genom att få dem att 
föröka sig och uttrycka flera proinflammatoriska signalmolekyler. Intressant nog så kan 
WNT stimulering även reducera en redan bakterie-inducerad inflammation i mikroglia, 
vilket tyder på att WNTs även har en antiinflammatorisk egenskap. Avhandlingen visar 
också att ett specifikt intracellulärt protein för WNT/Frizzled signaleringen; β-catenin, 
har ett förhöjt uttryck i aktiverade amöbaliknande mikroglia hos patienter med 
Alzheimers. Denna förhöjda β-catenin nivå visas även i mikroglia hos en Alzheimers 
musmodell och  hos äldre möss. Detta indikerar på att WNTs är involverat i mikroglias 
inflammatoriska aktivitet i hjärnan och kanske är ett möjligt mål för framtida 
farmaceutiska behandlingar av neurodegenerativa sjukdomar. 
 
Carina Halleskog 
48 
ACKNOWLEDGEMENTS 
Many people have supported me in different ways during my period as a PhD-student at the 
Department of Physiology and Pharmacology. This work would not have been accomplished 
without them. Therefore, I would like to express my gratitude to following people: 
 
The first and biggest thank you I would like to give to my supervisor, Gunnar Schulte, for giving 
me the opportunity to perform a PhD in his lab. I also would like to thank him for his 
supervision, creativity, encouragement and big optimism through my whole PhD period. 
Thank you for introducing me into the research field, this was a once in a life time experience 
and you have really been a great supervisor.  
 
Thank you to my co-supervisor, Vita Bryja for all the enthusiasm, support and good 
discussions. It has been really fun to get to know you, and I think it feels a bit sad that I never 
worked in your lab.  
 
Thank you professor Stefan Eriksson, head of the Department of Physiology and 
Pharmacology, for provide a good working atmosphere. 
 
Thank you Janet Holmén, for the excellent work in proof-reading the manuscripts, your eye 
for details is invaluable. 
 
Thank you professor Bertil B Fredholm for your expertise in research and for giving me 
valuable input with different perspectives.  
 
Thank you to all my co-authors, Jan Mulder, Ken Mackie, Tibor Hortobágyi, Hekki Tanila, 
Lakshman Kumar Puli, Katrin Färber, Tibor Harkany, J Carlos Villaescusa and Ernest Arenas 
for a fruitful collaboration. 
 
Huge thanks to Eva Lindgren for having shown me several techniques in the lab, for being a 
good friend and has always helped me when I needed it. Hope you know how much I 
appreciated it, I will never forget it. 
 
Special thanks to my colleague Jacomijn Dijksterhuis, we have had a great time together by 
sharing all our up and downs, both scientific and personal, I believe we have developed a 
special friendship. Thank you, Michaela Kilander for being a nice colleague and also always a 
nice and funny friend to hang around with outside the lab. Thank you to current and previous 
students in the Schulte group: Julian P, for always bring a happy smile to work, Elisa A, for 
texting med fun laboratory question any time, and keeping my mind clear, Marketa K, for 
being so glad and friendly, Jenny D, for counting microglia to the late afternoons, Javier B-O, 
for helping out with ICC and live-cell imaging techniques, and Tilman, Tobias, Natália, and 
Alice, all of you have done this time together great fun and memorable. 
 
Thank you Torun M, for being such a great person and special friend. Thank you Jens G, for 
always listen and share anxiety conversations with me. Both of you always make me feel 
joyful.  
WNT signaling in microglia 
  49 
Thank you to former Svensson’s group: Björn S, Lotta W, Åsa K-G, Sabina “Pixi”, Monica M 
and Anna M for introducing me to this department and inspiring me to perform a PhD. 
 
Thank you to current and former PhD-students and friends at the FyFa-department: Cecilia, 
Daniel, Maria, Magdalena, Sara, Klas, Markus, Anna, Angelica, Louise, Linn, Sandra, Frank, 
Martin, Therese, Ellinor, Lars, Aki, Carl, Olivia, Ebba, Karuna, Andreas, Michael, Olga, Stina, 
Jangning, Mei, Ebba, Tianle for a fun time together and have never made me feel alone.   
 
Tack till all personal på FyFa, Camilla F H, Eva G, Sarah L, Monika P-S, Freddie H, Ylva H, Ulla 
W, och Inger J, för ett alltid så trevligt och hjälpsamt bemötande oavsett min typ av fråga, ni 
gör FyFa till en verklig bra arbetsplats. Tack till Micke E för att du är sån superbra fixarkille, 
tack till Renée A för all it-hjälp och tack till Eva N, som hjälper till med posten, disken och 
påfyllning av pipettspetsar, institutionen skulle inte vara den samma utan er! Tack till 
”damerna en trappa upp”, Annika, Meta och Carina, för hjälpen och för lånet av 
spektrofotometern. Tack till Josefin och Emma på djuravdelningen som tagit hand om alla 
mina möss och hjälpt till varje gång jag förvirrat ska beställa nya.  
 
Tack till mina Uppsala-vänner: Lina, Maria och Sigrid, för att ni gjorde studenttiden så rolig 
och minnesvärd med allt festande, träning och plugg. Speciellt tack till Anna P, jag tycker att vi 
hade det jätte kul ihop, och vi kompletterade varandra så bra, särskilt under laborationerna.  
Tack till alla mina plugg-kompisar jag har lärt känna på vägen, speciellt Diana, Anette och Ida. 
Södertörns högskola och Stockholms Universitet hade inte varit detsamma utan er. 
 
Tack till Tina, min bästa vän från gymnasiet, för att vi kan ringa till varandra när som helst och 
prata om vad som helst och det fortfarande känns som vi aldrig skiljts åt.  
 
Tack till alla kära och fina vänner, för allt ert stöd och bara för att det är så kul att umgås med 
er: Sofia & Viktor, Åsa & Kris, Helena & Johan, Emelie & Tom, Ellen & Peter, Emelie & Fredrik, 
Emma & Jimmie, och Pers pappa Tomas och hans Eva. 
 
Tack till mina älskade föräldrar Eva och Robert, som alltid har trott på mig och uppmuntrat 
mina val i livet, även om ni säkerligen inte alltid har förstått dem. Ni har aldrig svikit mig och 
ert stöd och beröm har gjort att jag har klarat det här! Tack till min fina underbara lillasyster, 
Sofia, som alltid har fått mig att känna mig så ”stor” och duktig!  
 
Sista men verkligen inte det minsta tacket vill jag självklart ge till min stora kärlek, min kung 
och livskamrat, Per! Utan Dig hade jag inte lyckats med det här! Du har varit, och är alltid ett 
stort stöd för mig under hela vårt delade liv! Tänk att Du och Jag har två underbara barn ihop, 
Lova och Freja, och jag hoppas att det alltid kommer vara Vi. Jag älskar Dig fantastiskt mycket!  
 
This research was financially supported by grants from Karolinska Institutet, the Swedish 
Council (K2008-68P-20810-01-4, K2008-333 68X-20805-01-4, K2012-67X-20805-3), the 
Swedish Cancer Society (CAN 2008/539, 2011/690), the Swedish Alzheimer Foundation 
(Alzheimerfonden; #10-03-056), the Foundation Lars Hiertas Minne, the Signhild Engkvists 
Foundation, the Foundation of the National Board of Health and Welfare, , Knut & Alice 
Wallenberg Foundation (KAW 2008.0149), and the Swedish Foundation for international 
Cooperation in Research and Higher Education STINT.  
 
Carina Halleskog 
50 
REFERENCES 
Aguzzi, A., Barres, B. A., & Bennett, M. L. (2013) Microglia: scapegoat, saboteur, or 
something else? Science 339, 156-161. 
Ahn, S., Shenoy, S. K., Wei, H., & Lefkowitz, R. J. (2004) Differential kinetic and spatial 
patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II 
receptor. Journal of Biological Chemistry 279, 35518-35525. 
Ahumada, A., Slusarski, D. C., Liu, X., Moon, R. T., Malbon, C. C., & Wang, H. Y. (2002) 
Signaling of rat Frizzled-2 through phosphodiesterase and cyclic GMP. Science 298, 
2006-2010. 
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., 
Eikelenboom, P., Emmerling, M., Fiebich, B. L., Finch, C. E., Frautschy, S., Griffin, W. 
S. T., Hampel, H., Hull, M., Landreth, G., Lue, L. -F., Mrak, R., Mackenzie, I. R., 
McGeer, P. L., O'Banion, M. K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., 
Rydell, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F. L., 
Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., & Wyss-Coray, T. 
(2000b) Inflammation and Alzheimer’s disease. Neurobiology of Aging 21, 383-421. 
Akiyama, H., & McGeer, P. L. (1990) Brain microglia constitutively express beta-2 integrins. 
Journal of Neuroimmunology 30, 81-93. 
Alliot, F., Godin, I., & Pessac, B. (1999) Microglia derive from progenitors, originating from 
the yolk sac, and which proliferate in the brain. Brain Research Developmental Brain 
Research 117, 145-152. 
Alvarez, A. R., Godoy, J. A., Mullendorff, K., Olivares, G. H., Bronfman, M., & Inestrosa, 
N. C. (2004) Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. 
Experimental Cell Research 297, 186-196. 
Amor, S., Puentes, F., Baker, D., & van der Valk, P. (2010) Inflammation in 
neurodegenerative diseases. Immunology 129, 154-169. 
Anderton, B. H., Dayanadan, R., Killick, R. & Lovestone, S. (2000) Does dysregulation of 
the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease? 
Molecular Medicine Today 6, 54-59. 
Bafico, A., Gazit, A., Pramila, T., Finch, P. W., Yaniv, A., & Aaronson, S. A. (1999) 
Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor 
suggests alternative mechanisms for FRP inhibition of Wnt signaling. Journal of 
Biological Chemistry 274, 16180-16187. 
Bernatik, O., Ganji, R. S., Dijksterhuis, J., Konik, P., Cervenka, I., Polonio, T., Krejci, P., 
Schulte, G., & Bryja, V. (2011) Sequential activation and inactivation of dishevelled in 
the Wnt/β-catenin pathway by casein kinases. Journal of Biological Chemistry 286, 
10396-10410. 
Bikkavilli, R. K., Feigin, M. E., & Malbon, C. C. (2008) G alpha o mediates WNT-JNK 
signaling through dishevelled 1 and 3, RhoA family members, and MEKK 1 and 4 in 
mammalian cells. Journal of Cell Science 121, 234-245. 
Bikkavilli, R. K., & Malbon, C. C. (2009) Mitogen-activated protein kinases and Wnt/beta-
catenin signaling: Molecular conversations among signaling pathways. Communicative 
& integrative biology 2, 46-49. 
Bilic, J., Huang, Y. L., Davidson, G., Zimmermann, T., Cruciat, C. M., Bienz, M., & Niehrs, 
C. (2007) Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 
phosphorylation. Science 316, 1619-1622. 
Birnbaumer, L., Abramowitz, J., & Brown, A. M. (1990) Receptor-effector coupling by G 
proteins. Biochimica et Biophysica Acta 1031, 163-224. 
Bleasdale, J. E., Bundy, G. L., Bunting, S., Fitzpatrick, F. A., Huff, R. M., Sun, F. F., & Pike, 
J. E. (1989) Inhibition of phospholipase C dependent processes by U-73, 122. Advances 
in Prostaglandin, Thromboxane, and Leukotriene Research 19, 590-593. 
Blumenthal, A., Ehlers, S., Lauber, J., Buer, J., Lange, C., Goldmann, T., Heine, H., Brandt, 
E., & Reiling, N. (2006) The Wingless homolog WNT5A and its receptor Frizzled-5 
WNT signaling in microglia 
  51 
regulate inflammatory responses of human mononuclear cells induced by microbial 
stimulation. Blood 108, 965-973. 
Boje, K. M., & Arora, P. K. (1992) Microglial-produced nitric oxide and reactive nitrogen 
oxides mediate neuronal cell death. Brain Research 587, 250-256. 
Boland, G. M., Perkins, G., Hall, D. J., & Tuan, R. S. (2004) Wnt 3a promotes proliferation 
and suppresses osteogenic differentiation of adult human mesenchymal stem cells. 
Journal of Cellular Biochemistry 93, 1210-1230. 
Bonacci, T. M., Mathews, J. L., Yuan, C., Lehmann, D. M., Malik, S., Wu, D., Font, J. L., 
Bidlack, J. M., & Smrcka, A. V. (2006) Differential targeting of Gbetagamma-subunit 
signaling with small molecules. Science 312, 443-446. 
Bourhis, E., Tam, C., Franke, Y., Bazan, J. F., Ernst, J., Hwang, J., Costa, M., Cochran, A. 
G., & Hannoush, R. N. (2010) Reconstitution of a frizzled8.Wnt3a.LRP6 signaling 
complex reveals multiple Wnt and Dkk1 binding sites on LRP6. Journal of Biological 
Chemistry 285, 9172-9179. 
Braak, H., & Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes. 
Acta Neuropathologica 82, 239-259. 
Braak, H., & Braak, E. (1995) Staging of Alzheimer's Disease-Related Neurofibrillary 
Changes. Neurobiology of Aging 16, 278-284. 
Brown, G. C., & Neher, J. J. (2009) Inflammatory Neurodegeneration and Mechanisms of 
Microglial Killing of Neurons. Molecular Neurobiology 41, 242-247. 
Bryja, V., Schambony, A., Cajanek, L., Dominguez, I., Arenas, E., & Schulte, G. (2008) 
beta-arrestin and casein kinase 1/2 define distinct branches of non-canonical WNT 
signaling pathways. EMBO Reports 9, 1244-1250. 
Bryja, V., Schulte, G., & Arenas, E. (2007a) Wnt-3a utilizes a novel low dose and rapid 
pathway that does not require casein kinase 1-mediated phosphorylation of Dvl to 
activate beta-catenin. Cellular Signalling 19, 610-616. 
Bryja, V., Schulte, G., Rawal, N., Grahn, A., & Arenas, E. (2007b) Wnt-5a induces 
Dishevelled phosphorylation and dopaminergic differentiation via a CK1-dependent 
mechanism. Journal of Cell Science 120, 586-595. 
Cabrera, C. V., Alonso, M. C., Johnston, P., Phillips, R. G., & Lawrence, P. A. (1987) 
Phenocopies induced with antisense RNA identify the wingless gene. Cell 50, 659-663. 
Cabrera-Vera, T. M., Vanhauwe, J., Thomas, T. O., Medkova, M., Preininger, A., Mazzoni, 
M. R., & Hamm, H. E. (2003) Insights into G protein structure, function, and regulation. 
Endocrine Reviews 24, 765-781. 
Cadigan, K. M., & Liu, Y. I. (2006) Wnt signaling: complexity at the surface. Journal of Cell 
Science 119, 395-402. 
Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., 
Xing, Y., Lubischer, J. L., Krieg, P. A., Krupenko, S. A., Thompson, W. J., & Barres, B. 
A. (2008) A transcriptome database for astrocytes, neurons, and oligodendrocytes: a 
new resource for understanding brain development and function. Journal of 
Neuroscience 28, 264-278. 
Cajanek, L., Adlerz, L., Bryja, V., & Arenas, E. (2010) WNT unrelated activities in 
commercially available preparations of recombinant WNT3a. Journal of Cellular 
Biochemistry 111, 1077-1079. 
Candelario-Jalil, E., Yang, Y., & Rosenberg, G. A. (2009) Diverse roles of matrix 
metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and 
cerebral ischemia. Neuroscience 158, 983-994. 
Caricasole, A., Copani, A., Caraci, F., Aronica, E., Rozemuller, A. J., Caruso, A., Storto, M., 
Gaviraghi, G., Terstappen, G. C., & Nicoletti, F. (2004) Induction of Dickkopf-1, a 
negative modulator of the Wnt pathway, is associated with neuronal degeneration in 
Alzheimer's brain. Journal of Neuroscience 24, 6021-6027. 
Caricasole, A., Ferraro, T., Iacovelli, L., Barletta, E., Caruso, A., Melchiorri, D., Terstappen, 
G. C., & Nicoletti, F. (2003) Functional characterization of WNT7A signaling in PC12 
cells: interaction with A FZD5 x LRP6 receptor complex and modulation by Dickkopf 
proteins. Journal of Biological Chemistry 278, 37024-37031. 
Carina Halleskog 
52 
Carmon, K. S., & Loose, D. S. (2010) Development of a Bioassay for Detection of Wnt-
Binding Affinities for Individual Frizzled Receptors. Analytical Biochemistry401, 288-
294. 
Castelo-Branco, G., Sousa, K. M., Bryja, V., Pinto, L., Wagner, J., & Arenas, E. (2006) 
Ventral midbrain glia express region-specific transcription factors and regulate 
dopaminergic neurogenesis through Wnt-5a secretion. Molecular and Cellular 
Neurosciences 31, 251-262. 
Castelo-Branco, G., Wagner, J., Rodriguez, F. J., Kele, J., Sousa, K., Rawal, N., Pasolli, H. 
A., Fuchs, E., Kitajewski, J., & Arenas, E. (2003) Differential regulation of midbrain 
dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proceedings of the 
National Academy of Sciences of the United States of America 100, 12747-12752. 
Chacón, M. A., Varela-Nallar, L., & Inestrosa, N. C. (2008) Frizzled-1 is involved in the 
neuroprotective effect of Wnt3a against Abeta oligomers. Journal of Cellular 
Physiology 217, 215-227. 
Chao, C. C., Hu, S., Molitor, T. W., Shaskan, E. G., & Peterson, P. K. (1992) Activated 
microglia mediate neuronal cell injury via a nitric oxide mechanism. Journal of 
Immunology 149, 2736-2741. 
Chen, Y., & Bodles, A. M. (2007) Amyloid precursor protein modulates beta-catenin 
degradation. Journal of Neuroinflammation 4, 29. 
Chien, A. J., Conrad, W. H., & Moon, R. T. (2009) A Wnt survival guide: from flies to 
human disease. Journal of Investigative Dermatology 129, 1614-1627. 
Ching, W., Hang, H. C., & Nusse, R. (2008) Lipid-independent secretion of a Drosophila 
Wnt protein. Journal of Biological Chemistry 283, 17092-17098. 
Ching, W., & Nusse, R. (2006) A dedicated Wnt secretion factor. Cell 125, 432-433. 
Choi, M. S., Cho, K. S., Shin, S. M., Ko, H. M., Kwon, K. J., Shin, C. Y., & Ko, K. H. (2010) 
ATP induced microglial cell migration through non-transcriptional activation of matrix 
metalloproteinase-9. Archives of Pharmacal Research 33, 257-265. 
Choi, S. C., & Han, J. K. (2002) Xenopus Cdc42 regulates convergent extension movements 
during gastrulation through Wnt/Ca2+ signaling pathway. Developmental biologyl 244, 
342-357. 
Choi, S. -H., Aid, S., & Bosetti, F. (2009) The distinct roles of cyclooxygenase-1 and -2 in 
neuroinflammation: implications for translational research. Trends in Pharmacological 
Sciences 30, 174-181. 
Chu, W. M. (2013) Tumor necrosis factor. Cancer Letters 328, 222-225. 
Clevers, H.(2006) WNT/beta-catenin signaling in development and disease. Cell 127, 469-
480. 
Cohen, P., & Goedert, M. (2004) GSK3 inhibitors: development and therapeutic potential. 
Nature reviews. Drug discovery3, 479-487. 
Cook, D., Fry, M. J., Hughes, K., Sumathipala, R., Woodgett, J. R., & Dale, T. C. (1996) 
Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway 
which involves a protein kinase C. EMBO Journal 15, 4526-4536. 
Cordero, J. B., Macagon, J. P., Stefanatos, R. K., Strathdee, K. E., Cagan, R. L., & Vidal, M. 
(2010) Oncogenic ras diverts a host TNF tumor suppressor activity into tumor promoter. 
Developmental Cell 18, 999-1011. 
Davis P. D., Elliot L. H., Harris W., Hill C. H., Hurst S. A., Keech E., Kumar M. K., Lawton 
G., Nixon J. S., Wilkinson S. E. (1992) Inhibitors of protein kinase C. 2. Substituted 
bisindolylmaleimides with improved potency and selectivity. Journal of medicinal 
chemistry 35, 994-1001. 
De Ferrari, G. V., Chacón, M. A., Barría, M. I., Garrido, J. L., Godoy, J. A., Olivares, G., 
Reyes, A. E., Alvarez, A., Bronfman, M., & Inestrosa, N. C. (2003) Activation of Wnt 
signaling rescues neurodegeneration and behavioral impairments induced by beta-
amyloid fibrils. Molecular Psychiatry 8, 195-208. 
De Ferrari, G. V., & Moon, R. T. (2006) The ups and downs of Wnt signaling in prevalent 
neurological disorders. Oncogene 25, 7545-7553. 
De-Paula, V. J., Radanovic, M., Diniz, B. S., & Forlenza, O. V. (2012) Alzheimer's disease. 
Sub-Cellular Biochemistry 65, 329-352. 
WNT signaling in microglia 
  53 
Dejmek, J., Säfholm, A., Kamp Nielsen, C., Andersson, T., & Leandersson, K. (2006) Wnt-
5a/Ca2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 
1alpha signaling in human mammary epithelial cells. Molecular and Cellular Biology 
26, 6024-6036. 
Dheen, S. T., Kaur, C., & Ling, E. A. (2007) Microglial activation and its implications in the 
brain diseases. Current Medicinal Chemistry 14, 1189-1197. 
Dinamarca, M. C., Colombres, M., Cerpa, W., Bonansco, C., & Inestrosa, N. C. (2008) Beta-
amyloid oligomers affect the structure and function of the postsynaptic region: role of 
the Wnt signaling pathway. Neurodegener Dis 5, 149-152. 
Dorsam, R. T., & Gutkind, J. S. (2007) G-protein-coupled receptors and cancer. Nature 
Reviews Cancer 7, 79-94. 
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C. M., Perez-tur, J., Hutton, M., Buee, L., 
Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B., 
Hardy, J., & Younkin, S. (1996) Increased amyloid-beta42(43) in brains of mice 
expressing mutant presenilin 1. Nature 383, 710-713. 
Egger-Adam, D., & Katanaev, V. L. (2008) Trimeric G protein-dependent signaling by 
Frizzled receptors in animal development. Frontiers in Bioscience 13, 4740-4755. 
Farfara, D., Lifshitz, V., & Frenkel, D. (2008) Neuroprotective and neurotoxic properties of 
glial cells in the pathogenesis of Alzheimer's disease. Journal of Cellular and Molecular 
Medicine 12, 762-780. 
Ferrari, D., Villalba, M., Chiozzi, P., Falzoni, S., Ricciardi-Castagnoli, P., & Di Virgilio, F. 
(1996) Mouse microglial cells express a plasma membrane pore gated by extracellular 
ATP. Journal of Immunology 156, 1531-1539. 
Foord, S. M., Bonner, T. I., Neubig, R. R., Rosser, E. M., Pin, J. P., Davenport, A. P., 
Spedding, M., & Harmar, A. J. (2005) International Union of Pharmacology. XLVI. G 
protein-coupled receptor list. Pharmacological Reviews 57, 279-288. 
Ford, C. E., Qian Ma. S. S., Quadir, A., & Ward R. L. (2012) The dual role of the novel Wnt 
receptor tyrosine kinase, ROR2, in human carcinogenesis. International journal of 
cancer, doi: 10.1002/ijc.27984 [Epub ahead of print] 
Forrester, W. C. (2002) The Ror receptor tyrosien kinase family. Cellular and Molecular Life 
Sciences 59, 83-96. 
Fradkin, L. G., Dura, J. M., & Noordermeer, J. N. (2010) Ryks: new partners for Wnts in the 
developing and regenerating nervous system. Trends in Neurosciences 33, 84-92. 
Gao, C., & Chen, Y. G. (2010) Dishevelled: The hub of Wnt signaling. Cellular Signalling 
22, 717-727. 
Garthwaite, J. (1991) Glutamate, nitric oxide and cell-cell signalling in the nervous system. 
Trends in Neurosciences 14, 60-67. 
Garzia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., 
Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) 
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of 
Alzheimer disease. Neurobiology of Disease 24, 516-524. 
Gerlier, D., & Thomasset, N. (1986) Use of MTT colometric assay to measure cell activation. 
Journal of immunological methods 94, 57-63. 
Ghanevati, M., & Miller, C. A. (2005) Phospho-beta-catenin accumulation in Alzheimer's 
disease and in aggresomes attributable to proteasome dysfunction. Journal of Molecular 
Neuroscience 25, 79-94. 
Gilman, A. G. (1987) G proteins: transducers of receptor-generated signals. Annual Review of 
Biochemistry 56, 615-649. 
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, 
S. J., Ng, L. G., Stanley, E. R., Samokhvalov, I. M., & Merad, M. (2010) Fate mapping 
analysis reveals that adult microglia derive from primitive macrophages. Science 330, 
841-845. 
Giulian, D., & Baker T. J. (1986) Characetrization of ameboid microglia isolated from 
developing mammalian brain. The Journal of neuroscience 6, 2163-2178. 
Glinka, A., Wu, W., Delius, H., Monaghan, A. P., Blumenstock, C., & Niehrs, C. (1998) 
Dickkopf-1 is a member of a new family of secreted proteins and functions in head 
induction. Nature 391, 357-362. 
Carina Halleskog 
54 
Gong, Q. J., Li, Y. Y., Xin, W. J., Zang, Y., Ren, W. J., Wei, X. H., Zhang, T., & Liu, X. G. 
(2009) ATP induces long-term potentiation of C-fiber-evoked field potentials in spinal 
dorsal horn: the roles of P2X4 receptors and p38 MAPK in microglia. Glia 57, 583-591. 
González, P., Fernandez-Martos, C., Arenas, E., & Rodriguez, F. J. (2013) The Ryk Receptor 
Is Expressed in Glial and Fibronectin-Expressing Cells after Spinal Cord Injury. Journal 
of Neurotrauma, [Epub ahead of print]. 
Gonzalez-Sancho, J. M., Greer, Y. E., Abrahams, C. L., Takigawa, Y., Baljinnyam, B., Lee, 
K. H., Lee, K. S., Rubin, J. S., & Brown A M (2013) Functional Consequences of Wnt-
Induced Dishevelled2 Phosphorylation in Canonical and Non-Canonical Wnt Signaling. 
Journal of Biological Chemistry288, 9428-9437. 
Graeber, M. B. (2010) Changing face of microglia. Science 330, 783-788. 
Guillemin G. J., & Brew B. J. (2005) Microglia, macrophages, perivascular macrophages, 
and pericytes: a review of function and identification. Journal of leukocyte biology75, 
388-397. 
Gutkind, J. S. (2000) Regulation of mitogen-activated protein kinase signaling networks by G 
protein-coupled receptors. Science's STKE 2000, RE1. 
Habas, R., Dawid, I. B., & He, X. (2003) Coactivation of Rac and Rho by Wnt/Frizzled 
signaling is required for vertebrate gastrulation. Genes & Development 17, 295-309. 
Habas, R., Kato, Y., & He, X. (2001) Wnt/Frizzled activation of Rho regulates vertebrate 
gastrulation and requires a novel Formin homology protein Daam1. Cell 107, 843-854. 
Haertel-Wiesmann, M., Liang, Y., Fantl, W. J., & Williams, L. T. (2000) Regulation of 
cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells. Journal 
of Biological Chemistry 275, 32046-32051. 
Halleskog, C., Dijksterhuis, J. P., Kilander, M. B., Becerril-Ortega, J., Villaescusa, C. J., 
Lindgren, E., Arenas, E., & Schulte, G. (2012) Heterotrimeric G protein-dependent 
WNT-5A signaling to ERK1/2 mediates distinct aspects of microglia proinflammatory 
transformation. Journal of Neuroinflammation 9, 111. 
Halleskog, C., Mulder, J., Dahlström, J., Mackie, K., Hortobágyi, T., Tanila, H., Kumar Puli, 
L., Färber, K., Harkany, T., & Schulte, G. (2011) WNT signaling in activated microglia 
is pro-inflammatory. Glia 59, 119-131. 
Halleskog, C., & Schulte, G. (2013a) Pertussis toxin-sensitive heterotrimeric G(αi/o) proteins 
mediate WNT/β-catenin and WNT/ERK1/2 signaling in mouse primary microglia 
stimulated with purified WNT-3A. Cellular Signalling 25, 822-828. 
Halleskog, C., & Schulte, G. (2013b) WNT-3A and WNT-5A counteract lipopolysaccharide-
induced pro-inflammatory changes in mouse primary microglia. Journal of 
Neurochemistry, doi: 10.1111/jnc.12250. [Epub ahead of print]. 
Hanisch, U. K. (2002) Microglia as a source and target of cytokines. Glia 40, 140-155. 
Hanisch, U. K. (2013) Proteins in microglial activation - inputs and outputs by subsets. 
Current Protein & Peptide Science1, 3-15. 
Hanisch, U. K., & Kettenmann, H. (2007) Microglia: active sensor and versatile effector cells 
in the normal and pathologic brain. Nature Neuroscience 10, 1387-1394. 
Harrison, C., & Traynor, J. R. (2003) The [35S]GTPgammaS binding assay: approaches and 
applications in pharmacology. Life Sciences 74, 489-508. 
He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., 
Vogelstein, B., & Kinzler, K. W. (1998) Identification of c-MYC as a target of the APC 
pathway. Science 281, 1509-1512. 
He, X. (2003) A Wnt-Wnt Situation. Developmental Cell 4, 791-797. 
He, X., Saint-Jeannet, J. -P., Wang, Y., Nathans, J., Dawid, I., & Varmus, H. (1997) A 
Member of the Frizzled Protein Family Mediating Axis Induction by Wnt-5A. Science 
275, 1652-1654. 
Heese, K., Inoue, N., Nagai, Y., & Sawada, T. (2004) APP, NGF & the 'Sunday-driver' in a 
Trolley on the Road. Restorative Neurology and Neuroscience 22, 131-136. 
Heneka, M. T., O'Banion, M. K., Terwel, D., & Kummer, M. P. (2010) Neuroinflammatory 
processes in Alzheimer's disease. Journal of Neural Transmission 117, 919-947. 
Hooper, C., Killick, R., & Lovestone, S. (2008) The GSK3 hypothesis of Alzheimer's disease. 
Journal of Neurochemistry 104, 1433-1439. 
WNT signaling in microglia 
  55 
Hooper C., Pinteaux-Jones F., Fry V. A., Sevastou I.G., Baker D., Heales SJ, Pocock J.M 
(2009) Differential effects of albumin on microglia and macrophages; implications for 
neurodegeneration following blood-brain barrier damage. Journal of neurochemistry 109, 
694-705. 
Hooper, C., Sainz-Fuertes, R., Lynham, S., Hye, A., Killick, R., Warley, A., Bolondi, C., 
Pocock, J., & Lovestone, S. (2012) Wnt3a induces exosome secretion from primary 
cultured rat  microglia. BMC Neuroscience. 23, 13:144. 
Hwang, S. G., Ryu, J. H., Kim, I. C., Jho, E. H., Jung, H. C., Kim, K., Kim, S. J., & Chun, J. 
S. (2004) Wnt-7a causes loss of differentiated phenotype and inhibits apoptosis of 
articular chondrocytes via different mechanisms. Journal of Biological Chemistry 279, 
26597-26604. 
Ii, M., Yamamoto, H., Adachi, Y., Maruyama, Y., & Shinomura, Y. (2006) Role of matrix 
metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and 
angiogenesis. Experimental Biology and Medicine (Maywood, NJ) 231, 20-27. 
Inestrosa, N. C., & Arenas, E. (2010) Emerging roles of Wnts in the adult nervous system. 
Nature Reviews Neuroscience 11, 77-86. 
Inestrosa, N. C., & Toledo, E. M. (2008) The role of Wnt signaling in neuronal dysfunction 
in Alzheimer's Disease. Molecular Neurodegeneration 3, 9. 
Inestrosa, N. C., Varela-Nallar, L., Grabowski, C. P., & Colombres, M. (2007) 
Synaptotoxicity in Alzheimer's disease: the Wnt signaling pathway as a molecular 
target. IUBMB Life 59, 316-321. 
Jamieson, T., Clarke, M., Steele, C. W., Samuel, M. S., Neumann, J., Jung, A., Huels, D., 
Olson, M. F., Das, S., Nibbs, R. J., & Sansom, O. J. (2012) Inhibition of CXCR2 
profoundly suppresses inflammation-driven and spontaneous tumorigenesis. Journal of 
Clinical Investigation 122, 3127-3144. 
Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C., & Garcia, K. C. (2012) Structural basis 
of Wnt recognition by Frizzled. Science 337, 59-64. 
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., 
Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., Younkin, S. G., & 
Borchelt, D. R. (2004) Mutant presenilins specifically elevate the levels of the 42 
residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma 
secretase. Human Molecular Genetics 13, 159-170. 
Jernigan, K. K., Cselenyi, C. S., Thorne, C. A., Hanson, A. J., Tahinci, E., Hajicek, N., 
Oldham, W. M., Lee, L. A., Hamm, H. E., Hepler, J. R., Kozasa, T., Linder, M. E., & 
Lee, E. (2010) Gbetagamma activates GSK3 to promote LRP6-mediated beta-catenin 
transcriptional activity. Sci Signal 3, ra37. 
Ji, R. R., & Suter, M. R. (2007) p38 MAPK, microglial signaling, and neuropathic pain. 
Molecular Pain 3, 33. 
Jin, T., George Fantus, I., & Sun, J. (2008) Wnt and beyond Wnt: multiple mechanisms 
control the transcriptional property of beta-catenin. Cellular Signalling 20, 1697-1704. 
John, G. R., Lee, S. C., & Borsnas, C. F. (2003) Cytokines: powerful regulators of glial cell 
activation. Neuroscientist 9, 10-22. 
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) Glycogen Synthase Kinase-3 (GSK3): 
Inflammation, Diseases, and Therapeutics. Neurochemical Research 32, 577-595. 
Jounai, N., Kobiyama, K., Takeshita, F., & Ishii, K. J. (2012) Recognition of damage-
associated molecular patterns related to nucleic acids during inflammation and 
vaccination. Frontiers in Cellular and Infection Microbiology 2, 168. 
Julius, M. A., Schelbert, B., Hsu, W., Fitzpatrick, E., Jho, E., Fagotto, F., Costantini, F., & 
Kitajewski, J. (2000) Domains of axin and disheveled required for interaction and 
function in wnt signaling. Biochemical and Biophysical Research Communications 276, 
1162-1169. 
Jung, J. S., Shin, K. O., Lee, Y. M., Shin, J. A., Park, E. M., Jeong, J., Kim, D. H., Choi, J. 
W., & Kim, H. S. (2013) Anti-inflammatory mechanism of exogenous C2 ceramide in 
lipopolysaccharide-stimulated microglia. Biochimica et Biophysica Acta1831, 1016-
1026. 
Carina Halleskog 
56 
Kaminska, B., Gozdz, A., Zawadzka, M., Ellert-Miklaszewska, A., & Lipko, M. (2009) 
MAPK Signal Transduction Underlying Brain Inflammation and Gliosis as Therapeutic 
Target. Anatomical Record 292, 1902-1913. 
Kang, D. E., Soriano, S., Frosch, M. P., Collins, T., Naruse, S., Sisodia, S. S., Leibowitz, G., 
Levine, F., & Koo, E. H. (1999) Presenilin 1 facilitates the constitutive turnover of beta-
catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-
catenin-signaling pathway. Journal of Neuroscience 19, 4229-4237. 
Karner, C. M., Chirumamilla, R., Aoki, S., Igarashi, P., Wallingford, J. B., & Carroll, T. J. 
(2009) Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis. 
Nature Genetics 41, 793-799. 
Katanaev, V. L. (2010) The Wnt/Frizzled GPCR Signaling Pathway. Biochemistry 75, 1428-
1434. 
Katanaev, V. L., & Buestorf, S. (2009) Frizzled Proteins are bona fide G Protein-Coupled 
Receptors. Nature Precedings hdl:10101/npre.2, 
Katanaev, V. L., Ponzielli, R., Sémériva, M., & Tomlinson, A. (2005) Trimeric G protein-
dependent frizzled signaling in Drosophila. Cell 120, 111-122. 
Kaushal, V., Koeberle, P. D., Wang, Y., & Schlichter, L. C. (2007) The Ca2+-activated K+ 
channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent 
neurodegeneration. Journal of Neuroscience 27, 234-244. 
Kawahara, K., Yoshida, A., Koga, K., Yokoo, S., Kuniyasu, A., Gotoh, T., Sawada, M., & 
Nakayama, H. (2009) Marked induction of inducible nitric oxide synthase and tumor 
necrosis factor-a in rat CD40+ microglia by comparison to CD40- microglia. Journal of 
Neuroimmunology 208, 70-79. 
Kawano, Y., & Kypta, R. (2003) Secreted antagonists of the Wnt signalling pathway. Journal 
of Cell Science 116, 2627-2634. 
Keshet, Y., & Seger, R. (2010) The MAP kinase signaling cascades: a system of hundreds of 
components regulates a diverse array of physiological functions. Methods in Molecular 
Biology 661, 3-38. 
Kettenmann, H., Hanisch, U. K., Noda, M., & Verkhratsky, A. (2011) Physiology of 
microglia. Physiological Reviews 91, 461-553. 
Kettenmann, H., Kirchhoff, F., & Verkhratsky, A. (2013) Microglia: New Roles for the 
Synaptic Stripper. Neuron 77, 10-18. 
Kielian, T. (2004) Microglia and chemokines in infectious diseases of the nervous system: 
views and reviews. Frontiers in Bioscience 9, 732-750. 
Kikuchi, A., Yamamoto, H., & Kishida, S. (2007) Multiplicity of the interactions of Wnt 
proteins and their receptors. Cellular Signalling 19, 659-671. 
Kilander, M., Dijksterhuis, J., Ganji, R. S., Bryja, V., & Schulte, G. (2011a) WNT-5A 
stimulates the GDP/GTP exchange at pertussis toxin-sensitive heterotrimeric G proteins. 
Cellular Signalling 23, 550-554. 
Kilander, M., Halleskog, C., & Schulte, G. (2011b) Purified WNTs differentially activate 
beta-catenin-dependent and -independent pathways in mouse microglia-like cells. Acta 
Physiologica 203, 363-372. 
Kim, W. G., Mohney, R. P., Wilson, B., Jeohn, G. H., Liu, B., & Hong, J. S. (2000) Regional 
difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: 
role of microglia. Journal of Neuroscience 20, 6309-6316. 
Kishida, S., Yamamoto, H., & Kikuchi, A. (2004) Wnt-3a and Dvl induce neurite retraction 
by activating Rho-associated kinase. Molecular and Cellular Biology 24, 4487-4501. 
Kockeritz, L., Doble, B., Patel, S., & Woodgett, J. R. (2006) Glycogen synthase kinase-3—an 
over-achieving protein kinase. Current drug targets 7, 1377-1388. 
Koenigsknecht-Talboo, J., & Landreth, G. E. (2005) Microglial phagocytosis induced by 
fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory 
cytokines. Journal of Neuroscience 25, 8240-8249. 
Koistinaho, M., & Koistinaho, J. (2002) Role of p38 and p44/42 mitogen-activated protein 
kinases in microglia. Glia 40, 175-183. 
Koistinaho, Malm, T., & Goldsteins, G. (2011) Glycogen synthase kinase-3ß: a mediator of 
inflammation in Alzheimer's disease? International Journal of Alzheimer's Disease 
2011, 129753. 
WNT signaling in microglia 
  57 
Koval, A., & Katanaev, V. L. (2011) Wnt3a stimulation elicits G-protein-coupled receptor 
properties of mammalian Frizzled proteins. Biochemical Journal 433, 435-440. 
Krejci, P., Aklian, A., Kaucka, M., Sevcikova, E., Prochazkova, J., Masek, J. K., Mikolka, P., 
Pospisilova, T., Spoustova, T., Weis, M., Paznekas, W. A., Wolf, J. H., Gutkind, J. S., 
Wilcox, W. R., Kozubik, A., Jabs, E. W., Bryja, V., Salazar, L., Vesela, I., & Balek, L. 
(2012) Receptor tyrosine kinases activate canonical WNT/β-catenin signaling via MAP 
kinase/LRP6 pathway and direct β-catenin phosphorylation. PLoS One 7, e35826. 
Krupnik, V. E., Sharp, J. D., Jiang, C., Robison, K., Chickering, T. W., Amaravadi, L., 
Brown, D. E., Guyot, D., Mays, G., Leiby, K., Chang, B., Duong, T., Goodearl, A. D., 
Gearing, D. P., Sokol, S. Y., & McCarthy, S. A. (1999) Functional and structural 
diversity of the human Dickkopf gene family. Gene 238, 301-313. 
Kühl, M., Sheldahl, L. C., Malbon, C. C., & Moon, R. T. (2000a) Ca(2+)/calmodulin-
dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes 
ventral cell fates in Xenopus. Journal of Biological Chemistry 275, 12701-12711. 
Kühl, M., Sheldahl, L. C., Park, M., Miller, J. R., & Moon, R. T. (2000b) The Wnt/Ca2+ 
pathway: a new vertebrate Wnt signaling pathway takes shape. Trends in Genetics 16, 
279-283. 
Kurayoshi, M., Oue, N., Yamamoto, H., Kishida, M., Inoue, A., Asahara, T., Yasui, W., & 
Kikuchi, A. (2006) Expression of Wnt-5a is correlated with aggressiveness of gastric 
cancer by stimulating cell migration and invasion. Cancer Research 66, 10439-10448. 
Kurayoshi, M., Yamamoto, H., Izumi, S., & Kikuchi, A. (2007) Post-translational 
palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. Biochemical 
Journal 402, 515-523. 
Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990) Heterogeneity in the distribution 
and morphology of microglia in the normal adult mouse brain. Neuroscience 39, 151-
170. 
Leeman, M. F., Curran, S., & Murray, G. I. (2002) The structure, regulation, and function of 
human matrix metalloproteinase-13. Critical Reviews in Biochemistry and Molecular 
Biology 37, 149-166. 
Lefkowitz, R. J. (2007) Seven transmembrane receptors: something old, something new. Acta 
Physiol (Oxf) 190, 9-19. 
Lehnardt, S. (2010) Innate immunity and neuroinflammation in the CNS: the role of 
microglia in Toll-like receptor-mediated neuronal injury. Glia 58, 253-263. 
Li, C., Chen, H., Hu, L., Xing, Y., Sasaki, T., Villosis, M. F., Li, J., Nishita, M., Minami, Y., 
& Minoo, P. (2008) Ror2 modulates the canonical Wnt signaling in lung epithelial cells 
through cooperation with Fzd2. BMC Molecular Biology 9, 11. 
Li, C., Zhao, R., Gao, K., Wei, Z., Yin, M. Y., Lau, L. T., Chiu, D., & Hoi Yu, A. C. (2011) 
Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. 
Current Alzheimer Research 8, 67-80. 
Li, H., Malbon, C. C., & Wang, H. Y. (2004) Gene profiling of Frizzled-1 and Frizzled-2 
signaling: expression of G-protein-coupled receptor chimeras in mouse F9 
teratocarcinoma embryonal cells. Molecular Pharmacology 65, 45-55. 
Li, L., Hutchins, B. I., & Kalil, K. (2009) Wnt5a induces simultaneous cortical axon 
outgrowth and repulsive axon guidance through distinct signaling mechanisms. Journal 
of Neuroscience 29, 5873-5883. 
Li, V.S., Ng, S.S., Boersema, P.J., Low T.Y., Karthaus, W.R., Gerlach, JP, Mohammed, S, 
Heck,A.J., Maurice, M.M., Mahmoudi, T.,& Clevers, H. (2012) Wnt signaling through 
inhibition of β-catenin degradation in an intact Axin1 complex. Cell 149:1245-56. 
Lin, M. W., Tsao, L. T., Chang, L. C., Chen, Y. L., Huang, L. J., Kuo, S. C., Tzeng, C. C., 
Lee, M. R., & Wang, J. P. (2007) Inhibition of lipopolysaccharide-stimulated NO 
production by a novel synthetic compound CYL-4d in RAW 264.7 macrophages 
involving the blockade of MEK4/JNK/AP-1 pathway. Biochemical Pharmacology 73, 
1796-1806. 
Ling, E. -A., & Wong, W. -C. (1993) The Origin and Nature of Ramified and Amoeboid 
Microglia: A Historical Review and Current Concepts. Glia 7, 9-18. 
Carina Halleskog 
58 
Liu, T., DeCostanzo, A. J., Liu, X., Wang, H., Hallagan, S., Moon, R. T., & Malbon, C. C. 
(2001) G protein signaling from activated rat frizzled-1 to the beta-catenin-Lef-Tcf 
pathway. Science 292, 1718-1722. 
Liu, X., Liu, T., Slusarski, D. C., Yang-Snyder, J., Malbon, C. C., Moon, R. T., & Wang, H. 
(1999) Activation of a frizzled-2/beta-adrenergic receptor chimera promotes Wnt 
signaling and differentiation of mouse F9 teratocarcinoma cells via Galphao and 
Galphat. Proceedings of the National Academy of Sciences of the United States of 
America 96, 14383-14388. 
Liu, X., Rubin, J. S., & Kimmel, A. R. (2005) Rapid, Wnt-induced changes in GSK3beta 
associations that regulate beta-catenin stabilization are mediated by Galpha proteins. 
Current Biology 15, 1989-1997. 
Logan, C. Y., & Nusse, R. (2004) The Wnt signaling pathway in development and disease. 
Annual Review of Cell and Developmental Biology 20, 781-810. 
Lovestone, S., Killick, R., Di Forti, M., & Murray, R. (2007) Schizophrenia as a GSK-3 
dysregulation disorder. Trends in neuroscience 30, 142-149. 
Lynch, M. A. (2009) The multifaceted profile of activated microglia. Molecular 
Neurobiology 40, 139-156. 
Ma, L., & Wang, H. Y. (2006) Suppression of cyclic GMP-dependent protein kinase is 
essential to the Wnt/cGMP/Ca2+ pathway. Journal of Biological Chemistry 281, 30990-
31001. 
MacDonald, B. T., Tamai, K., & He, X. (2009) Wnt/beta-catenin signaling: components, 
mechanisms, and diseases. Developmental Cell 17, 9-26. 
Maeda K., Kobayashi Y., Udagawa N., Uehara S., Ishihara A., Mizoguchi T, Kikuchi Y., 
Takada I, Kato S, Kani S, Nishita M, Marumo K, Martin TJ, Minami Y, Takahashi N 
(2012) Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors 
enhances osteoclastogenesis. Nature medicine 18, 405-412. 
Magdesian, M. H., Carvalho, M. M., Mendes, F. A., Saraiva, L. M., Juliano, M. A., Juliano, 
L., Garcia-Abreu, J., & Ferreira, S. T. (2008) Amyloid-beta binds to the extracellular 
cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. Journal of 
Biological Chemistry 283, 9359-9368. 
Malaterre, J., Ramsay, R. G., & Mantamadiotis, T. (2007) Wnt-Frizzled signalling and the 
many paths to neural development and adult brain homeostasis. Frontiers in Bioscience 
12, 492-506. 
Malbon, C. C., Wang, H., & Moon, R. T. (2001) Wnt signaling and heterotrimeric G-
proteins: strange bedfellows or a classic romance? Biochemical and Biophysical 
Research Communications 287, 589-593. 
Mao, B., Wu, W., Li, Y., Hoppe, D., Stannek, P., Glinka, A., & Niehrs, C. (2001) LDL-
receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411, 321-325. 
Marais, M., Maloney, S. K., & Gray, D. A. (2011) Brain IL-6- and PG-dependent actions of 
IL-1ß and lipopolysaccharide in avian fever. American Journal of Physiology 
Regulatory, Integrative and Comparative Physiology 301, 791-800. 
Marchetti, B., & Pluchino, S. (2013) Wnt your brain be inflamed? Yes, it Wnt!. Trends in 
Molecular Medicine 19, 144-156 
Marin-Teva, J. L., Cuadros, M. A., Martin-Olivia, D., & Navascués, J. (2011) Microglia and 
neuronal cell death. Neuron Glia Biology 7, 25-40. 
Marzio, R., Mauël, J., & Betz-Corradin, S. (1999) CD69 and regulation of the immune 
function. Immunopharmacology and Immunotoxicology 21, 565-582. 
Matsui, T., Svensson, C. I., Hirata, Y., Mizobata, K., Hua, X. Y., & Yaksh, T. L. (2010) 
Release of prostaglandin E(2) and nitric oxide from spinal microglia is dependent on 
activation of p38 mitogen-activated protein kinase. Anesthesia and Analgesia 111, 554-
560. 
McDonald, D. R., Brunden, K. R., & Landreth, G. E. (1997) Amyloid fibrils activate tyrosine 
kinase-dependent signaling and superoxide production in microglia. Journal of 
Neuroscience 17, 2284-2294. 
Medzhitov, R., & Janeway, C. J. (2000) Innate immunity. New England Journal of Medicine 
343, 338-344. 
WNT signaling in microglia 
  59 
Mikels, A. J., & Nusse, R. (2006a) Wnts as ligands: processing, secretion and reception. 
Oncogene 25, 7461-7468. 
Mikels, A. J., & Nusse, R. (2006b) Purified Wnt5a protein activates or inhibits beta-catenin-
TCF signaling depending on receptor context. PLoS Biology 4, e115. 
Miller, K. R., & Streit, W. J. (2007) The effects of aging, injury and disease on microglial 
function: a case for cellular senescence. Neuron Glia Biology 3, 245-253. 
Milligan, G. (2003) Principles: extending the utility of [35S]GTP gamma S binding assays. 
Trends in Pharmacological Sciences 24, 87-90. 
Minghetti, L., & Levi, G. (1998) Microglia as effector cells in brain damage and repair: focus 
on prostanoids and nitric oxide. Progress in Neurobiology 54, 99-125. 
Mitchell, J. A., Larkin, S., & Williams, T. J. (1995) Cyclooxygenase-2: regulation and 
relevance in inflammation. Biochemical Pharmacology 50, 1535-1542. 
Montcouquiol, M., Crenshaw, E. B., & Kelley, M. W. (2006) Noncanonical Wnt signaling 
and neural polarity. Annual Review of Neuroscience 29, 363-386. 
Moon, R. T., Campbell, R. M., Christian, J. L., McGrew, L. L., Shih, J., & Fraser, S. (1993) 
Xwnt-5A: a maternal Wnt that affects morphogenetic movements after overexpression 
in embryos of Xenopus laevis. Development 119, 97-111. 
Moon, R. T., Kohn, A. D., De Ferrari, G. V., & Kaykas, A. (2004) WNT and beta-catenin 
signalling: diseases and therapies. Nature Reviews Genetics 5, 691-701. 
Morales, I., Farías, G., & Maccioni, R. B. (2010) Neuroimmunomodulation in the 
pathogenesis of Alzheimer's disease. Neuroimmunomodulation 17, 202-204. 
Morioka, N., Tanabe, H., Inoue, A., Dohi, T., & Nakata, Y. (2009) Noradrenaline reduces the 
ATP-stimulated phosphorylation of p38 MAP kinase via beta-adrenergic receptors-
cAMP-protein kinase A-dependent mechanism in cultured rat spinal microglia. 
Neurochemistry International 55, 226-234. 
Mosmann (1983) Rapid colometric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. Journal of immunological methods 65, 55-63. 
Nemeth, M. J., Topol, L., Anderson, S. M., Yang, Y., & Bodine, D. M. (2007) Wnt5a inhibits 
canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. 
Proceedings of the National Academy of Sciences of the United States of America 104, 
15436-15441. 
Neumann, J., Schaale, K., Farhat, K., Endermann, T., Ulmer, A. J., Ehlers, S., & Reiling, N. 
(2010) Frizzled1 is a marker of inflammatory macrophages, and its ligand Wnt3a is 
involved in reprogramming Mycobacterium tuberculosis-infected macrophages. FASEB 
Journal 24, 4599-4612. 
Nichols, A. S., Floyd, D. H., Bruinsma, S. P., Narzinski, K., & Baranski, T. J. (2013) Frizzled 
receptors signal through G proteins. Cellular Signallin 25, 1468-1475. 
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) Resting microglial cells are highly 
dynamic surveillants of brain parenchyma in vivo. Science 308, 134-138. 
Nolte, C., Möller, T., Walter, T., & Kettenmann, H. (1996) Complement 5a controls motility 
of murine microglial cells in vitro via activation of an inhibitory G-protein and the 
rearrangement of the actin cytoskeleton. Neuroscience 73, 1091-1107. 
Nordstedt, C., & Fredholm, B. B. (1990) A modification of a protein-binding method for 
rapid quantification of cAMP in cell-culture supernatants and body fluid. Analytical 
Biochemistry 189, 231-234. 
Nq, J., Fredholm, B. B., Jondal, M., & Andersson, T. (1988) Regulation of receptor-mediated 
calcium influx across the plasma membrane in a human leukemic T-cell line: evidence 
of its dependence on an initial calcium mobilization from intracellular stores. 
Biochimica et Biophysica Acta 971, 207-214. 
Nusse, R. (2003) Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling 
mechanisms at the cell surface. Development 130, 5297-5305. 
Nusse, R., Brown, A., Papkoff, J., Scambler, P., Shackleford, G., McMahon, A., Moon, R., & 
Varmus, H. (1991) A new nomenclature for int-1 and related genes: the Wnt gene 
family. Cell 64, 231. 
Nusse, R., & Varmus, H. E. (1982) Many tumors induced by the mouse mammary tumor 
virus contain a provirus integrated in the same region of the host genome. Cell 31, 99-
109. 
Carina Halleskog 
60 
O'Brien, W. T., & Klein, P. S. (2009) Validating GSK3 as an in vivo target of lithium action. 
Biochemical Society Transactions 37, 1133-1138. 
O'Callaghan, J. P., Sriram, K., & Miller, D. B. (2008) Defining "neuroinflammation". Annals 
of the New York Academy of Sciences 1139, 318-330. 
O'Callaghan, K., Kuliopulos, A., & Covic, L. (2012) Turning receptors on and off with 
intracellular pepducins: new insights into G-protein-coupled receptor drug development. 
Journal of Biological Chemistry 287, 12787-12796. 
Ohm, T. G. (2007) The dentate gyrus in Alzheimer's disease. Progress in Brain Research 
163, 723-740. 
Oishi, I., Suzuki, H., Onishi, N., Takada, R., Kani, S., Ohkawara, B., Koshida, I., Suzuki, K., 
Yamada, G., Schwabe, G. C., Mundlos, S., Shibuya, H., Takada, S., & Minami, Y. 
(2003) The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK 
signalling pathway. Genes to Cells 8, 645-654. 
Oitzl, M. S., van Oers, H., Schöbitz, B., & de Kloet, E. R. (1993) Interleukin-1 beta, but not 
interleukin-6, impairs spatial navigation learning. Brain Research 613, 160-163. 
Olah, M., Biber, K., Vinet, J., & Boddeke, H. W. (2011) Microglia phenotype diversity. CNS 
& neurological disorders drug targets 10, 108-118. 
Oldham, W. M., & Hamm, H. E. (2008) Heterotrimeric G protein activation by G-protein-
coupled receptors. Nature Reviews Molecular Cell Biology 9, 60-71. 
Opdenakker, G., Froyen, G., Fiten, P., Proost, P., & Van Damme, J. (1993) Human monocyte 
chemotactic protein-3 (MCP-3): molecular cloning of the cDNA and comparison with 
other chemokines. Biochemical and Biophysical Research Communications 191, 535-
542. 
Palmer, A. M. (2011) Neuroprotective therapeutics for Alzheimer's disease: progress and 
prospects. Trends in Pharmacological Sciences 32, 141-147. 
Paredes, R. M., Etzler, J. C., Watts, L. T., Zheng, W., & Lechleiter, J. D. (2008) Chemical 
Calcium Indicators. Methods 46, 143-151. 
Park, E., Kim, G. H., Choi, S. C., & Han, J. K. (2006) Role of PKA as a negative regulator of 
PCP signaling pathway during Xenopus gastrulation movements. Developmental 
Biology 292, 344-357. 
Park, S. E., Sapkota, K., Kim, S., Kim, H., & Kim, S. J. (2011) Kaempferol acts through 
mitogen-activated protein kinases and protein kinase B/AKT to elicit protection in a 
model of neuroinflammation in BV2 microglial cells. British Journal of Pharmacology 
164, 1008-1025. 
Pei, J. J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. 
(1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains 
staged for Alzheimer disease neurofibrillary changes. Journal of Neuropathology and 
Experimental Neurology 58, 1010-1019. 
Pereira, C., Schaer, D. J., Bachli, E. B., Kurrer, M. O., & Schoedon, G. (2008) 
Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and 
is a target for the antiinflammatory action of activated protein C and interleukin-10. 
Arteriosclerosis, Thrombosis, and Vascular Biology 28, 504-510. 
Phiel, C. J., Wilson, C. A., Lee, V. M., & Klein, P. S. (2003) GSK-3alpha regulates 
production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439. 
Phillis, J. W., Horrocks, L. A., & Farooqui, A. A. (2006) Cyclooxygenases, lipoxygenases, 
and epoxygenases in CNS: their role and involvement in neurological disorders. Brain 
Res Rev 52, 201-243. 
Pierce, K. L., Maudsley, S., Daaka, Y., Luttrell, L. M., & Lefkowitz, R. J. (2000) Role of 
endocytosis in the activation of the extracellular signal-regulated kinase cascade by 
sequestering and nonsequestering G protein-coupled receptors. Proceedings of the 
National Academy of Sciences of the United States of America 97, 1489-1494. 
Pishvaian, M. J., & Byers, S. W. (2007) Biomarkers of WNT signaling. Cancer Biomark 3, 
263-274. 
Pocock, J. M., & Kettenmann, H. (2007) Neurotransmitter receptors on microglia. Trends in 
Neurosciences 30, 527-535. 
Pocock, J. M., & Liddle, A. C. (2001) Microglial signalling cascades in neurodegenerative 
disease. Progress in Brain Research 132, 555-565. 
WNT signaling in microglia 
  61 
Pocock, J. M., Liddle, A. C., Hooper C., Taylor D. L., Davenport C. M., & Morgan S. C. 
(2002) Activated microglia in Alzheimer’s disease and stroke. Ernst Schering Research 
Foundation workshop (39), 105-132. 
Polazzi, E., & Monti, B. (2010) Microglia and neuroprotection: from in vitro studies to 
therapeutic applications. Progress in Neurobiology 92, 293-315. 
Ponomarev, E. D., Shriver, L. P., & Dittel, B. N. (2006) CD40 Expression by Microglial 
Cells Is Required for Their Completion of a Two-Step Activation Process during Central 
Nervous System Autoimmune Inflammation. Journal of Immunology 176, 1402-1410. 
Porzig, R., Singer, D., & Hoffmann, R. (2007) Epitope mapping of mAbs AT8 and Tau5 
directed against hyperphosphorylated regions of the human tau protein. Biochemical and 
Biophysical Research Communications 358, 644-649. 
Prinz, M., Kann, O., Draheim, H. J., Schumann, R. R., Kettenmann, H., Weber, J. R., & 
Hanisch, U. K. (1999) Microglial activation by components of gram-positive and -
negative bacteria: distinct and common routes to the induction of ion channels and 
cytokines. Journal of Neuropathology and Experimental Neurology 58, 1078-1089. 
Pukrop T., & Binder C. (2008) The complex pathways of Wnt 5a in cancer porgression. 
Journal of molecular medicine 86, 259-266. 
Pukrop, T., Dehghani, F., Chuang, H. N., Lohaus, R., Bayanga, K., Heermann, S., Regen, T., 
Rossum, D. V., Klemm, F., Schulz, M., Siam, L., Hoffmann, A., Trümper, L., 
Stadelmann, C., Bechmann, I., Hanisch, U. K., & Binder, C. (2010) Microglia promote 
colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia 58, 
1477-1489. 
Pukrop, T., Klemm, F., Hagemann, T., Gradl, D., Schulz, M., Siemes, S., Trümper, L., & 
Binder, C. (2006) Wnt 5a signaling is critical for macrophage-induced invasion of breast 
cancer cell lines. Proceedings of the National Academy of Sciences of the United States 
of America 103, 5454-5459. 
Ranshoff, R. M., & Cardona, A. E. (2010) The myeloid cells of the central nervous system 
parenchyma. Nature 468, 253-262. 
Rattner, A., Hsieh, J. C., Smallwood, P. M., Gilbert, D. J., Copeland, N. G., Jenkins, N. A., & 
Nathans, J. (1997) A family of secreted proteins contains homology to the cysteine-rich 
ligand-binding domain of frizzled receptors. Proceedings of the National Academy of 
Sciences of the United States of America 94, 2859-2863. 
Righi, M., Mori, L., De Libero, G., Sironi, M., Biondi, A., Mantovani, A., Donini, S. D., & 
Ricciardi-Castagnloi, P. (1989) Monokine production by microglial cell clones. 
European Journal of Immunology 19, 1443-1448. 
Rijsewijk, F., Schuermann, M., Wagenaar, E., Parren, P., Weigel, D., & Nusse, R. (1987) The 
Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment 
polarity gene wingless. Cell 50, 649-657. 
Rivest, S. (2009) Regulation of innate immune responses in the brain. Nature Reviews 
Immunology 9, 429-439. 
Rock, B. R., & Peterson, P. K. (2006) Microglia as a Pharmacological Target in Infectious 
and Inflammatory Diseases of the Brain. J Neuroimmune Pharmacol 1, 117-126. 
Rosso, S. B., Sussman, D., Wynshaw-Boris, A., & Salinas, P. C. (2005) Wnt signaling 
through Dishevelled, Rac and JNK regulates dendritic development. Nature 
Neuroscience 8, 34-42. 
Säfholm, A., Leandersson, K., Dejmek, J., Nielsen, C. K., Villoutreix, B. O., & Andersson, T. 
(2006) A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair 
migration of human breast epithelial cells. Journal of Biological Chemistry 281, 2740-
2749. 
Saijo, K., & Glass, C. K. (2011) Microglial cell origin and phenotypes in health and disease. 
Nature Reviews Immunology 11, 775-787. 
Salinas, P. C. (2012) Wnt signaling in the vertebrate central nervous system: from axon 
guidance to synaptic function. Cold Spring Harbor perspectives in biology 4, pli: 
a008003. 
Saneyoshi, T., Kume, S., Amasaki, Y., & Mikoshiba, K. (2002) The Wnt/calcium pathway 
activates NF-AT and promotes ventral cell fate in Xenopus embryos. Nature 417, 295-
299. 
Carina Halleskog 
62 
Sarafi, M. N., Garcia-Zepeda, E. A., MacLean, J. A., Charo, I. F., & Luster, A. D. (1997) 
Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a 
structural and functional homologue of human MCP-1. Journal of Experimental 
Medicine 185, 99-109. 
Satoh, J., & Kuroda, Y. (2000) Beta-catenin expression in human neural cell lines following 
exposure to cytokines and growth factors. Neuropathology 20, 113-123. 
Schaale, K., Neumann, J., Schneider, D., Ehlers, S., & Reiling, N. (2011) Wnt signaling in 
macrophages: augmenting and inhibiting mycobacteria-induced inflammatory 
responses. European Journal of Cell Biology 90, 553-559. 
Schambony, A., & Wedlich, D. (2007) Wnt-5A/Ror2 regulate expression of XPAPC through 
an alternative noncanonical signaling pathway. Developmental Cell 12, 779-792. 
Scheffel, J., Regen, T., Van Rossum, D., Seifert, S., Ribes, S., Nau, R., Parsa, S., Harris, R. 
A., Boddeke, H. W. G. M., Chuang, H. -N., Pukrop, T., Wessels, J. T., Jurgens, T., 
Merkler, D., Brück, W., Schnaars, M., Simons, M., Kettenmann, H., & Hanisch, U. -K. 
(2013) Toll-like receptor activation reveals developmental reorganization and unmasks 
responder subsets of microglia. Glia 60, 1930-1943. 
Schellenberg, G. D., & Montline, T. J. (2012) The genetics and neuropathology of 
Alzheimer's disease. Acta Neuropathologica 124, 305-323. 
Scheller, J., Ohnerorge, N., & Rose-John, S. (2006) Interleukin-6 Trans-Signalling in Chronic 
Inflammation and Cancer. Scandinavian Journal of Immunology 63, 321-329. 
Schlange, T., Matsuda, Y., Lienhard, S., Huber, A., & Hynes, N. E. (2007) Autocrine WNT 
signaling contributes to breast cancer cell proliferation via the canonical WNT pathway 
and EGFR transactivation. Breast Cancer Research 9, R63. 
Schulte, G. (2010b) International Union of Basic and Clinical Pharmacology. LXXX. The 
Class Frizzled Receptors. Pharmacological Reviews 62, 632-667. 
Schulte G. (2013) Frizzleds as G protein-coupled receptors in “Wnt Signaling in Development 
and Disease: Molecular Mechanisms and Biological Functions”. Ed: S Hoppler, RT 
Moon. Wiley – in press 
Schulte, G., & Bryja, V. (2007) The Frizzled family of unconventional G protein-coupled 
receptors. Trends in Pharmacological Sciences 28, 518-525. 
Schulte, G., Bryja, V., Rawal, N., Castelo-Branco, G., Sousa, K. M., & Arenas, E. (2005) 
Purified Wnt-5a increases differentiation of midbrain dopaminergic cells and 
dishevelled phosphorylation. Journal of Neurochemistry 92, 1550-1553. 
Seifert, J. R., & Mlodzik, M. (2007) Frizzled/PCP signalling: a conserved mechanism 
regulating cell polarity and directed motility. Nature Reviews Genetics 8, 126-138. 
Selcher, J. C., Atkins, C. M., Trzaskos, J. M., Paylor, R., & Sweatt, J. D. (1999) A necessity 
for MAP kinase activation in mammalian spatial learning. Learning & Memory 6, 478-
490. 
Semenov, M. V., Habas, R., Macdonald, B. T., & He, X. (2007) SnapShot: Noncanonical 
Wnt Signaling Pathways. Cell 131, 1378. 
Shan, J., Shi, D. L., Wang, J., & Zheng, J. (2005) Identification of a specific inhibitor of the 
dishevelled PDZ domain. Biochemistry 44, 15495-15503. 
Sheldahl, L. C., Park, M., Malbon, C. C., & Moon, R. T. (1999) Protein kinase C is 
differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent 
manner. Current Biology 9, 695-698. 
Sheldahl, L. C., Slusarski, D. C., Pandur, P., Miller, J. R., Kühl, M., & Moon, R. T. (2003) 
Dishevelled activates Ca2+ flux, PKC, and CamKII in vertebrate embryos. Journal of 
Cell Biology 161, 769-777. 
Shimizu, H., Julius, M. A., Giarré, M., Zheng, Z., Brown, A. M., & Kitajewski, J. (1997) 
Transformation by Wnt family proteins correlates with regulation of beta-catenin. Cell 
Growth & Differentiation 8, 1349-1358. 
Slusarski, D. C., Corces, V. G., & Moon, R. T. (1997a) Interaction of Wnt and a Frizzled 
homologue triggers G-protein-linked phosphatidylinositol signalling. Nature 390, 410-
413. 
WNT signaling in microglia 
  63 
Slusarski, D. C., Yang Snyder J., Busa W. B., and Moon R.T. (1997b) Modulation of 
embryonic intracellular Ca2+ signaling by Wnt-5A. Developmental biology 182, 114-
120. 
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) Role of pro-inflammatory cytokines 
released from microglia in neurodegenerative diseases. Brain Research Bulletin 87, 10-
20. 
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) Cyclooxygenases: structural, cellular, 
and molecular biology. Annual Review of Biochemistry 69, 145-182. 
Soriano, S., Kang, D. E., Fu, M., Pestell, R., Chevallier, N., Zheng, H., & Koo, E. H. (2001) 
Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 
signaling independently of beta-amyloid precursor protein and notch processing. 
Journal of Cell Biology 152, 785-794. 
Sriram, K., & O'Callaghan, J. P. (2007) Divergent roles for tumor necrosis factor-alpha in the 
brain. J Neuroimmune Pharmacol 2, 140-153. 
Staal, F. J., Luis, T. C., & Tiemessen, M. M. (2008) WNT signalling in the immune system: 
WNT is spreading its wings. Nature Reviews Immunology 8, 581-593. 
Stella, N. (2009) Endocannabinoid signaling in microglial cells. Neuropharmacology 56, 
244-253. 
Streit, W. J. (2002) Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 
40, 133-139. 
Streit, W. J., Mrak, R. E., & Griffin, W. S. (2004) Microglia and neuroinflammation: a 
pathological perspective. Journal of Neuroinflammation 1, 14. 
Takada, R., Satomi, Y., Kurata, T., Ueno, N., Norioka, S., Kondoh, H., Takao, T., & Takada, 
S. (2006) Monounsaturated fatty acid modification of Wnt protein: its role in Wnt 
secretion. Developmental Cell 11, 791-801. 
Tetsu, O., & McCormick, F. (1999) Beta-catenin regulates expression of cyclin D1 in colon 
carcinoma cells. Nature 398, 422-426. 
Toledo, E. M., Colombres, M., & Inestrosa, N. C. (2008) WNT signaling in neuroprotection 
and stem cell differentiation. Progress in Neurobiology86, 281-296 
Toledo, E. M., & Inestrosa, N. C. (2009) Activation of Wnt signaling by lithium and 
rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an 
APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Molecular Psychiatry 15, 
272-285. 
Topol, L., Jiang, X., Choi, H., Garrett-Beal, L., Carolan, P. J., & Yang, Y. (2003) Wnt-5a 
inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin 
degradation. Journal of Cell Biology 162, 899-908. 
Trinchieri, G. (1998) Proinflammatory and immunoregulatory functions of interleukin-12. 
International Reviews of Immunology 16, 365-396. 
Turjanski, A. G., Vaqué, J. P., & Gutkind, J. S. (2007) MAP kinases and the control of 
nuclear events. Oncogene 26, 3240-3253. 
Uren, A., Reichsman, F., Anest, V., Taylor, W. G., Muraiso, K., Bottaro, D. P., Cumberledge, 
S., & Rubin, J. S. (2000) Secreted frizzled-related protein-1 binds directly to Wingless 
and is a biphasic modulator of Wnt signaling. Journal of Biological Chemistry 275, 
4374-4382. 
van Amerongen, R., Mikels, A., & Nusse, R. (2008) Alternative wnt signaling is initiated by 
distinct receptors. Sci Signal 1, re9. 
van Rossum, D., & Hanisch, U. K. (2004) Microglia. Metabolic Brain Disease 19, 393-411. 
Vinson, C. R., Conover, S., & Adler, P. N. (1989) A Drosophila tissue polarity locus encodes 
a protein containing seven potential transmembrane domains. Nature 338, 263-264. 
von Bernhardi, R., & Eugenín, J. (2004) Microglial reactivity to beta-amyloid is modulated 
by astrocytes and proinflammatory factors. Brain Research 1025, 186-193. 
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., & Stella, N. 
(2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. 
Journal of Neuroscience 23, 1398-1405. 
Walter, L., & Neumann, H. (2009) Role of microglia in neuronal degeneration and 
regeneration. Seminars in Immunology 31, 513-525. 
Carina Halleskog 
64 
Wen, J., Ribeiro, R., & Zhang, Y. (2011) Specific PKC isoforms regulate LPS-stimulated 
iNOS induction in murine microglial cells. Journal of Neuroinflammation 8, 
West, R. E., Moss, J., Vaughan, M., Liu, T., & Liu, T. Y. (1985) Pertussis toxin-catalyzed 
ADP-ribosylation of transducin. Cysteine 347 is the ADP-ribose acceptor site. Journal 
of Biological Chemistry 260, 14428-14430. 
Wiedau-Pazos, M., Wong, E., Solomon, E., Alarcon M., & Geshwind D. H. (2009) Wnt-
pathway activation during the early stage of neurodegeneration in FTDP-17 mice. 
Neurobiology of Aging 30, 14-21 
Wilkinson, K., & El Khory, J. (2012) Microglial Scavenger Receptors and Their Roles in the 
Pathogenesis of Alzheimer's Disease. International journal of Alzheimer’s disease 2012, 
489456. 
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. 
R., & Nusse, R. (2003) Wnt proteins are lipid-modified and can act as stem cell growth 
factors. Nature 423, 448-452. 
Willert, K., & Nusse, R. (2012) Wnt proteins. Cold Spring Harbor perspectives in biology 4: 
a007864. 
Willert, K. H. (2008) Isolation and application of bioactive Wnt proteins. Methods in 
Molecular Biology 468, 17-29. 
Wolf, J., Mašek, J., Krejci, P., Wilcox, W. R., Kozubík, A., Schulte, G., Gutkind, J. S., & 
Bryja, V. (2011) Mitogen-activated protein kinases promote WNT/beta-catenin 
signaling via phosphorylation of LRP6. Molecular and Cellular Biology 31, 179-189. 
Wong, G. T., Gavin, B. J., & McMahon, A. P. (1994) Differential transformation of 
mammary epithelial cells by Wnt genes. Molecular and Cellular Biology 14, 6278-6286. 
Wong, H. C., Bourdelas, A., Krauss, A., Lee, H. J., Shao, Y., Wu, D., Mlodzik, M., Shi, D. 
L., & Zheng, J. (2003) Direct binding of the PDZ domain of Dishevelled to a conserved 
internal sequence in the C-terminal region of Frizzled. Molecular Cell 12, 1251-1260. 
Woodcock, T., & Morganti-Kossmann, M. C. (2013) The Role of Markers of Inflammation 
in Traumatic Brain Injury. Frontiers in Neurology 4, [Epub ahead of print] 
Wymann M.P., & Schultz C. (2012) The chemical biology of phosphoinositide 3-kinases. 
Chembiochem 13, 2022-2035. 
Xu, Y. K., & Nusse, R. (1998) The Frizzled CRD domain is conserved in diverse proteins 
including several receptor tyrosine kinases. Current Biology 8, R405-R406. 
Yun, K., & Im, S. H. (2007) Lef1 regulates COX-2 transcription in chondrocytes. 
Biochemical and Biophysical Research Communications 364, 270-275. 
Yun, M. S., Kim, S. E., Jeon, S. H., Lee, J. S., & Choi, K. Y. (2005) Both ERK and 
Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation. Journal of Cell 
Science 118, 313-322. 
Zhang, H., Wang, F. -W., Yao, I. -L., & Hao, A. -J. (2011) Microglia- friend or foe. Frontiers 
in Bioscience 3, 869-883. 
 
